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A bst r a c t
Exogenous melatonin (0.5-10 mg) has been shown to entrain the free-running circadian 
rhythms of some blind subjects, yet questions still remain as to the most effective dose and 
the most appropriate circadian time (CT) at which to commence melatonin treatment. Some 
melatonin phase response curves (PRCs) have been constructed by studying entrained sighted 
subjects and these show that melatonin produces phase delays if administered between CT18- 
6 and phase advances if administered between CT6-18. The protocols for these PRC studies 
are flawed, in that they do not conform to the classical PRC protocol whereby subjects should 
be free-running in constant lighting conditions.
The aims of the present studies were to define further the properties of exogenous melatonin 
both as a phase shifting and an entraining agent in blind subjects with free-running circadian 
rhythms, together with one abnormally entrained individual. Specifically these aims were to 
investigate the entraining effects of daily administration of 0.5 mg melatonin on the free- 
running cortisol rhythm and its acute effects compared to placebo on the sleep-wake cycle in 
blind subjects. A study was also designed to assess whether a single dose of melatonin (5 mg) 
could shift the phase of endogenous circadian rhythms (melatonin and 6-suphatoxymelatonin) 
in free-running blind subjects, in order to construct a PRC.
Melatonin (0.5 mg daily) administered to a blind subject with entrained, but abnormally 
advanced, circadian rhythms in a step-wise manner shifted the cortisol rhythm, probably by 
phase delay (cumulative phase delay of 2.5 h). This change of phase improved sleep by 
decreasing sleep latency, total number of night awakenings, the number and duration of night 
awakenings in the second half of the night and the number and duration of daytime naps.
Most of the ten free-running blind subjects who took 0.5 mg melatonin daily for one full 
circadian beat cycle exhibited an entrained or shortened cortisol period during melatonin 
treatment. The subjects who entrained did so when melatonin treatment commenced in the
phase advance portion of the melatonin PRC (CT6-18). Three subjects failed to entrain with 
initial melatonin treatment commencing in the phase delay portion of the PRC. During 
melatonin treatment there was a significant increase in night time sleep duration and a 
reduction in the number and duration of daytime naps. The CT of melatonin administration 
may be an important in determinant of entrainment. The efficacy of different doses, 
formulations and length of treatment need further investigation.
The melatonin PRC was carried out in seven subjects, one of whom took part in the study 
twice. The majority of phase shifts were phase delays (6, compared to 3 phase advances), and 
some were opposite in direction to that expected on the basis of the most recently published 
PRC. This may be due to the fact that the original PRC was constructed from multiple doses 
of melatonin (0.5 mg daily for four days) and the subjects were all sighted and entrained. 
Moreover the current study used a higher (5 mg) single dose of melatonin. It is also possible 
that each individual has a different PRC based on individual circadian period. The assessment 
of more subjects should clarify these issues and enable the construction of a frill PRC.
These studies show that low dose melatonin can entrain free-running rhythms in blind people 
as well as improving sleep and confirm melatonin as the treatment of choice for non 24 hour 
sleep wake disorder in the blind. The results of the preliminary PRC study, if  confirmed, 
suggest that the PRC for free-running people is different to that of entrained people. This may 
explain why some subjects do not entrain to melatonin taken at specific circadian times.
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1.0 Introduction
1.1 The Organisation of the Mammalian Circadian System
A rhythm is a regularly recurring oscillation, and the time required to complete one cycle of 
the rhythm is referred to as the period, or tau (x). The nomenclature for cycle length is based 
on the geophysical environment. Ultradian rhythms are those that have a period of less than a 
day, and include biological rhythms such as heart rate. Circadian rhythms are those with 
periods of approximately 24 hours such as melatonin and core body temperature. Infradian 
rhythms such as the menstrual cycle have periods of more than 24 hours.
These biological rhythms are endogenous, in that they are driven by a self-sustaining internal 
‘clock’ or clocks within the human body. The endogenous period is synchronised to the 
environment by time cues (zeitgebers) such as the 24 h light-dark cycle. On removal of 
zeitgebers, as shown in human isolation experiments (Aschoff, 1965; Haus et al., 1968; 
Weitzman et al., 1979; Wever, 1979), the period of the circadian rhythm is desynchronised 
from 24 hours and the rhythm free-runs at its own endogenous period.
Circadian rhythms in cortisol, core body temperature and melatonin in young and older 
healthy volunteers show that the intrinsic period of the human circadian pacemaker averages 
24.18 h ± 0.04 (Czeisler et al., 1999) when measured in conditions of forced desynchrony. 
Exposure to dim light and/or a scheduled sleep-wake cycle can entrain this near 24 hour 
period of the pacemaker to the 24 h day (Wright et al., 2001).
1.1.1 Retina
As the eyes and therefore the retina are the only light input pathway to the circadian system 
they are essential to entrainment. The part of the visual system innervating the hypothalamic 
suprachiasmatic nuclei (SCN) appears to be distinct from the classical visual system. 
Circadian responses to light still occur in mice that lack rods and cones (Freedman et al.,
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1999; Lucas et al., 1999). It is thought that a non-visual photoreceptor may be responsible for 
the regulation of circadian rhythms in humans (Brainard et al., 2001; Thapan et al., 2001).
Photic information that is transmitted through the retina affects circadian rhythms by 
modifying the period or frequency of the SCN pacemaker. The SCN functions as a clock that 
is entrained primarily by light via the retinohypothalamic tract (RHT). The phase of the 
entrained circadian rhythm, the rate of phase shift following a shift in the light dark cycle, and 
the period in constant light are also modulated by a second retina-SCN pathway, the 
geniculohypothalamic tract (GHT).
1.1.1.1 Circadian photoreception
A potential circadian photopigment called melanopsin can be found in light sensitive retinal 
ganglion cells. Melanopsin was first discovered in the dermal melanophores of Xenopus 
laevis (Provencio et al., 1998), and can be found exclusively in mammalian retinal ganglion 
cells (Provencio et al., 2000). In mammals these retinal ganglion cells project predominantly 
to the SCN (Gooley et al., 2002; Hannibal et al., 2002a; Hatter et al., 2002) and the 
intergeniculate leaflet (IGL), both of which are key centres for circadian photoentrainment. 
Melanopsin containing retinal ganglion cells respond to light, even when isolated from other 
neurons (Berson et al., 2002; Hatter et al., 2002; Lucas et al., 2003). These melanopsin 
ganglion cells differ from rods and cones in a number of responses. The light response in 
melanopsin ganglion cells is depolarizing, whereas in rods and cones it is hyperpolarizing. 
The melanopsin ganglion cell response to light is sustained during continuous light exposure, 
while rods and cones exhibit adaptation. In mammals the melanopsin ganglion cell irradiance 
thresholds are higher and the integration times are much longer than for rods and cones.
Cells expressing melanopsin are widely distributed all over the ganglion cell layer of the 
mammalian retina (Hannibal et al., 2002b; Hatter et al., 2002; Provencio et al., 1998). The
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dendrites of melanopsin ganglion cells are photoreceptive (Berson et al., 2002) and overlap to 
form a photoreceptive net within the inner retina (Provencio et al., 2002).
Evidence that melanopsin has a role in photoentrainment comes from studies using 
melanopsin-knockout mice. Bright light can phase shift melanopsin-knockout mice but not as 
much as mice with melanopsin (Panda et a l, 2002). Also the lengthening of period in 
melanopsin-knockout mice associated with being kept in constant light is attenuated (Panda et 
a l, 2002). Pupillary light reflexes are also partially impaired in melanopsin-knockout mice 
(Lucas et a l, 2003). Even though melanopsin appears to be a significant contributor to 
circadian function, these knockout mice studies indicate that melanopsin is not essential for 
entrainment.
The retinal ganglion cell layer is resistant to outer and inner retinal neuronal loss, and 
photoreception is still possible in a retina with extreme neuronal degradation (Semo et al., 
2003). These findings are applicable to studies in the blind, indicating that visual blindness 
does not necessarily result in the loss of circadian photoreceptive functions of the eye.
It is possible that photopigments other than melanopsin are involved in circadian 
photoreception. Ciyptochromes (Cryl and Cry 2) are vitamin-B2-based and are found in the 
mammalian retina (Miyamoto and Sancar, 1999). An input of the rods and cones can not be 
completely excluded from having any effect at this stage.
1.1.2 Suprachiasmatic Nuclei
The SCN is the major pacemaker in mammals. The SCN is made up of coupled circadian 
oscillators that function as a pacemaker. It is widely concluded that the SCN is the principal 
circadian pacemaker due to the fact that its removal results in the loss of circadian function 
(Moore and Eichler, 1972; Stephan and Zucker, 1972). Furthermore, circadian function is 
maintained in isolated SCN both in vivo (Inouye and Kawamura, 1979) and in vitro (Shibata 
and Moore, 1988).
3
The SCN exhibit a circadian rhythm in neuronal firing rate and glucose utilisation, both being 
higher during the subjective day than the subjective night (Shibata and Moore, 1988). Studies 
on the circadian rhythms of the SCN indicate that the neuronal network of the SCN does not 
need to be intact for the maintenance of circadian functioning (Schwartz et al., 1987).
The circadian rhythm of glucose utilisation in the rat SCN begins in foetal life (Reppert et al.,
1995), and it is thought that circadian functioning is initiated before a neural network has been 
formed (Moore and Bernstein, 1989).
1.1.2.1 SCN Afferents
1.1.2.1.1 Raphe Nucleus
The SCN receives input from several areas that are all likely to be involved in the modulation 
of the pacemaker. One of the largest inputs arises from the serotonin neurons of the midbrain 
raphe nuclei with a terminal plexus that overlaps the RHT and GHT projections (Moore et al., 
1978). Selective destruction of the raphe input to the SCN causes an alteration of the free- 
running period and in the phase angle of entrainment (PAE; the interval between the phase 
resetting agent and the phase of a circadian rhythm at steady state entrainment) (Smale et al., 
1990).
1.1.2.1.2 Retinohvpothalamic Tract
In early studies it was found that sectioning all of the visual pathways but leaving the optic 
chiasm, led to visual loss but not the capacity for entrainment of circadian rhythms (Klein and 
Moore, 1979). The primary pathway mediating photic entrainment is the RHT that projects to 
the SCN of the hypothalamus (Hendrickson et al., 1972).
The RHT has several components, the largest projects to the SCN. There are also projections 
to the lateral and anterior hypothalamic areas, and the retrochiasmatic area (Johnson et al., 
1988a). Sectioning the RHT leads to the abolishment of entrainment (Johnson et al., 1988b).
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Glutamate and adenylate cyclase-activating polypeptide (PACAP) are the principal 
neurotransmitters of the RHT (see Hannibal, 2003 for a review). In the rat glutamate is co­
stored with PACAP in RHT projecting ganglion cells (Hannibal et al., 2000). Both glutamate 
and PACAP can phase shift activity rhythms of rodents (see Hannibal, 2003 for a review).
1.1.2.1.3 Geniculohvpothalamic Tract
The GHT arises from the IGL, and projects to the same parts of the SCN as the RHT (Card 
and Moore, 1989). The integrity of the GHT is not essential for the photic entrainment of 
circadian rhythms (Pickard et al., 1987), although lesions cause changes in rhythmicity. 
Lesions slow the rate of reentrainment after phase shifts, reduce the magnitude of phase 
advances and reduce the free-running period in constant light conditions (Pickard et a l , 1987; 
Harrington and Rusak, 1988; Johnson et al., 1989).
1.1.3 Intergeniculate Leaflet
The IGL receives photic information from retinal ganglion cells. Lesions of the IGL 
significantly alter the period of circadian locomotor activity of animals kept in constant 
lighting conditions (Inouye et al., 1993; Johnson et a l, 1989; Pickard, 1989; Redlin et a l, 
1999), and also decreases the level of locomotor activity (Lewandowski and Usarek, 2002).
The IGL is characterised by a population of neuropeptide-Y (NPY) containing neurons that 
project to the SCN. NPY has been identified as the neurotransmitter in the GHT for mediating 
photic information to the SCN. A complete lesion of the IGL also causes a decrease in the 
level of NPY in the SCN (Goel et a l, 1999). Stimulation of the IGL or perfusion of NPY into 
the region of the SCN produces changes in the phase of free running circadian rhythm.
1.1.4 The Pineal Gland
In some birds and lower vertebrates, the pineal acts as the master rhythm generator, whereas 
in mammals it is incapable of self-sustaining oscillation.
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The most important input of the pineal gland is the light-dark transitions transmitted from the 
eye via a multi-synaptic pathway that indicate day length or photoperiod. Photoperiod is used 
as the primary environmental input in seasonal animals for changes in reproduction, coat 
growth and puberty (Arendt, 1986; Lincoln and Short, 1980; Reiter, 1980).
In mammals five cell types have been described, the pinealocyte, the interstitial cell, the 
perivascular phagocyte, neurons, and peptidergic neuron-like cells. The pinealocyte is the cell 
that produces melatonin.
1.1.5 Clock Genes
Circadian oscillations within individual SCN cells are produced by a rhythmic expression of 
clock genes and a transcriptional/translational negative-feedback loop (Reppert and Weaver, 
2001).
The first clock gene to be isolated was the period gene in Drosophila (Bargiello et al., 1984; 
Reddy et al., 1984). Since this other genes such as timeless and frequency have been 
discovered in Drosophila and Neurospora.
In mammals, homologues of the Drosophila period genes, mPerl, mPer2 and mPerS, have 
been identified as well as mtim {timeless) and two other genes called clock and BMAL1 (see 
Okamura et al., 2002 for a review). Subsequent studies have suggested that mPerl and mPer2 
have the capability of generating oscillations, whereas mPer2 knockout mice show little 
change in their circadian rhythms.
In mice Perl, Per2 and Decl are induced at different circadian times. Decl is induced 
throughout the subjective night, Perl at the beginning and end of the subjective night, and 
Per2 only at the beginning of the subjective night. These differences suggest that they 
perform different functions and may receive light via different transduction pathways.
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1.2 Circadian Rhythms
1.2.1 Melatonin and Cortisol
The endogenous period of a rhythm is an inheritable characteristic. The phase and period of 
the circadian system can be measured from a number of endogenous circadian rhythms. 
Melatonin, specifically the dim light melatonin onset (DLMO) (Lewy et al., 1985) is the most 
commonly used circadian marker when measuring melatonin in plasma or saliva. Midrange 
crossing, 25% rise, 50% rise, and acrophase are also common variables. Measuring DLMO 
which by definition uses a threshold of 10 pg/ml, can become problematic in people who have 
lower than normal melatonin amplitudes or a higher than normal melatonin baseline. The 
major metabolite of melatonin, 6-sulphatoxymelatonin (aMT6s) can be measured in urine, the 
acrophase of the rhythm is used and is considered to be a very good reflection of plasma 
melatonin (Bojkowski et al., 1987) and of circadian phase. In studies where exogenous 
melatonin is administered, making melatonin and aMT6s values unusable for phase 
assessment, cortisol can be measured in urine, plasma or saliva. Cortisol has been shown to be 
phase locked to DLMO (Nakagawa et a l , 1992; Weibel and Brandenberger, 2002) and 
aMT6s (Skene et al., 1999a). Core body temperature (CBT) is also tightly coupled to the 
melatonin rhythm with the acrophase of melatonin corresponding to the nadir of the CBT 
(Shanahan and Czeisler, 1991).
Comparisons of the variability of phase marker assessments has shown that methods of 
calculating circadian phase from plasma melatonin data were less variable than those 
calculated from CBT or cortisol data (Klerman et al., 2002a). It is thought that there is less 
variance in the plasma melatonin data because cortisol and CBT are influenced more by other 
factors.
1.2.2 Sleep
Initially a two-process model for sleep was developed (Borb61y, 1982), whereby a combined 
action of circadian (process C) and homeostatic (process S) processes determines sleep
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propensity. Process C represents sleepiness due to circadian influences. Process S is the 
increasing need for sleep since awakening, and the decrease in need for sleep since falling 
asleep. Since this time many developments and experiments have been conducted to test this 
theory (see Borbely and Achermann, 1999 for a review).
There is a relationship between the melatonin onset and the onset of habitual evening 
sleepiness (Zhdanova et al., 1997; Wehr et al., 2001; Martin and Eastman, 2002). Subjective 
sleep diaries of young healthy adults showed that the DLMO was about 3 hours before sleep 
onset and 10 hours before wake time, and was most strongly correlated with the mean 
midpoint of sleep from the last 5 days (Martin and Eastman, 2002). Total nights sleep and 
sleep architecture are dependent on the circadian phase of CBT (Czeisler et al., 1980). It is 
thought that even a small degree of desynchrony can result in symptoms of insomnia (Morris 
etal., 1990).
People who like to go to sleep early and get up early are morning types (larks) and tend to 
have a shorter period than those who prefer to sleep later and are evening types (owls) (Duffy 
etal., 2001).
Older people have different sleep patterns than young adults, in that they tend to wake earlier 
in the morning and have difficulty maintaining sleep (Foley et al., 1995). However, these age- 
related changes are not thought to be related to circadian phase (Duffy and Czeisler, 2002). 
The intrinsic circadian period was not significantly different between older (period 24.16 ± 
0.14 h) and younger subjects (period 24.15 ± 0.13 h), even though the wake times of the older 
subjects (07:07 ± 0:57) were significantly earlier than the younger subjects (8:11 ± 1:05). 
Subjects who had shorter periods rated themselves as more moming-like, and those with 
longer periods rated themselves as more evening-like. It was concluded that the age-related 
increase in early morning awakenings and difficulty in maintaining sleep may result from an 
inability to sustain sleep at certain circadian phases.
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Sleep itself may feedback onto the circadian pacemaker, but it appears to be a weak zeitgeber 
in humans (Danilenko et al., 2003).
1.2.3 Core Body Temperature
A two-component thermoregulatory system of a core and periphery exists, where the core is 
regulated to approximately 37°C, and the periphery depends largely on environmental 
temperature. Core body temperature shows a strong circadian rhythm that is opposite to that 
of melatonin, in that its nadir corresponds to the melatonin acrophase. Heat production and 
skin temperature also show circadian rhythms (Krauchi and Wirz-Justice, 1994).
There is a fall in CBT after sleep onset in subjects going to bed at their habitual time (Barrett 
et al., 1993) that remains low during sleep compared to subjects kept awake overnight. 
Although CBT still decreased in those subjects kept awake, a sharper drop in CBT following 
sleep onset was observed in subjects that were allowed to sleep. However, temperature 
changes after waking were not significantly different between the two groups. The sharper 
drop in CBT when subjects are allowed to sleep can be explained due to the fact that these 
subjects become totally relaxed, causing a shift in heat distribution from the core to the 
periphery.
The degree of dilation of blood vessels in the hands and feet is the best physiological 
predictor of sleep onset (Krauchi et al., 1997; Krauchi et al., 1999), in that the greater the 
dilation, the shorter the sleep latency is. Vasodilation begins, followed by a drop in CBT, in 
the early evening as sleepiness increases. Even the effect of lying down increased temperature 
in the feet and increased sleepiness (Krauchi et al. 1997). It has been predicted that sleep 
hypnotics and sleeping aids all cause vasodilation and heat loss before the onset of sleep.
An increase in distal vasodilation (and hence heat loss) occurs at the same time as an 
induction of sleepiness and a reduction of sleep latency (Krauchi and Wirz-Justice, 2001).
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1.3 Melatonin
1.3.1 Production and Metabolism
Melatonin is a hormone produced in the pineal gland and was first discovered in 1958 by 
Aaron Lemer. It has high water and lipid solubility, so it can enter various fluid, tissue and 
cellular compartments when released into the circulation from the pineal gland (Reiter, 1995).
Melatonin is rapidly metabolised by cytochrome P450 in humans. The liver is the primary site 
for melatonin metabolism, with most of the hormone being converted via 6-hydroxymelatonin 
to aMT6s in humans (see Figure 1.1). CYP1A2, an isoform of cytochrome P450, is an 
important catalyst of the 6-hyrdoxylation of melatonin (Facciola et al., 2001; Skene et al., 
2001; Ursing et al., 2002; Yeleswaram et al., 1999). Therefore a potential for drug interaction 
between melatonin and drugs metabolised by CYP1A2 exists. Also CYP1A has been shown 
to be induced by cigarette smoking (Buchthal et al., 1995), this could result in low levels of 
exogenous melatonin being metabolised and consequentially a lack its pharmacological 
effects.
The pineal gland secretes melatonin in a rhythmic fashion with peak secretion occurring at 
nighttime (Arendt, 1985). In normal humans the evening rise of melatonin occurs at 
approximately 2100 h, with the acrophase occurring between 0200 -  0400 h, dropping back to 
baseline day time levels by 1000 h. The rhythm of melatonin is endogenous, generated from 
the SCN (Moore and Klein, 1974), and can be entrained and suppressed by light. In this way, 
during a long day in the summer, the duration of night-time secretion of melatonin is reduced. 
Therefore the duration of melatonin secretion is correlated to the length of the night and 
consequently encodes the photoperiodic message in seasonal breeders.
The rhythm of melatonin production is endogenous and is generated in the SCN. Entrainment 
via the light dark cycle primarily occurs through the RHT projection to the SCN. The 
paraventricular nucleus (PVN) acts as a relay station (Klein et al., 1983), after which the
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neural pathways convey the signal to the superior cervical ganglion (SCG). This pathway as 
well as the synthetic pathway for production of melatonin is shown in Figure 1.1.
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Figure 1.1: Neural and biochemical pathways controlling melatonin production. Adapted from Arendt, 
1998. NA = noradrenaline, SCG = Superior cervical ganglion, PVN = paraventricular nucleus, NAT = 
N-acetyltransferase, HIOMT = Hydroxyindole-O-methyltransferase.
1.3.2 Melatonin Receptors
Melatonin binding sites have been identified in many tissues (see Dubocovich et al., 2003 for 
a review). These tissues include various parts o f the brain including the SCN and the pituitary 
gland, the spleen, spermatozoa, ovaries, testis, and kidney.
There are two melatonin receptor subtypes, MTj and MT2, found in humans. These two 
receptors show 60% homology at the amino acid level and are encoded by separate genes 
(Reppert et al., 1995).
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The MTi receptors are membrane bound high affinity G-protein coupled receptors. The 
localisation of these receptors varies within species. In mammals they can be found in the pars 
tuberalis, the SCN, the retina, the PVN and peripheral tissues. The function of the receptors is 
thought to depend on its locality. The receptors in the SCN are likely to mediate circadian 
effects of melatonin, whereas the receptors in peripheral tissues such as the cerebral and 
caudal arteries are thought to play a part in thermoregulation.
The MT2 receptors are also membrane bound G-protein coupled receptors. Activation of the 
MT2 melatonin receptor signalling through protein kinase C mediates the phase shifting 
effects of melatonin in Long Evans rats (Hunt et al., 2001) and C3H/HeN mice (Dubocovich 
etal., 1998).
1.3.3 Effect of Light on the Melatonin Rhythm
The synthesis of melatonin is acutely suppressed by light. Light-induced suppression of 
nocturnal melatonin is used as an indicator that light input mechanisms to the circadian 
system and pineal gland are intact. Melatonin suppression requires light of less intensity than 
needed to produce a phase shift, in subjects under entrained conditions (Hashimoto et al.,
1996). This has led to the suggestion that there are two different mechanisms underlying the 
two different effects of light on melatonin rhythms.
The results of Campbell and Murphy (1998) showing extraocular light phase shifted CBT and 
salivary melatonin triggered other groups to study the effect of extraocular light. These 
studies found that extraocular light exposure did not suppress nighttime melatonin secretion 
(Lockley et al., 1998; Hebert et al., 1999; Lindbolm et al., 2000; Wright and Czeisler, 2002). 
Different wavelengths of light have an effect on the amount of melatonin suppression 
(Brainard et al., 2001; Thapan et al., 2001). Light induced melatonin suppression was studied 
with monochromatic wavelengths of light from 420-600 nm. Brainard and colleagues 
identified 446-477 nm, whereas Thapan and colleagues identified 457-462 nm to be the most
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potent wavelength for inducing suppression. Both studies concluded that it supported a 
principal role for a novel short-wavelength photopigment, which was neither a rod nor cone, 
in light-induced melatonin suppression. Similarly, recent studies have shown that short 
wavelengths of light are not entirely responsible for phase advancing effects of light (Warman 
et al., 2003; Lockley et al., 2003).
1,4 Circadian Rhythms in the Blind
1.4.1 Classification of Circadian Rhythms in the Blind
Different secretory patterns were first identified in the plasma cortisol (Orth et al., 1979) and 
melatonin rhythms (Smith et al. 1981) more than 20 years ago. If a blind subjects’ melatonin 
onsets were stable and occurred at a normal phase, then they are said to be normally entrained 
to 24 hours, and if melatonin onsets were stable but occur at an atypical phase then they are 
said to be abnormally entrained to 24 hours (showing similar symptoms in sighted humans as 
advance and delayed sleep phase syndrome; ASPS and DSPS). The most common type of 
phase abnormality in totally blind subjects with no light perception (NPL) is free-running 
rhythms, that is the circadian rhythms run at a period different from, and usually greater than, 
24 hours. The rhythm can also be called unclassified when it has no distinct pattern.
Miles et al., (1977) reported one of the first blind free-running subjects. A young man was 
found to have a free-running rhythm of 24.9 hours that could not be entrained with a strict 
sleep-wake cycle. At the time it was thought that there was a lunar link, due to the lunar day 
being 24.84 hours, and the coincidence between sleep onset and a local low tide.
The amount of light perceived determines the type of circadian rhythm abnormality (Lockley 
et al., 1997a). Most blind people with light perception were shown to have normally entrained 
aMT6s rhythms, whereas free-running rhythms were normally only observed in blind people 
with no light perception (Lockley et al., 1997a; Skene et al., 1999b). This means that the daily 
rhythms of the majority of totally blind people are not entrained to a normal 24-hour day, and
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instead they free-run. Unilaterally or bilaterally enucleated individuals within the NPL group 
had a higher incidence of circadian aMT6s abnormalities compared to those with intact eyes 
(Lockley et al., 1997a).
Some blind subjects with no light perception may have either normally or abnormally 
entrained rhythms (Lockley et al., 1997a). Abnormally entrained and normally entrained 
subjects may somehow still receive photic input to the SCN (Czeisler et a l, 1995). For 
example they may have an intact and functional RHT. The integrity of the RHT is essential 
for appropriate synchronisation of circadian rhythms to the 24-hour clock by light. Visual 
blindness caused by retinal destruction or an interruption of the RHT can affect the 
entrainment of circadian rhythms in humans. This entrainment is lost when bilateral 
transection of the optic nerve or the RHT occurs, but remains intact after bilateral transection 
of the primary optic tract. Alternatively, the subjects may have circadian periods close to 24 
hours so that a free-running period may not be distinguishable from 24 hours unless the 
subjects are studied over a very long period of time.
Free-running rhythms in the blind have circadian periods similar to those of sighted people 
living in temporal isolation. Therefore it is plausible to predict that their rhythms reflect the 
endogenous period that is no longer entrained to environmental time cues. Sleep times and 
social time cues appear to have little effect on the free-running melatonin rhythm (Sack et al., 
1992), which can stay stable over a number of months. Free-running plasma cortisol levels 
were first identified in a blind person in 1979 (Orth et al.,). Plasma cortisol data from some 
free-running blind subjects show that the rhythm is phase-locked with the melatonin rhythm 
(Sack et al., 1992), suggesting that they are driven by a common oscillator. It has also been 
shown that sleep propensity runs in parallel with melatonin in free-running subjects (Sack and 
Lewy, 1997; Lockley et al., 2002).
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The duration of melatonin secretion in totally blind people is the same for that in sighted 
people (Klerman et ah, 2001). It was thought that the duration of melatonin secretion would 
be longer in blind people because they had been exposed to a long period in the dark. 
However, as the secretion periods were similar to those of sighted people it is thought that 
prolonged absence of light exposure has little influence on the duration of melatonin 
secretion.
Free-running circadian rhythms can also sometimes seen in sighted people. Again, CBT has 
been shown to correlate well with plasma DLMO in sighted subjects with non-24 sleep-wake 
syndrome (Shibui et ah, 1998).
1.4.2 Sleep in the Blind
The best indication of whether a blind person has abnormal circadian rhythms is a disturbed 
sleep-wake cycle (Arendt et ah, 1988, Aldhous and Arendt, 1991; Lockley et ah, 1997b; 
1999). Blind subjects with normally entrained rhythms have significantly fewer naps of a 
shorter duration than subjects that are abnormally entrained or free-running (Lockley et ah, 
1997b; Skene et ah, 1999b). When the free-running cycle passes out of phase with the desired 
sleep time, the most common symptoms that occur are night-time disturbances in sleep and 
daytime napping (Lockley et ah, 1997b).
An epidemiological study was undertaken to see if there was any relationship between the 
severity of sleep disorder and the subjects’ visual pathology (Lockley et ah, 1997a; Tabandeh 
et ah, 1998). It was found that the relationship between the different visual groups (NPL, light 
perception (LP) and sighted) and sleep abnormality, scored by the Pittsburgh Sleep Quality 
Index (PSQI), was significant in that people with NPL had a higher incidence and more 
severe sleep disturbances than LP subjects (Tabandeh et ah, 1998). There was no significant 
difference in the PSQI scores in relation to congenital versus acquired blindness, the type of 
field loss, or the duration and rapidity of visual loss.
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Sleep quality and its relationship with melatonin secretion was investigated in a study of blind 
children (Tzischinsky et ah, 1991). Nine of the children had congenital retrolentalfibrosis, one 
had glaucoma and one suffered an optic tract tumour. It was found that delayed secretory 
peaks in melatonin were significantly associated with disturbed sleep and an increase in 
napping and fatigue during the day.
Sleep onset time and duration show a significant relationship with aMT6s phase in entrained 
blind subjects (Lockley et ah, 1999). When the aMT6s rhythm is advanced then sleep onset is 
advanced, when the aMT6s rhythm is delayed then sleep onset is delayed. In free-running 
subjects there is a significant change in sleep offset with aMT6s acrophase. The duration of 
daytime naps and night sleep also changed in relation to the changes in aMT6s phase. The 
number of daytime naps is at a maximum when the aMT6s rhythm is out of phase and 
minimum when in phase. Night sleep duration is reduced when the aMT6s rhythm is out of 
phase and greatest when it is in normal phase. The timing of naps also appears not to be 
random (Lockley et ah, 1999). Subjects with abnormally entrained aMT6s rhythms have 
significantly more naps within the 5-hours before and after the aMT6s peak.
Polysomnography in 26 free-running blind subjects showed that total sleep time, sleep 
efficiency and total REM sleep were significantly lowered compared to matched controls 
(Leger et ah, 2002).
1.4.3 Nonphotic Entrainment in the Blind
In humans photic stimuli are stronger at entraining circadian rhythms than nonphotic stimuli, 
although nonphotic time cues may be responsible for the entrainment of a blind person to a 
24-hour day.
Klerman et ah, (1998) have investigated a number of possibilities for entrainment in blind 
people that do not show light-induced melatonin suppression. These were photic
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synchronisation of the circadian clock despite absence of detectable light-induced melatonin 
suppression; an intrinsic period that free-runs but is very close to 24 hours; circadian 
synchronisation via extraocular receptors; and circadian synchronisation by nonphotic stimuli. 
It was shown that imposed schedules of sleep and activity were successful in entraining a 
single subject to a 24 hour day (Klerman et al., 1998; Klerman et al., 2002b). This is the first 
evidence of nonphotic entrainment in the blind.
In contrast to the human studies, behavioural nonphotic entrainment has been shown in 
various animal studies. For example, scheduled food availability has been shown to have a 
weak entraining effect on mice (Mistlberger, 1996), rats (Abe et al., 1989) and Syrian 
hamsters (Mistlberger, 1993). Effects of exercise on entrainment has been shown in hamsters 
(Mrosovsky and Salmon, 1987) and mice (Edgar and Dement, 1991). A phase response curve 
to activity in hamsters has also been reported (Reebs and Mrosovsky, 1989).
An early study to investigate the possible phase shifting effects of exercise in humans failed 
to show any conclusive results (Van Cauter et al., 1993). Three hours of physical activity 
were undertaken under constant routine conditions where the activity occurred either at CBT 
minimum or 3 hours before the CBT minimum. However, since then, exercise has been 
shown to phase shift melatonin in humans, and that the magnitude of the shift is dependent 
upon the time of day of the exercise (Buxton et al., 1997; Miyazaki et al., 2001). A study has 
recently shown that a single 3 hour episode of low intensity nocturnal exercise produced 
phase shifts of similar magnitudes in both young (20-32 years old) and old (55-73 years old) 
adults (Baehr et al., 2003).
The common feature in all of these nonphotic stimuli is that they are typically associated with 
arousal or increased activity. Although it is not known how nonphotic cues work, it is 
believed that the IGL is a necessary component in nonphotic entrainment of this type, as
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lesions of the IGL block the advancing effects of induced wheel running in hamsters 
(Wickland and Turek, 1994).
1.4.4 Non Visual Light Responses in the Blind
Photic input may still be able to synchronise the pacemaker in some blind individuals that 
have entrained rhythms. A way to test this would be to see if bright light suppresses their 
melatonin.
Some blind subjects who have no pupillary reflexes have demonstrated light-induced 
melatonin suppression (Czeisler et al., 1995). Melatonin suppression testing in the blind can 
provide information about the functional integrity of the neuroanatomic pathways linking the 
retina to the pineal. All of the subjects in the Czeisler study had no perception of light. 
However, only three of the eleven subjects showed melatonin suppression and these subjects 
were all normally entrained. Light-induced suppression of melatonin has also been shown in 7 
out of 7 blind people in a study by Hatonen et al., (1998). The average post light melatonin 
levels for the blind subjects were suppressed by 51%. Also, light has been shown to phase 
shift the circadian rhythms of 2 totally blind people who have no pupillary reflexes and do not 
show light induced melatonin suppression (Klerman et al., 2002b). Both phase advances and 
delays were seen in three subjects in response to bright light.
In contrast our group has failed to show light-induced melatonin suppression in blind NPL 
subjects (Lockley et al., unpublished data). Nine abnormally entrained and normally entrained 
blind NPL subjects were exposed to broad spectrum white light (700-11000 lux, 420-7200 
pW/cm2) for 30 to 60 minutes. None of the subjects showed light-induced melatonin 
suppression. Seventeen totally blind subjects, 8 of whom were entrained, 7 free-running and 2 
unclassified, who had previously failed to show light induced melatonin suppression, also 
showed an absence of an increase of the duration of melatonin production that was expected 
due to no light input representing a ‘short day’ (Klerman et al., 2001).
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Unlike evidence from sighted humans (Eastman, 1990), this latest data suggests that attempts 
to use light treatment to correct the disrupted circadian rhythms of the blind and stabilise them 
to a normal 24 h day would be unsuccessful.
1.4.5 Blind Subjects as Models
In circadian rhythm research, isolation from natural and man-made time cues is necessaiy to 
observe independent endogenous rhythms. Temporal isolation is relatively easy to accomplish 
in animal work, but in humans the facilities are expensive and the lengthy experiments 
inconvenient to the subject. In free-running blind subjects, however, the effects of sleep and 
activity can be averaged out and the underlying rhythms unmasked. Also, the free-running 
rhythms and sleep-wake cycle occur in a predictable way, without the influences of the light- 
dark cycle.
1.5 Exogenous Melatonin Administration
1.5.1 Acute Effects of Melatonin Administration
1.5.1.1 Effect on the Endogenous Melatonin Rhythm
The amplitude of endogenous melatonin secretion is not affected by administration of 
exogenous melatonin in humans (Matsumoto et al., 1997). In the Matsumoto study a blind 
subject was given 50 mg melatonin daily at bedtime for 37 days and although a phase shift 
was seen, the amplitude of the endogenous melatonin rhythm remained unaltered.
1.5.1.2 Effect on Sleep
The timing of human sleep coincides with the period of melatonin secretion from the pineal 
gland. Melatonin can stabilise sleep to a 24-hour rhythm in some free-running blind subjects 
and can improve sleep in subjects that are abnormally entrained (Arendt et al., 1997). In a 
blind man with free-running circadian rhythms who was given 5 mg melatonin for 31 days, 
the most pronounced effect of melatonin was the elimination of daytime naps and stabilisation
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of sleep onset times (Folkard et al., 1990). The subjective ratings of mood assessment also 
improved. However, the CBT and urinary cortisol rhythms continued to free-run. Lockley et 
al., (unpublished data) have shown that the sleep wake cycle does not entrain in blind subjects 
when their cortisol rhythms free-run during 5 mg melatonin treatment. These results suggest 
that melatonin has soporific effects on sleep independent of its affect on the circadian 
oscillator. This points to the importance of melatonin being used as a chronobiotic treatment 
timed to their individual circadian phase and not just as a sleeping aid taken at bedtime in 
free-running blind subjects.
Sleep propensity is also affected by melatonin administration in a time-dependent manner 
(Tzischinksy et al., 1992a). Unlike hypnotics, melatonin exerts its effects after a variable time 
delay which is dependent upon the time of administration. Melatonin administered at 1200 h 
considerably increased the mid afternoon sleepiness peak. Melatonin administered at 1700 h 
advanced the timing of the evening sleep onset. Melatonin may promote sleep by 
counteracting the daytime alertness process generated by the circadian system (Sack et al.,
1997).
There appears to be a dose dependent response to melatonin on sleep parameters (Dollins et 
al., 1994; Deacon and Arendt, 1995; Zhdanova et al., 1996). Treatments that result in 
pharmacological levels of circulating melatonin induce sleep and promote sleep onset in a non 
dose-dependent manner, whereas treatments that result in physiological levels demonstrate a 
dose dependency of the soporific effect. A dose of 1.0 mg melatonin, but not 0.3 mg, was 
shown to increase sleep efficiency and total sleep time (Attenburrow et al., 1996a).
Melatonin exerts effects on the main characteristics of human sleep (Dijk and Cajochen,
1997). Administration of melatonin during the daytime increases sleep propensity. After 
melatonin administration the EEG during daytime sleep exhibits features similar to the 
nocturnal sleep EEG in that there is increased spindle activity and reduced slow wave sleep
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activity. Unlike some hypnotics, melatonin does not inhibit REM sleep (Zhdanova et al., 
1996). Administration of 5 mg or higher prior to nocturnal sleep results in an increase in REM 
sleep (Cajochen et al., 1997), as well as reduce the latency to the first REM episode 
(Cajochen et al., 1998). Melatonin (5 mg) administered immediately before daytime sleep 
after partial sleep deprivation did not significantly affect nonREM sleep stages or REM 
duration. However, changes in EEG activity and power density similar to those seen with 
benzodiazpenes were observed. A 6 mg dose of melatonin showed similar effects to 0.125 mg 
triazolam on sleep architecture when given at 1330 h (Satomura et al., 2001).
When given in the evening melatonin can reduce sleep latency, increase sleep efficiency 
(Attenborrow et al., 1996a) and can affect the EEG. A 1 and 5 mg dose of orally administered 
melatonin at 2245 h did not affect the sleep architecture, or mood and alertness on the day 
following administration (James et al., 1987). However, at doses of 1.0 mg (Attenburrow et 
al., 1996a) and 5 mg (James et al., 1987) an increase in REM latency can be seen. Another 
study (Montes et al., 2003) found no difference between the effects of placebo and two doses 
of melatonin (0.3 and 1.0 mg) on EEG in subjects with primary insomnia. These results are 
contradictory and have led to the conclusion that at these low doses melatonin is not effective 
as a sedative (Stone et al., 2000).
The sleep promoting effects of melatonin are likely to be due to an acute modulation of the 
sleep-promoting processes and the ability of melatonin to phase shift the underlying circadian 
pacemaker. The mechanisms of melatonins hypnotic actions remain unclear, although it has 
been shown that they are not mediated by benzodiazepine or cannabinoid receptors (Sugden, 
1995).
A number of studies have been conducted to determine the efficacy of melatonin as a 
hypnotic in normal subjects and subjects with sleep disorders that are not circadian in origin 
(see Mendelson, 1997; and Wirz-Justice and Armstrong, 1996 for reviews). From these
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studies, the majority of subjects did not report a subjective improvement in sleep, and the 
majority of improvements seen in sleep parameters were that of reduced sleep latency. 
Therefore it is thought that its usefulness as a general hypnotic is somewhat limited as not all 
sleep complaints result from an inability to get to sleep.
Sleep quality in older people is known to deteriorate (Foley et al., 1995). Fast release 
melatonin (5 mg) did not improve the quality of sleep in older subjects with age-related sleep 
maintenance problems (Baskett et al., 2003). Some patients who have insomnia have been 
shown to have decreased melatonin secretion (Haimov et al., 1994; Attenburrow et al., 
1996b). However, in the study by Baskett and colleagues (2003), there was no difference in 
the way low and high secretors of endogenous melatonin responded to the treatment, 
indicating that a reduction in melatonin levels is not the main cause of the sleep problems.
Melatonin also has effects on neurobehavioural performance. A pharmacological dose of 
melatonin (5-80 mg) administered during the daytime significantly decreased performance 
and reaction times compared to placebo (Lieberman et al., 1984; Dollins et al., 1993; Rogers 
et al., 1998). The profile of these performance decrements closely corresponded to the profile 
of salivary melatonin levels.
1.5.1.3 Effects on Core Body Temperature
Melatonin can induce a significant suppression and reduced alertness of CBT 2.5 h after the 
dose at 1700 h (Cagnacci et al., 1992; Deacon et al., 1994). The mechanisms through which 
exogenous melatonin administration decreases CBT are unclear and there are several theories 
to explain it (see Cagnacci et al., 1997 for a review). It is likely that the effect of melatonin to 
reduce CBT is exerted in the hypothalamus, where thermoregulatory centres are found.
Administration of melatonin during the day decreased CBT by about 0.3 to 0.4 °C, and during 
light-induced melatonin suppression at night, the CBT increases by roughly the same
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magnitude. Melatonin administration at 1300 h can induce a sharp increase in foot 
temperature with a decrease in CBT, as well as inducing sleepiness (Krauchi et al., 1997)..
1.5.2 Effects of Exogenous Melatonin on Phase Shifting Circadian Rhythms 
Arendt et al., (1985) were the first to describe the phase shifting effects of melatonin in 
humans after giving daily 2 mg doses at 1700 h for 4 weeks in the spring or 3 weeks in the 
autumn. Five of the twelve subjects showed a 1-3 hour phase advance in their endogenous 
plasma melatonin rhythms.
The degree of phase shift in the endogenous melatonin rhythm is reported to correlate with 
the amount of temperature suppression, suggesting that it may be an important part of the 
phase shifting mechanism. A dose-response relationship between melatonin-induced 
temperature suppression and the degree of phase shift of the endogenous melatonin was also 
evident (Deacon and Arendt, 1995).
A study to investigate the short term effects of melatonin treatment (8 mg at 2200 h for four 
days) in sighted people (Mallo et al., 1988) showed that there was a progressive phase shift of 
the plasma melatonin and prolactin rhythm, which was significant on the third day after 
withdrawal of treatment. No changes in the plasma cortisol levels or rhythms were observed 
which was unexpected as most studies concur that melatonin and cortisol rhythms are phase 
locked and are possibly driven by the same oscillator. This was also the first study to 
demonstrate statistically significant phase advancing effects of melatonin in sighted people.
Phase advances in the endogenous melatonin rhythm can be seen when melatonin is 
administered in the late subjective day, just before the onset of endogenous melatonin 
production (circadian time (CT) 6-18).
Phase shifts using 0.5 mg of melatonin have been shown to be almost as great as those 
induced by 5 mg (Sack et al., 1991) suggesting that even lower doses of melatonin are
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capable of phase shifting. The dose-response curve (Deacon and Arendt, 1995) shows a log- 
linear relationship between the dose of melatonin and the magnitude of phase shift in DLMO 
for doses of 0.05, 0.5 and 5.0 mg melatonin. It was also shown that a measurable phase shift 
occurs 1 day after a single dose.
Phase shifts induced by exogenous melatonin also occur in the blind (Sack et al., 1991), 
providing a useful tool to help stabilise sleep times to a normal pattern. Using a dose of 5 mg 
melatonin administered daily at 2200 h for 3 weeks to blind subjects, Sack et al., (1991) 
showed phase shifts of about 24 minutes per day. The phase shifts observed were more 
prominent in blind than in sighted individuals (Sack et al., 1991). This finding may be 
because there is competition from the effects of light exposure in sighted people.
Phase delays following exogenous melatonin administration are less well documented in 
humans than phase advances. The only evidence comes from the various phase response 
curves (PRC) (Lewy et al., 1992; Zaidan et a l, 1994; Middleton et a l, 1997; Lewy et a l,
1998). Recently evidence to suggest that phase delays following a single dose of melatonin 
may not even occur has been presented by Wirz-Justice et a l, (2000; 2002). Melatonin (5 mg) 
given at 0700 h failed to show a phase shift in dim light melatonin onset or offset, or in heart 
rate or skin temperature rhythms in 9 sighted males. The rise in CBT occurred earlier and 
declined later following melatonin administration producing a longer peak duration, but this 
could not be interpreted as a straightforward phase delay. In other mammals the data also is 
inconclusive. A single exposure of melatonin to rat SCN slices in vitro failed to produce 
phase delays in the SCN electrical activity rhythm when given at different circadian times 
(McArthur et a l, 1991). However, a single dose of melatonin given between CT22 and CT2 
caused delays in the activity rhythms of 5 out of 19 mice (Benloucif and Dubocovich, 1996). 
When the mice were given melatonin for 3 consecutive days, delays were induced in 60% of 
the mice. It may be that the opportunity during which melatonin can produce phase delays is
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in a narrow window and that by using repeated administration it is more likely to hit that 
window. More studies are needed in this area.
1.5.3 The Phase Response Curve for Melatonin
Like the light PRC, the melatonin PRC has important clinical applications, and melatonin 
may one day replace light as the treatment of choice for some circadian phase disorders. 
Exogenous melatonin can produce phase delays and phase advances as explained in the 
previous section (1.5.2). Figure 1.2 shows the constructed PRC for melatonin based on these 
phase shifts (Lewy et al., 1998). Timing of melatonin administration to a particular circadian 
time is vital in determining the degree and direction of phase shift that occurs. A PRC can 
predict the amount of phase shift, and whether phase delays or phase advances are produced. 
This makes the PRC a useful tool in treating patients with abnormal circadian rhythms.
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Figure 1.2: The phase response curve (PRC) for melatonin. Different subjects are shown with different 
symbols. Taken from Lewy et ah, 1998
Exogenous melatonin can phase shift circadian rhythms in both sighted and blind individuals. 
To obtain a PRC for these shifts it is necessary to treat subjects in repeated trials at different 
times with respect to the individuals’ endogenous circadian rhythm.
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There are two types of PRCs, type 1 and type 0 which are demonstrated in Figure 1.3. Type 1 
exhibits relatively small phase shifts and shows a gradual crossover from phase delays to 
advances. Type 0 shows larger shifts and the transition from phase delay to phase advance (or 
vice versa) is sudden and does not involve a gradual crossover. The terms type 1 and type 0 
refer to the average slope of the curve when plotted as new phase versus initial phase (phase 
transition curve). Whether a type 1 or type 0 PRC is exhibited largely depends on the strength 
of the stimulus, for example increasing drug dosage can convert a type 1 PRC to a type 0 
PRC. The melatonin PRC established by Lewy et al., (1998) in sighted subjects is a type 1 
PRC.
Type 0 PRC
Circadian time (hrs) Circadian time (hrs)
Figure 13: Type 1 and type 0 PRCs. - refers to a delay, + to an advance. Adapted from Johnson, 1999. 
Phase response curves can be determined by a number of methods (Aschoff, 1965) which are 
listed below.
1. The stimulus is applied while the oscillator is free-running in constant darkness (DD)
2. The stimulus is applied in DD a short while after being in a light dark cycle (LD)
3. The stimulus is a step from one condition to the other (DD to LL or vice versa)
4. The stimulus is applied repeatedly (e.g. daily) whilst in DD
5. The stimulus is applied after a transition of LD to LL
6. The stimulus is applied whilst in LD
The first on the list is considered to be the classical way of conducting phase shifting 
experiments and construction of a PRC (Aschoff, 1965). The range of the curve (the 
difference between the maximal delay and advance) determines the range of entrainment.
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In the following section there is a brief description of the melatonin PRC studies that have 
been carried out to date. These studies are also summarised in Table 1.1.
Lewy et al., (1991; 1992) were the first to establish a melatonin PRC in human subjects. Nine 
sighted subjects kept a constant sleep-wake schedule in a trial that ran for 2 weeks. Melatonin 
onset was determined on the 7th day of each week. The subjects were administered placebo for 
the first six days of the first week and the second two days of the second week. During the last 
4 days of the second week, 0.5 mg melatonin was administered. There were 30 trials in total 
and administration of clock time was varied in each. Placebo or melatonin was taken in split 
doses of 0.25 mg each, 2 h apart for the first 27 trials. The split dose was designed to mimic a 
sustained-release formulation that would have resulted in a longer duration melatonin signal. 
One single dose of 0.5 mg melatonin was used in the later trials and it was reported that the 
split dose was not necessary. Subjects avoided light exposure of >50 lux for at least 1-2 h 
before melatonin onset and during the blood sampling for the plasma melatonin 
measurements. They found that the amount of phase shift of the endogenous melatonin 
plasma rhythm was proportional to the time interval between exogenous melatonin 
administration and the individuals’ DLMO, providing the time of administration was less than 
six hours prior to the endogenous melatonin onset. Phase advances occurred between CT5 and 
CT12 with maximal advances occurring when melatonin was administered at about CT 8 (six 
hours before endogenous melatonin onset). Between CT12 and CT18 there was a “dead zone” 
where no phase shift was seen, and between CT19 and CT5 delay responses of up to 90 
minutes occurred.
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Zaidan et al., (1994) studied 7 sighted subjects who were also kept under a constant sleep- 
wake schedule where day time naps were forbidden. Three-hour i.v. infusions of melatonin 
(20 pg) were given at different times of the day -  starting at 0400 h, 1200 h, 1600 h and 2000 
h. Light levels were kept below 150 lux during sampling sessions, and below 5 lux during the 
night. The starting time of the infusion was randomly distributed and the infusions were given 
at weekly intervals. Control sessions were also included using saline infusions. Plasma 
cortisol and melatonin concentrations were determined and results showed a phase advance in 
the endogenous melatonin rhythm when infusions began in the late afternoon/early evening 
and a phase delay when given in the early morning/noon. Phase shifts were seen within the 
first 24 hours suggesting that the phase shifting effect of melatonin is almost immediate. The 
constructed PRC showed a good similarity with those constructed by Lewy’s group 
(1991;1992), although Zaidan and co-authors’ PRC showed greater phase advances with an 
evening dose of melatonin rather than a dose in the afternoon. This difference may be because 
the afternoon infusion would not have combined with the endogenous melatonin onset. 
Surprisingly there were no phase shifts observed in the cortisol rhythm. It is important to 
phase shift the entire circadian system so that it is synchronised.
Middleton et al., (1997) conducted a study with 10 sighted subjects that were kept in constant 
dim light (<8 lux) for two periods of 30 days in order to establish free-running circadian 
rhythms. Subjects received either melatonin or placebo at 2000 h for 15 days in a randomised 
crossover design. After the first melatonin dose (5 mg) phase shifts were assessed in CBT and 
it was found that maximum phase advances occurred when the melatonin treatment was given 
2 hours after the temperature acrophase at CT12.
Lewy et al.} (1998) conducted another study to compare the melatonin PRC with the PRC for 
light. For the melatonin PRC six sighted individuals took part in a total of 12 trials each, 
where they kept a constant sleep-wake schedule. Light conditions were not controlled big 
problem but subjects noted sunlight/bright light exposure at half-hour intervals in a diary.
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Twelve data points approximately 2 hours apart were obtained for each individual. Placebo 
and melatonin capsules were administered at the same clock time for a given trial. For each 
trial the DLMO was obtained twice at weekly intervals, and a baseline DLMO was 
determined before a week of placebo treatment. The same two-week trials were completed as 
in both previous experiments. Results were very similar to the previously determined PRCs. 
The PRC for this is shown in Figure 1.1. It was found that phase advances occur between 
CT6-18 and phase delays occur between CT18-6.
The published melatonin PRC studies have limitations for a number of reasons. Sighted, 
entrained subjects in light/dark (LD) conditions have been used, whereas subjects in constant 
darkness with free-running rhythms would be preferable. Middleton et al., (1997) however, 
studied free-running subjects in constant dim light conditions (<8 lux) but they were sighted, 
and it could be argued that they were still experiencing a light dark cycle when they closed 
their eyes to sleep. In addition, the subjects had a self-selected sleep wake cycle (not constant) 
that in effect meant their light dark cycle was not maintained to the same regular hours.
1.5.3.1 Limitations of Current Melatonin PRCs
In totally blind subjects the phase shifting effects of melatonin are not confounded by light 
and these subjects are therefore the model of choice. Also, by using free-running subjects and 
giving melatonin at the same clock time in each leg of a study, melatonin will most likely be 
given in a different circadian phase. Another criticism about the Lewy studies (1991; 1992;
1998) is that melatonin was administered in multiple doses before calculating any change in 
phase. This repeated protocol gives a summation of phase shifts rather than a phase shift due 
to a single dose/pulse that is used in all classical PRCs. It is thus necessary to know the action 
of a single dose before drawing conclusions from the multiple dose data.
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1.5.4 Entrainment of Free-Running Circadian Rhythms bv Exogenous Melatonin
Entrainment is the setting of the period of the endogenous pacemaker to 24 hours. Stable 
entrainment is reached when the phase shift corrects the difference between the period and the 
zeitgeber cycle. An endogenous rhythm represents a self-sustained oscillation, and can only 
be entrained to frequencies that do not deviate too much from its natural rhythm. Anything 
beyond this is outside the range of entrainment and will cause the rhythm to free-run.
Entraining stimuli such as light or melatonin have different effects depending on the circadian 
time (CT) that they are received. Circadian time refers to the time in hours in relation to 
circadian phase. For example the acrophase of plasma melatonin is considered to occur at 
CT19. In animal studies Zeitgeber time (ZT) is used in studies with light and dark conditions 
(lights on, ZTO, and lights off, ZT12), and circadian time is used in studies with constant light 
conditions.
1.5.4.1 Animal Studies
Redman et al., (1983) were the first to demonstrate that melatonin could entrain free-running 
circadian rhythms. The free-running activity rhythms of rats were entrained by daily 
melatonin injections (1 mg/Kg) at 1530 h for at least 52 days. These authors showed that the 
timing of melatonin administration was crucial as entrainment only occurred when the onset 
of activity coincided with the melatonin injections.
Recently Slotten et al., (2002) have reported that the activity rhythms of the diurnal rodent 
Arvicanthis ansorgei can entrain to melatonin administration with both phase delaying and 
phase advancing stimuli. The tau range of the animals was 23.47 -24.42 h, animals with a tau 
of less than 24.0 h entrained by phase delay, and animals with a tau greater than 24. 0 h 
entrained by phase advance. Three animals had taus very close to 24.0 h and these animals 
entrained to both phase delaying and advancing stimuli. The animals became entrained by 
phase advance when melatonin administration coincided with a time corresponding to the late
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subjective day. Entrainment by phase delay occurred when melatonin was administered in the 
early subjective day. In contrast to the blind study of Lockley et al., (2000), there was no link 
between the circadian time at which melatonin treatment started and whether the animal 
entrained or not.
There is a differential effect on entrainment if melatonin is administered by infusion for 
different durations (Pitrosky et al., 1999). Melatonin infusions were given to free-running rats 
for 1, 8 or 16 hours. With the 1 and 8 hour infusion, 94% of rats entrained, whereas only 42% 
of rats entrained with the 16 hour infusion. In addition, once the rats became entrained the 
PAE between the onset of infusion and the onset of activity or acrophase of body temperature 
increased with the duration of infusion. There was also an effect of melatonin on the free- 
running periods of the rats in that the period lengthened before entrainment occurred.
1.5.4.2 Human Studies
The results of previous investigations of the ability of melatonin to entrain a desynchronised 
circadian system in sighted humans remain ambiguous. Exogenous melatonin (5 mg) 
appeared to stabilise (but not necessarily entrain) sleep-wake cycles but failed to entrain CBT 
rhythms consistently in sighted humans when administered daily for 16 days (Middleton et 
al., 1997). In some subjects a shortening of the CBT rhythm rather than entrainment occurred. 
The 24 h period of the sleep-wake cycle in the presence of a non-entrained circadian system 
suggests that melatonin’s soporific properties may account for the apparent stabilisation of 
sleep in this study. A similar observation was made in a free-running totally blind man, who 
demonstrated stabilisation of the sleep-wake cycle during melatonin treatment, whilst his 
underlying circadian rhythms of cortisol and CBT continued to free-run with an unchanged 
period (Arendt et al., 1988; Folkard et al., 1990).
Later attempts to correct sleep disorders in free-running blind subjects resulted in an apparent 
improvement in sleep with either no entrainment or a shortening of the period of endogenous
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circadian rhythms (Aldhous and Arendt, 1991; Sack et al., 1991; Lapierre and Dumont, 1995; 
Jan and O’Donnell, 1996; Arendt et al., 1997; Palm et al., 1997; Sack and Lewy, 1997).
Sack et al., (1991) reported that melatonin administration for 21 days was insufficient to 
entrain blind subjects with free-running rhythms. Other previous attempts at entraining free- 
running blind people with daily melatonin administration (5 mg) had also failed (reviewed by 
Sack and Lewy, 1997). There was clear evidence of phase shifting but it was assumed that 
entrainment of free-running rhythms could not easily be achieved. It was thought that subjects 
with a long circadian period may not have been able to entrain with melatonin at these doses.
Evidence of melatonin successfully entraining free-running circadian rhythms in the blind has 
only been shown recently (Lockley et al., 2000; Sack et al., 2000; Lewy et al., 2001a; Lewy 
et al., 2002). In the first study by Lockley, melatonin (5 mg) was administered daily for an 
entire beat cycle at 2100 h. Four of the seven NPL blind subjects demonstrated a shortened 
cortisol tau that was indistinguishable from entrainment. Three of these subjects had a free- 
running tau greater than 24.4 h dismissing the previous idea (Sack and Lewy, 1997) that 
individuals with long taus are not entrainable with 5 mg melatonin. The three subjects that 
were not entrained in the Lockley study began the melatonin treatment at a circadian time that 
was in the delay portion of the melatonin PRC (CT18-6). These findings suggested that 
entrainment might depend upon the circadian time at which the melatonin treatment starts.
If period is greater than 24.0 h then the subject would need to advance daily to maintain 
entrainment. Sack et al., (2000) reported that three subjects who initially entrained with a 10 
mg dose, continued to be entrained when the dose was lowered step wise to a final dose of 0.5 
mg. The latest study by Lewy et al., (2001a) shows entrainment in the same three subjects 
who started with a lower dose of 0.5 mg melatonin, concluding that a lower dose does not 
only maintain entrainment but can also entrain free-running rhythms. The question of which 
dose of melatonin is most effective is often asked. Recently, Lewy and colleagues (2002)
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reported that an individual with a long period (24.9 h) who did not entrain to 10 mg or 20 mg 
melatonin but did entrain when administered 0.5 mg. The long endogenous period of this 
individual and the apparent inverse dose-response suggests that there are complex interactions 
between dose, and an individual’s period, PRC and the limits of entrainment to melatonin. 
The length of melatonin treatment may also play a role in whether or not the subject entrains.
The lack of concordance between the magnitude of phase shifting reported in the melatonin 
PRC data (up to ~1.5 hours advance and delay) and the daily advance required to entrain most 
free-running blind people (<1 hour/day), remains unresolved. Possible explanations include 
dose and/or duration of melatonin treatment, individual PRC characteristics, individual 
differences in melatonin pharmacokinetics, or melatonin receptor number or sensitivity, 
although these have yet to be investigated systematically.
It is unsure what the effective dose of melatonin to capture free-running rhythms and sustain 
entrainment is. Even a dose of 0.5 mg melatonin, which has recently been shown to entrain 
three free-running blind subjects (Lewy et a l, 2001a), is considered to be a pharmacological 
dose. However, care needs to be taken when stating what are physiological levels of 
melatonin, due to melatonin concentrations being different in different body tissues and fluids 
(Reiter and Tan, 2003). An example of this is that melatonin concentrations in the 
cerebrospinal fluid is 20 times higher than in plasma (Skinner and Malpaux, 1999).
It is important to administer melatonin at the correct circadian time in order to achieve the 
appropriate phase shift response, i.e. a phase delay or advance of the circadian clock and its 
output. A PRC can predict the degree of phase shift, and whether phase delays or phase 
advances will be produced, when melatonin is given at a particular circadian time. This 
makes melatonin useful in treating patients with abnormal circadian rhythms such as the 
blind. Tzischinsky et al., (1992b) tried to treat a blind adolescent boy with melatonin to
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stabilise his sleep-wake patterns, and were only successful when they applied the melatonin 
PRC to the timing of initial administration.
Lewy et al., (2001b) report that in free-running blind subjects with periods of less than 24.6 h, 
the tau can predict the steady state phase angle of entrainment (PAE) to melatonin. The 
crossover time between delays and advances of the PRC is 8 hours before the 10 pg/ml 
threshold for the DLMO. Therefore if the PAE between the time of melatonin administration 
and the DLMO is greater than 8 hours then the melatonin dose would be in the delay portion 
of the PRC which would mean entrainment could not occur. This is shown in Figure 1.4. It is 
important however to take care that melatonin administration is given at the correct clock time 
to ensure that entrainment occurs at the correct phase.
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Figure 1.4: The pre treatment period predicts the phase PAE, indicating that entrainment with 10 mg 
melatonin will fail if the PAE is more than 8 hours (Adapted from Lewy et al., 2001b).
1.5.5 Toxicology of Melatonin
Very few side effects have been reported from taking oral melatonin. These include 
sleepiness, headache, nausea and feeling dizzy. In order to capture and entrain a blind 
person’s free-running rhythm it is necessary for them to take melatonin every day, and hence
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there is the question of toxicology and safety in the long-term use of melatonin. Adverse side 
effects could affect the central nervous system, the cardiovascular system, glucose 
metabolism, fertility, immunology and cancer (Guardiola-Lemaiatre, 1996). No withdrawal or 
long-term side effects (assessed by blood haematology and biochemistry) were noted in a 
blind man who had been taking melatonin for 9 years (Arendt, 1997), however, this man was 
of an age where he did not want any more children so effects upon fertility could not be 
commented on. In a recent study (Luboshitzky et al., 2002) two out of eight men experienced 
a decrease in sperm concentration and motility whilst taking 3 mg melatonin for 6 months. 
One of these men still had these differences 6 months after treatment had ceased. Another 
study has also shown that melatonin is not mutagenic (Neville et al., 1989).
1.6 Aims
The aims of the present studies were to further define the properties of melatonin as both a 
phase shifting and an entraining agent in blind subjects. Specifically these were to look at the 
entraining effects of 0.5 mg melatonin on the cortisol rhythm and its acute effects on the 
sleep-wake cycle in an abnormally entrained blind subject (Chapter 3), and blind free-running 
subjects (Chapter 4). Studies were also designed to assess whether a single dose of melatonin 
(5 mg) can shift the phase of circadian rhythms (melatonin, cortisol) in free-running blind 
subjects (Chapters 5 and 6). Eventual aims of the latter experiment are to establish a PRC for 
melatonin in free-running blind subjects.
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2.0 Methods
2.1 Introduction
This chapter describes the generic methods that have been used in the protocols. Methods of 
analysis that are specific to a particular protocol have been included in their relevant chapter.
2.2 Pre-Studv Measurements
All subjects completed a pre-study questionnaire on general health to establish any health 
problems, cause and details of blindness, and medication that may affect the circadian clock 
in general or specifically the melatonin rhythm. The Pittsburgh Sleep Quality Index (PSQI) 
(Buysse et a l, 1989) and a general sleep and health questionnaire (devised by Dr H. 
Tabandeh; Appendix A) were completed to ascertain the severity and nature of their sleep 
complaints. The PSQI assesses sleep quality and disturbance during the previous month, with 
certain components such as sleep latency and total sleep time contributing to the final score 
(0-21), with a score of > 5 indicating a subjective sleep disorder.
In the studies using subjects with free-running circadian rhyhtms, a four week protocol was 
performed whereby the subjects kept daily sleep and nap diaries, and carried out weekly 
sequential urine collections for 48 hours prior to the study to confirm that the subject had free- 
running aMT6s rhythms.
2.3 Methods of Data Recording bv the Subjects
Subjects were provided with information about the studies in a way that was most convenient 
to them. The formats used were audiotape, floppy disk or via email. Subjects also recorded 
their data in these formats (either directly or by recording in Braille first and then 
transcribing) and sent them regularly to the University so that any mistakes or missing data 
could be quickly rectified. Data were then transcribed from these sources directly into Excel 
spreadsheets ready for analysis.
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2.4 Study Design
Information on each protocol (Chapters 3,4 and 5) can be found in the relevant chapter.
2.5 Data Collection
The three different study protocols used the same collection methods as are detailed below. 
Subjects were asked to record any times using the 24 hour clock.
2.5.1 Sleep and Nap Diaries
Subjects kept a daily sleep diary by answering the following questions in the morning 
immediately after waking up:
1. What is the date (please give the date on which you woke up on)?
2. What time did you go to bed?
3. What time did you start trying to fall asleep?
4. How long did it take you to fall asleep?
5. How many times did you wake up in the night? (Please try and give the exact times and 
duration you wake up for, for each wake period)
6. How many minutes sleep did you lose?
7. What time did you wake up?
8. What time did you get up?
9. Please rate your sleep quality on a 1 to 9 scale where 1 = the best sleep ever, 5 = neither 
the best nor worst sleep and 9 = the worst sleep ever.
Subjects also kept a daily nap diary, as shown below. Naps were defined as any sleep in 
periods outside their bedtime.
1. What is the date and time?
2. What time did the nap start?
3. What time did the nap end?
4. How long was the nap?
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2.5.2 Mood Scales
Subjects completed four mood scales at times defined by the protocol. Mood is rated on a 1 to 
9 scale. The numbers 1, 3, 5, 7 and 9 were defined but subjects were told to feel free to also 
use the even numbers in between. Subjects answered the following questions:
1. What is the date and time?
2. Please rate your alertness on a 1 to 9 scale.
Let 1 = very alert, 3 = alert, 5 = neither alert nor sleepy, 7 = sleepy and 9 = very sleepy.
3. Please rate your cheerfulness on a 1 to 9 scale.
Let 1 = very cheerful, 3 = cheerful, 5 = neither cheerful nor miserable, 7 = miserable 9 = 
very miserable.
4. Please rate your calmness on a 1 to 9 scale.
Let 1 -  very calm, 3 = calm, 5 = neither calm nor tense, 7 = tense and 9 = very tense.
5. Please rate your depression on a 1 to 9 scale.
Let 1 = very depressed, 3 = depressed, 5 = neither depressed nor elated, 7 = elated, 9 = 
very elated.
2.5.3 Urine Sampling
Subjects collected sequential four hourly urine samples (8 hourly overnight) during days 
defined by the protocol. Subjects collected urine samples into large plastic bottles. The weight 
of the urine and the bottle, and time of collection was recorded for each collection period. 
Weight was ascertained using speaking scales (Cobalt Systems Ltd., Reedham, Norfolk, UK). 
A 5 ml aliquot was then transferred into a plastic vial using a plastic Pasteur pipette and 
frozen at -20°C. The vials were posted at room temperature to the laboratory. The urine was 
aliquoted into smaller portions and these were refrozen prior to analysis of aMT6s and 
cortisol by radioimmunoassay (RIA) (see sections 2.6.1 and 2.6.2).
2.5.4 Blood Sampling
A trained nurse or phlebotomist fitted subjects with an indwelling cannula in the arm. Blood 
samples were collected at intervals as specified by the protocol. Immediately after collection 
into tubes containing lithium heparin to prevent coagulation, the tubes were gently inverted
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and then centrifuged (3000 rpm for 10 minutes). The plasma was removed and frozen (- 20 
°C) before assay by RIA for melatonin (see section 2.6.3).
2.5.5 Saliva Sampling
Saliva samples were collected into plastic vials or salivettes (Sarstedt Ltd, Leicester, UK) at 
times specified by the protocol. Samples were immediately frozen (- 20 °C) prior to melatonin 
assay by RIA (see section 2.6.4).
2.5.6 Core Body Temperature
Core body temperature was measured continuously (at five minute intervals) by rectal 
temperature probes attached to an ambulatory recording device (Squirrel Memory Loggers, 
Grant Data Loggers, Cambridge, UK) for the duration of the time as specified by the protocol. 
Subjects were able to remove the probes when showering and for defaecating. The data were 
downloaded using a software program (SQREM, Grant Data Loggers, Cambridge, UK) and 
imported into Excel spreadsheets for analysis.
2.5.7 Performance Tests
Subjects completed auditory serial reaction time tests (ASRT) at times defined by the 
protocol. If tests were completed at the same time as the mood scales (section 2.4.2) they 
were always carried out after the mood scale to prevent the performance test having any effect 
on mood. The tests were performed on a hand held Psion organiser (Psion Organiser n, 
Model LZ, Psion pic, London, UK). The test consists of four sounds which are an octave 
apart, presented in a random order, a total of 40 times each. Each of the four sounds 
corresponds to a button on the Psion and the subject was asked to press the correct button as 
quickly as possible. Parameters recorded for the test were reaction time and number of 
incorrect and correct responses for both the left and right hands. The data were downloaded 
onto a floppy disk and imported into Excel spreadsheets for analysis.
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2.5.8 Actigraphv
Ambulatory activity was measured continuously using wrist-worn activity monitors 
(Actigraphs, Ambulatory Monitoring Inc., USA; Actiwatches, Cambridge Neurotechnology 
Ltd, UK). Subjects were asked to remove the Actigraph/Actiwatch when it could get wet or 
damaged (e.g. bathing, washing up etc.), and the subject recorded any removals or excessive 
activity. The data were downloaded using computer software (Actigraphs: Action3, 
Ambulatory Monitoring Inc., USA; Actiwatches: Actiwatch Sleep Analysis, Cambridge 
Neurotechnology Ltd, UK) and imported into Excel spreadsheets for analysis.
2.6 Radioimmunoassay
The technique of RIA is based upon known amounts of radiolabelled antigen competing with 
unknown amounts of sample for a limited number of specific antibody binding sites. A 
standard curve with increasing amounts of known antigen is set up from which the unknown 
samples can be calculated.
2.6.1 aMT6s RIA
The RIA of aMT6s in human urine has been modified from Arendt et a l, (1985) to use an 
iodinated form of aMT6s (125I-aMT6s) (Aldhous and Arendt, 1988). A standard curve is 
constructed from aMT6s standards made up in charcoal stripped urine (aMT6s-free urine). 
The urine samples and quality controls (low, medium and high amounts of aMT6s) are diluted 
in tricine buffer (1:250 dilution) in duplicate. A specific aMT6s antiserum that has been raised 
in sheep (Stockgrand Ltd, UK; batch number G/S/l 118-23884; diluted in tricine buffer, 
1:20,000) is added to all tubes except the total and non-specific binding tubes and are 
incubated for 30 mins at room temperature. Trace amounts of 125I-aMT6s (100 pi containing 
approximately 8000 -  10,000 cpm) are then added to each tube and left to incubate for 15-18 
hours at 4 °C. The next day the free and antibody-bound fractions of aMT6s are separated by 
centrifugation (3500 ipm for 15 minutes at 4 °C) following addition of a dextran-coated
41
charcoal suspension. The supernatant is removed, and the pellet containing the free aMT6s 
fraction is counted in a gamma counter (Wallac 1470 Wizard automatic gamma counter, 
Wallac, Milton Keynes, UK). A software program (RIAcalc) produces the standard curve and 
from this calculates the quality contrail and unknown sample concentrations.
2.6.2 Urinary Cortisol RIA
This assay is adapted from an RIA for cortisol in human saliva (Riad-Fahmy et a l, 1979). A 
standard curve is constructed from standards (Sigma Ltd, UK) made up in cortisol-free urine. 
The urine samples and quality controls (low, medium and high amounts of urinary cortisol) 
are first extracted to remove any urinary compounds that may interfere with the RIA and give 
unreliable results. Samples and quality controls (500 pi) are added to 500 pi double glass 
distilled water in glass tubes, and then dichloromethane (5 ml) is added. All tubes are then 
vortexed for 30 mins, and the aqueous (upper) phase is removed. Aliquots of 100 pi are then 
allowed to evaporate in glass tubes in the fume cupboard (1.25 h) and are then reconstituted 
with 200 pi of phosphate-citrate buffer. A specific antiserum raised in sheep (sheep anti- 
cortisol-3-0-(carboxymethyl) oxime-bovine serum; Scottish Antiserum Production Unit, UK; 
diluted with phosphate-citrate buffer, 1:8000) and trace amounts (100 pi containing 
approximately 8000 -  10,000 cpm) of 125I-cortisol (cortisol-3-0-(carboxymethyl)-oximino- 
125iodohistamine; Amersham International, UK) were added to all tubes (in duplicate) except 
the totals and non-specific binding tubes and were incubated for 2 hours at room temperature. 
The free and antibody-bound fractions of cortisol are separated using a solid phase separation 
system (this uses a solid phase second antibody raised against sheep IgG (IDS, Bolden, UK) 
and a brij/saline wash solution). The free cortisol fraction is precipitated with the solid phase 
during centrifugation (2000 rpm for 15 minutes) and the radioactivity counted in a gamma 
counter (Wallac 1470 Wizard automatic gamma counter, Wallac, Milton Keynes, UK). A 
software program (RIAcalc) produces the standard curve and from this calculates the quality 
contrail and unknown sample concentrations.
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2.6.3 Plasma Melatonin RIA
The RIA for melatonin in human plasma was described by Fraser et al., (1983). A standard 
curve is constructed from melatonin standards (Sigma Ltd, UK) (0.5 ng/ml) made up in 
affinity stripped melatonin-free plasma. Duplicate plasma samples and quality controls (very 
low, low, medium and high amounts of melatonin in plasma) (500 pi) were aliquoted. A 
specific antiserum to melatonin raised in a sheep (Stockgrand Ltd, UK; batch number 
G/S/704-8483; diluted with tricine buffer, 1:4000) was added to all tubes except totals and 
non specific binding tubes and incubated for 30 minutes at room temperature. Trace amounts 
(100 pi containing approximately 4000 cpm) of tritiated melatonin (Amersham International, 
UK) are then added and left to incubate for 18 hours at 4 °C. The free and antibody-bound 
fractions of melatonin are separated using a dextran-coated charcoal suspension. The free 
melatonin fraction is precipitated with the charcoal pellet during centrifugation (1500 ipm for 
10 minutes at 4 °C). The radioactivity in the supernatant (the bound fraction) is decanted into 
scintillation vials containing scintillation fluid (toluene based, made by adding 12.5g 2,5- 
diphenyloxazole (PPO; Acros Organics, Geel, Belgium) and 0.75g dimethyl-POPOP 
(Lancaster Synthesis, Eastgate, UK) to 2.51 toluene; 4 ml), shaken for 1 hour and counted in a 
scintillation counter (Wallac 1409 scintillation counter, Wallac, Milton Keynes, UK). A 
software program (RIAcalc) produces the standard curve and from this calculates the quality 
contrail and unknown sample concentrations.
2.6.4 Salivary Melatonin RIA
The RIA of melatonin in human saliva uses an iodinated tracer and antiserum against 
melatonin conjugated at the 2 position (English et al., 1993). A standard curve is constructed 
from a melatonin standard stock solution. Duplicate saliva samples and quality controls (500 
pi) are aliquoted into tubes before adding a specific antiserum that has been raised in rabbits 
(Stockgrand Ltd, batch no AB/R/03; UK; diluted with tricine buffer, 1:30,000) and incubating 
for 30 mins at room temperature. Trace amounts (100 pi containing approximately 8000 -
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10,000 cpm) of 125I-melatonin (Amersham International, UK) are then added and left to 
incubate for 15-18 hours at 4°C. The next day the free and antibody-bound fractions of 
melatonin are separated using a solid phase separation system which uses a solid phase 
second antibody raised against rabbit IgG (IDS, Bolden, UK) and a brij/saline wash solution. 
The free melatonin fraction is precipitated with the solid phase during centrifugation (1500 
rpm for 10 minutes) and the radioactivity counted in a gamma counter (Wallac 1470 Wizard 
automatic gamma counter, Wallac, Milton Keynes, UK). A software program (RIAcalc) 
produces the standard curve and from this calculates the quality contrail and unknown sample 
concentrations.
2.7 General Methods of Data Analysis
Various methods of general data analysis are described below. Specific in-depth analysis for 
each protocol can be found within the relevant chapter.
2.7.1 aMT6s Analysis
After assaying the urine samples the concentrations of aMT6s (ng/ml) were corrected for 
urine weight (g) and length of collection period (h) to determine the aMT6s excretion rate in 
ng/h. These values were used to determine acrophase times for aMT6s by cosinor analysis 
(Nelson et al., 1979) using a programme written by Dr. D.S. Minors, University of 
Manchester, UK. Cosinor-derived acrophase times were used for further analysis of phase and 
period if the probability of fit (P) was <0.05 for aMT6s (Lockley et al., 2000). Midrange 
crossing analysis (the mid-point of the upward and downward mean crossing times; Lockley 
et a l, 2000) was used to validate phase and period estimates from cosinor analysis, and was 
also used when cosinor analysis did not give a significant result. The slope of the best-fit 
regression ine fitted through statistically significant acrophase times was used to calculate the 
period of the rhythm (± 95% confidence limits) (Lockley et a l, 1997a). The period was 
considered to be a free-running rhythm (i.e., not entrained to 24 h) if the 95% confidence
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limits of the regression analysis did not cross 0 (i.e. 24 h), and entrained if the 95% limits 
crossed 0.
2.7.2 Urinary Cortisol Analysis
After assaying urinary cortisol (nmol/L) the same methods of analysis as for aMT6s were 
used (cosinor and midrange crossing analysis of cortisol nmol/h). For the cosinor analysis 
acrophase times were accepted if the probability of fit (P) was <0.20. The slope of the best-fit 
regression line fitted through statistically significant acrophase times was used to calculate the 
period of die rhythm (± 95% confidence limits) (Skene et al., 1999b). The period was 
considered to be a free-running rhythm (i.e., not entrained to 24 h) if the 95% confidence 
limits of the regression analysis did not cross 0, and entrained if the 95% limits crossed 0.
2.7.3 Plasma Melatonin Analysis
The plasma samples were assayed for melatonin by RIA (Fraser et a l, 1983). The acrophase 
of the plasma rhythm was determined using two methods. These were cosinor analysis and 
midrange crossing analysis (as previously described in section 4.7.2). The acrophase 
determined by midrange crossing was used to determine the circadian time of administration 
of melatonin/placebo because plasma melatonin profiles do not always conform to a cosine 
wave form. The plasma melatonin acrophase is taken as being CT19, therefore the difference 
between the acrophase and time of treatment administration can be used to determine the CT 
of administration.
The plasma melatonin onset (MO) and offset (MOff) were also calculated. This was done by 
two methods using 2 x the limit of detection (LoD) of the assay, and 50% of the peak (where 
by the peak was determined using the average of the 3 highest concentrations). The first 
melatonin value above the 2 x LoD where subsequently the melatonin continued to rise was 
used as the MO.
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2.7.4 Salivary Melatonin Analysis
Salivary melatonin data were analysed in the same way as the plasma melatonin (section 
2.7.3).
2.7.5 CBT Analysis
Data where the probe had been removed due to the probe not being fully inserted, seen as low 
temperature (values < 35.5°C), were removed from the analysis. The nadir of the CBT rhythm 
was calculated using two methods. They were cosinor analysis (using Action3 software) and 
Tmin. Cosinor analysis calculates the acrophase so 12 hours were added to this value to 
determine the nadir. The Tmin method uses 1 hour moving averages to calculate the lowest 10 
temperatures, the times of which are then averaged, and the times are then averaged again to 
give Tmin. This was found to be the best method of analysing the CBT data because it 
smoothed the data and reflected the nadir of the visual inspection given by data, and CBT 
profiles do not always conform to a cosine wave form.
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Chapter 3: Melatonin Administration to Produce Phase Delays in an
Abnormally Entrained Blind Subject
3.1 Introduction
The ability of melatonin administration to entrain free-running circadian rhythms has been 
described in Chapter 1 (Section 1.5.4). In this present case study we attempted to phase delay 
an abnormally entrained blind subject (LPS22) with melatonin.
In a previous study a blind subject with abnormally entrained circadian rhythms (mean peak 
time of aMT6s secretion 1400 h) was given melatonin (5 mg) in order to phase shift his 
circadian system to a more normal phase (Skene et al., 1999). The melatonin treatment 
regime was designed to correct the abnormal circadian rhythms by phase advance. Melatonin 
(5 mg) or placebo administration was staggered, starting at 0200 h and advanced by 1 h each 
day for 5 days and then held constant at 2200 h for 23 days. The melatonin treatment 
significantly advanced sleep onset, delayed sleep offset and reduced daytime napping 
compared with placebo. Evaluation of the subject’s endogenous aMT6s rhythm nine days 
after cessation of melatonin treatment revealed a normally timed aMT6s peak at 0542 h.
Using the published PRC for melatonin (Lewy et al., 1998) to calculate the appropriate time 
of melatonin administration, it is possible that staggering the time of melatonin treatment 
could also phase delay the circadian system until the melatonin peak is at a normal phase 
(peak aMT6s approximately 0400 h). According to the PRC (Lewy et al., 1998), phase delays 
occur when melatonin is administered between CT18 and CT6, with the greatest delay shift 
occurring around CT22. As the present subject’s aMT6s acrophase was in the evening (20.6 ± 
0.1 h), a phase delay protocol to phase shift her to a normal circadian phase would be more 
appropriate. This phase delay protocol would avoid having to give melatonin during the day, 
which may cause unwanted sleepiness (Chapter 1, Section 1.5.1.2).
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The debate over whether a single dose of melatonin is able to produce a phase shift of the 
circadian system is described in Chapter 1 (Section 1.5.2). The aim of the present study was 
to show if phase delays are possible with daily administration of so that a blind person’s 
abnormally timed circadian rhythms could be phase shifted to a normal circadian phase.
3,2 Methods
3.2.1 The Subject
The subject (LPS22) was a post menopausal 56 year old female (not taking hormone 
replacement therapy) who had lost her sight in both eyes due to retinal detachment over a 
number of years, completely losing her sight in 1985 at the age of 41. LPS22 had previously 
been shown to have abnormally advanced circadian rhythms (aMT6s acrophase time (mean ± 
SD), 20.6 ± 0.1 h (Lockley et al., 1997a), cortisol acrophase time 5.0 ± 1.9 h) and an 
advanced sleep offset (5.3 ± 0.7 h) (Lockley, 1997). In a previous study Lockley et al., 
(unpublished data), had also shown that LPS22 did not suppress melatonin following 
exposure to bright light (715 lux, 455 pW/cm2 for 60 mins and 11350 lux, 7200 pW/cm2 for 
60 mins). This lack of light-induced melatonin suppression suggests that the retina SCN- 
pathway is not functional and that light is unable to entrain her circadian system. Thus light 
treatment would be inappropriate for normalising the timing of her advanced circadian system 
and sleep (advanced sleep phase syndrome, ASPS). Anecdotally, this subject had previously 
taken 5 mg melatonin to try to improve her sleep, but she suffered side effects in the form of 
headaches and discontinued treatment. In the present study a lower dose of 0.5 mg melatonin 
was thus used.
3.2.2 Study Design
The subject completed daily sleep, nap and ‘want to nap’ diaries (see Chapter 2, Section 2.5.1 
for details) for the duration of the study (58 days), and also collected sequential four-hourly 
urine samples (plus an overnight collection) for periods of 48 hours each week (see Chapter 2, 
Section 2.5.3 for details). During weeks 4-7, urine was not collected continuously for 48
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hours due to it being inconvenient for the subject to do so. Instead, urine was collected for 
approximately 16-18 hours on 2 consecutive days, with the first morning collection being 
missed out. The urine samples were assayed for aMT6s (Aldhous and Arendt 1988), and 
urinary cortisol (Riad-Fahmy et al., 1979) by RIA (both RIAs were performed by a research 
student, Vikki Warman). On the days of urine collections mood ratings were recorded every 
two hours from waking until bedtime. Mood ratings were also completed at the same time 
once per day for the duration of the study (see Chapter 2, Section 2.5.2 for details). To 
measure the concentration of exogenous melatonin remaining in the circulation the following 
morning, a single saliva sample was also collected once a week upon waking.
Administration of melatonin was designed as a single-blind study with daily placebo 
treatment (lactose filled gelatin capsules) administered for 28 days, followed by daily 
administration of 0.5 mg melatonin for another 28 days. The pills were identical in size and 
weight and were numbered and labelled so as not to prompt the subject into suspecting which 
pills were being administered. The treatment schedule is shown in Table 3.1
Table 3.1: Melatonin/placebo treatment schedule
Dav Treatment time
1 2000 h
2 2030 h
3 2100 h
4 2130 h
5 2200 h
6 2230 h
7 2300 h
8 2330 h
9-28 2400 h
Based on the melatonin PRC (Lewy et al., 1998), treatment times were chosen to produce 
expected phase delays in an attempt to shift the aMT6s acrophase from 2000 h to 
approximately 0230 h during days 1-14. Once at this acrophase time (0230 h) it was still 
possible to administer melatonin at bedtime (2400 h) while in the phase delay portion (CT18) 
of the melatonin PRC for days 15-28. Table 3.2 shows the expected daily shifts caused by 
melatonin treatment.
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Table 3.2: Predicted phase delays produced by 0.5 mg melatonin given daily in a staggered manner
Day Day aMT6S\|/(CT21) Treatment time CT of treatment Expected delay (hrs)
1 Mon 2000 h 2000 h CT21 0.5
2 Tue 2030 h 2030 h CT21 0.5
3 Wed 2100 h 2100 h CT21 0.5
4 Thurs 2130 h 2130 h CT21 0.5
5 Fri 2200 h 2200 h CT21 0.5
6 Sat 2230 h 2230 h CT21 0.5
7 Sun 2300 h 2300 h CT21 0.5
8 Mon 2330 h 2330 h CT21 0.5
9 Tue 0000 h 0000 h CT21 0.5
10 Wed 0030 h 0000 h CT20.5 0.5
11 Thurs 0100 h 0000 h CT20 0.5
12 Fri 0130 h 0000 h CT19.5 0.5
13 Sat 0200 h 0000 h CT19 0.5
14 Sun 0230 h 0000 h CT18.5 0.5
15 Mon 0300 h 0000 h CT18 0
16 Tue 0300 h 0000 h CT18 0
17 Wed 0300 h 0000 h CT18 0
18 Thurs 0300 h 0000 h CT18 0
19 Fri 0300 h 0000 h CT18 0
20 Sat 0300 h 0000 h CT18 0
21 Sun 0300 h 0000 h CT18 0
22 Mon 0300 h 0000 h CT18 0
23 Tue 0300 h 0000 h CT18 0
24 Wed 0300 h 0000 h CT18 0
25 Thurs 0300 h 0000 h CT18 0
26 Fri 0300 h 0000 h CT18 0
27 Sat 0300 h 0000 h CT18 0
28 Sun 0300 h 0000 h CT18 0
iy = acrophase
Taking melatonin at CT18, may induce further 30 minutes phase delays making the aMT6s 
acrophase on day 15 0330 h. However, taking melatonin at 0000 h (CT17.5) should phase 
advance the aMT6s rhythm by 30 mins, therefore advancing the aMT6s acrophase to 0300 h. 
In this way the subject’s circadian rhythms should remain entrained to the melatonin dose.
The study schedule for each treatment (melatonin or placebo) lasting 28 days is shown in 
Figure 3.1.
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Daily sleep/nap diary
Daily mood Scales
Urine collection
Administration time
1
Treatment times:
□  2200 h
□  2030 h 
0  2100 h
□  2130h
J  2200 h
□  2230 h 
■  2300 h
□  2330 h
28 0  0000 h7 14 21
Study Day
Figure 3.1: Study schedule for each 28 day period of placebo and melatonin administration.
3.2.3 Assays
Urinary aMT6s levels were measured by RIA (Aldhous and Arendt, 1988), see Section 2.6.1 
for details. The limit o f sensitivity o f the assay was 0.7 ng/ml. The interassay coefficients of 
variation (CV) were 13 % at 3 ng/ml (low batch 1 n=3), 4 % at 19 ng/ml (n=3) and 9 % at 39 
ng/ml (n=3).
Urinary cortisol was extracted using dichloromethane and measured by RIA (Riad-Fahmy et 
al., 1979), see Section 2.6.2 for details. The limit o f sensitivity o f the assay was 13.4 nmol/L. 
The interassay CVs were 22 % at 39 nmol/L (n=6), 17% at 96 nmol/L (medium batch 1 n=6), 
and 7% at 598 nmol/L (n=6).
3.2.4 Rhythm Analysis
The basic methods used to analyse urinary aMT6s and cortisol acrophases and periods have 
been detailed in Chapter 2 (Sections 2.7.1 and 2.7.2).
3.2.5 Sleep Analysis
The following sleep and nap parameters were derived from the sleep diaries: sleep latency 
(time to fall asleep); sleep onset; number and duration o f night awakenings; sleep offset; total 
night sleep duration; sleep quality (rated on a 1 to 9 scale, l=best, 9=worst); number and 
duration of naps. The daily sleep and nap parameters during placebo and melatonin treatments 
were compared using unpaired Student’s t-tests.
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3.2.6 Mood Analysis
During the study the subject completed four mood ratings every two hours from waking until 
bedtime during the 2 day period when collecting urine, and once a day for the duration of the 
study. The subject was asked to rate their alertness on a scale of 1-9 with 1 being very alert 
and 9 being very sleepy. Of the four mood scales (see section 2.5.2), alertness appears to be 
the most sensitive indicator of circadian changes particularly related to entrainment (Lockley, 
1997). Alertness data from the days when the subject collected urine were separated into two 
groups, placebo versus melatonin. All these data were binned into five time periods, 7.00 -
11.00 h, 11.00 -15.00 h, 15.00 h to 19.00 h, 19.00 -  23.00 h and 23.00 -  7.00 h, and a mean 
was obtained for each time period for each treatment (melatonin and placebo). Paired 
Student’s t-tests were carried out to determine any differences between the treatments.
3.3 Results
3.3.1 Effect of Melatonin on Sleep
Figure 3.2 shows the sleep map for LPS22 during the course of the study. During the placebo 
treatment (P) the sleep pattern was typical of a person who has abnormally entrained circadian 
rhythms. The subject retired to bed early (mean sleep onset 22.7 ± 1.2 h) during placebo. This 
advanced sleep onset corresponds to an advanced aMT6s acrophase (21.9 ± 1.5 h) during 
placebo.
The subject’s sleep while taking melatonin changed compared to placebo (Figure 3.2). 
Unpaired Student’s t-tests assuming unequal variances were carried out to compare the sleep 
parameters while taking placebo compared with melatonin. Figure 3.3 shows the outcome of 
these tests. Separate analyses were performed on the two halves of the night. The two halves 
of each night were calculated by determining the midpoint of the sleep period (onset to 
offset).
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Figure 3.3: The effect of placebo (P) and melatonin (M) on subjective sleep parameters. Unpaired 
Student’s t-tests * P<0.05, ** P<0.01
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3.3.2 Effect of Melatonin on the Cortisol Rhythm
The aMT6s and cortisol rhythms during placebo were entrained to 24 h (24.09 ± 0.5 h; 24.09 
± 0.15 h, respectively).
Raw plots of the urinary cortisol rhythm are shown in Figure 3.5. During weeks 4-7, urine 
was not collected continuously for 48 hours due to it being inconvenient for the subject to do 
so (instead, urine was collected for approximately 16-18 hours on 2 consecutive days, with 
the first morning collection being missed out, indicated by dotted lines in Figure 3.4). The 
sleep map (Figure 3.2) also shows the cortisol and aMT6s acrophases. The figure shows that 
the mean cortisol acrophase (4.9 ± 0.9 h) was abnormally advanced during placebo. During 
administration of melatonin the cortisol rhythm had a mean acrophase time of 7.5 ± 0.3 h 
(representing a cumulative phase delay of approximately 2.5 h).
3.3.3 Effect of Melatonin on Salivary Melatonin
A saliva sample was taken once a week in the morning on waking during melatonin and 
placebo treatment. All the saliva samples (n=5) showed that the circulating levels of 
exogenous melatonin had returned to endogenous baseline levels the morning after treatment, 
as shown in Table 3.3. This finding shows that a low dose of melatonin (0.5 mg) is cleared 
quickly from the circulation and is not likely to produce drowsiness the day after 
administration.
Table 3.3: Salivary melatonin levels the morning after melatonin/placebo administration
Treatment Time of sample (h) Melatonin concentration (pg/ml)
Placebo 0615 10.3
Placebo 0500 4.5
Placebo 0615 11.7
Melatonin 0630 2.0
Melatonin 0600 4.5
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Figure 3.4: Cortisol rhythms during placebo (left) and melatonin administration (right). The vertical dotted 
lines show the mean cortisol acrophase during placebo (4.9 ± 0.9 h) and melatonin (7.5 ± 0.3 h). Dotted 
lines joining data points represent periods where no samples were given.
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3.3.4 Effect of Melatonin on Alertness
Alertness data was collected once a day at the same time for the duration o f the study and 
every two hours during urine collection periods (see Section 4.2.6.1 for details), and binned 
into four different time periods (there was no data for 2300 -  0700 h). Figure 3.5 shows the 
results.
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Figure 3.5: Alertness in relation to the time of day comparing placebo and melatonin
The graph shows that the subject was more alert in the evening and early morning during 
melatonin treatment, although this was not significant.
3.4 Discussion
The results show that daily 0.5 mg melatonin staggered to produce a cumulative phase delay 
improved the majority o f sleep parameters compared to placebo.
During placebo treatment many factors concerning the sleep parameters pointed towards an 
advanced circadian rhythm. Napping before bedtime was observed indicating that she was 
tired before going to bed. The first half of the night did not show a lot o f awakenings, whereas 
the second half o f the night showed many awakenings o f longer duration than in the first half 
o f the night. This pattern is similar to a normally entrained person sleeping past their normal 
wake up time, with many awakenings being observed.
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Most of the expected sleep changes caused by entrainment by melatonin administration based 
on a delay of the sleep period, occurred apart from a slight non-significant decrease in sleep 
quality. The disappearance of naps in the evening during melatonin administration was a clear 
indication that the subject was not as tired before bedtime compared with placebo.
The results from the sleep parameters alone indicate that melatonin worked as predicted by 
the melatonin PRC and treatment scheduling and has delayed the subject’s sleep period. The 
subject fell asleep later (22.8 ± 1.3 h, sleep onset) and slept at a more normal time (22.80 -
06.00 h, mean sleep onset -  offset) while taking melatonin. This was also reflected in a 
significant decrease in the number of awakenings in the second half of the night, an increase 
in total sleep time, and a delay in sleep offset (Figure 3.3). These findings show that the 
subject had phase shifted and was experiencing a more ‘normal’ nights sleep in terms of 
timing and duration.
The findings show that the step-wise melatonin treatment also phase shifted the cortisol 
rhythm. This shift was most likely by a phase delay of approximately 2.5 h (from 4.9 to 7.5 
h). If the subject had shifted by a phase advance this would equate to approximately 21.5 h, 
which, over such a short space of time, is highly unlikely. During the placebo treatment the 
aMT6s acrophases were variable and differed by approximately 2 - 3  hours. This variability 
could be explained by an error in the urine collections, for example if the subject failed to 
collect all of her urine.
In contrast to our findings, a recent report suggests that a single 5 mg dose of melatonin did 
not induce a phase delay in humans (Wirz-Justice et al., 2000, 2002). However, in this study 
only one time point and one dose was tested and the subjects used were not blind. Our 
findings show that melatonin can induce phase delays in the cortisol rhythm and timing of the 
sleep-wake cycle when administered repeatedly in a step-wise manner for several days. 
Repeated administration of melatonin in the phase delay portion of the PRC may be required 
to produce significant phase delays rather than a single dose.
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Chapter 4: Daily 0.5 mg Melatonin Administration to Blind People
4.1 Introduction
According to some studies phase shifts using 0.5 mg of melatonin are almost as great as those 
induced by 5 mg (Sack et al., 1991; Deacon and Arendt, 1995) suggesting that even lower 
doses of melatonin may be capable of phase shifting and entrainment. While this present 
study was being conducted, Lewy and colleagues demonstrated entrainment of free-running 
rhythms in three blind subjects (Lewy et al., 2001) with 0.5 mg melatonin.
Previous studies have shown that chronic usage of melatonin is necessary for free-running 
blind people to remain entrained to the 24 hour day (Lockley et al., 2000; Sack et a l, 2000; 
Lewy et al., 2001a). Therefore a lower dose would always be preferable to a higher dose for 
long-term treatment in order to reduce possible side effects. The present study is an in-depth 
study which further investigates the ability of a low dose of melatonin to entrain free-running 
rhythms as well as to investigate its acute effect on sleep and alertness. See Section 1.5.4 in 
Chapter 1 for more detailed review of the literature.
4.2 Methods
4.2.1 Subject Details
Ten totally blind subjects (9 males, 1 female) were studied. Subject details are shown in Table 
4.1. The University of Surrey Advisory Committee on Ethics approved the study and all 
subjects gave informed consent. Throughout the study subjects were instructed not to take any 
medication that could affect melatonin or cortisol production or sleep (e.g., p-blockers, 
monoamine oxidase inhibitors, tricyclic antidepressants, and benzodiazepines). All subjects 
were confirmed as having free-running aMT6s rhythms prior to commencing melatonin 
treatment (range 24.16- 24.96 h). Briefly, this initial investigation consisted of a four week 
study in which subjects collected sequential 4-hourly (8 hourly overnight) urines for 48 h at 
weekly intervals for the assessment of aMT6s rhythmicity.
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Table 4.1 Subject details
Subject Age Diagnosis
No. of 
eyes 
intact
Onset of 
visual 
loss
Rapidity 
of visual 
loss
Baseline
aMT6s
period
No. days 
melatonin 
/  placebo
SLS44 65 Measles & ocular trauma 1 1940 Days 24.35 h 70
DNS45 47 Ocular trauma 0 1986 Days 24.96 h 26
PRS51 65 Retinoblastoma 1 Birth Years 24.50 h 49
DHS66 32 Unknown 2 Birth - 24.62 h 39
AAS70 38 Chronic uveitis 2 1968 Years 24.16 h 81
JCS71 64 Unknown 2 1936 Years 24.70 h 35
MSS76 43 Secondary glaucoma 1 1979 Years 24.60 h 42
DMS77 44 Glaucoma 0 Birth - 24.31 h 78
NOS78 49 Retinopathy of prematurity 2 Birth - 24.58 h 42
MDS79 35 Ocular trauma 1 1990 Days 24.45 h 54
not applicable
4.2.2 Study Design
Subjects were assessed for 15-36 weeks depending upon their endogenous circadian period. 
They kept daily sleep and nap diaries (see Section 2.5.1 for details) and collected sequential 
4-hourly (8 hourly overnight) urines for 24 or 48 h at weekly intervals (see Section 2.5.3 for 
details) for the assessment of aMT6s and cortisol by RIA (see Sections 2.6.1 and 2.6.2 for 
details).
Subjects completed four mood scales at the same time once a day every day, and every two 
hours whilst awake during the urine collection periods (see Section 2.5.2 for details).
In a placebo-controlled, single-blind design, subjects received 0.5 mg melatonin p.o. (Penn 
Pharmaceuticals, Tredegar, Gwent, UK) or placebo (identical lactose-filled capsule) daily at 
2100 h for at least one circadian beat cycle according to their baseline aMT6s period (range of 
treatment 26-81 days) (i.e., the number of days to complete one full cycle, 360 degrees). 
Table 4.1 shows the duration of treatment for each subject.
4.2.3 Assay Details
Urinary aMT6s levels were measured by RIA (Aldhous and Arendt, 1988) with reagents 
donated by Stockgrand Ltd., University of Surrey, UK (see Section 2.6.1 for details). The 
limit of sensitivity for the assay was 1.9 ng/ml. The interassay CVs were 17 % at 3 ng/ml
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(low batch 1, n=23), 20 % at 4 ng/ml (low batch, 2 n=32), 12 % at 24 ng/ml (n=57) and 8 % 
at44ng/ml(n=51).
Urinary cortisol was extracted using dichloromethane and measured by RIA (Riad-Fahmy et 
al., 1979) (see Section 2.6.2 for details). The limit of sensitivity for the assay was 14.5 
nmol/L. The interassay CVs were 14 % at 51 nmol/L (n=53), 20 % at 162 nmol/L (medium 
batch 1, n=20), 15 % at 93 nmol/L (medium batch 2, n=3), 20 % at 144 nmol/L (medium 
batch 3, n=23) and 15 % at 763 nmol/L (n=55).
4.2.4 Rhythm Analysis
The basic methods used to determine the characteristics of urinary aMT6s and cortisol 
acrophases and determine circadian period (tau) have been detailed in Chapter 2 (Sections
2.7.1 and 2.7.2). One subject (SLS44) had insufficient aMT6s acrophases derived from 
cosinor analysis to perform regression analysis so the acrophases were determined by 
midrange crossing analysis. The period was considered to be a free-running rhythm (i.e., not 
entrained to 24 h) if the 95% confidence limits of the regression analysis did not cross 0, and 
entrained if the 95% limits crossed 0. In three cases where there were large 95% confidence 
limits, however, the rhythm was considered free-running when the period > 24.3 h. Placebo 
and no treatment data prior to melatonin treatment were combined for period determination.
In subjects who did not appear to entrain within 7 days upon visual inspection of the data, the 
point at which they entrained was established by determining the first acrophase that was not 
within the 95% confidence limits extrapolated from the pre-melatonin treatment cortisol 
regression analysis. The preceding cortisol acrophase was taken as the first day of 
entrainment. This analysis was not possible for one subject (NOS78) who appeared to have 
exhibited a phase shift within the first few days of melatonin. In this subject day 25 was taken 
as the first day of entrainment as regression analysis of the acrophases after this point gave a 
period close to 24 h.
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The average cortisol phase was calculated in entrained subjects and considered normal when 
it fell within the range previously determined in stably entrained blind subjects (mean ± SD, 
9.9 ±1.8 h; Skene et al., 1999). The CT at which the first melatonin capsule was taken was 
calculated by extrapolation of the aMT6s period prior to melatonin treatment, with aMT6s 
acrophase designated as CT21 (Lockley et al., 2000). For subjects who did not entrain within 
7 days, the CT for the first day that they were entrained was calculated using the first cortisol 
acrophase that was considered to be entrained, and expressed relative to aMT6s phase using 
the individuaPs average phase angle between cortisol and aMT6s acrophases from pre- 
melatonin data
The cortisol and aMT6s periods before and after melatonin treatment were also compared 
(paired Student’s t-tests) to examine any persistent effect of melatonin treatment on period.
4.2.5 Sleep Analysis
The following sleep and nap parameters were derived from the sleep diaries: sleep latency 
(time to fall asleep); sleep onset; number and duration of night awakenings; sleep offset; total 
night sleep duration; sleep quality (rated on a 1 to 9 scale, l=best, 9=worst); number and 
duration of naps. For each subject the daily nap parameters during placebo and melatonin 
treatments were compared using unpaired Student’s t-tests. Each subject’s sleep parameters 
were averaged and compared for each treatment condition using paired Student’s t-tests. Data 
obtained when neither placebo nor melatonin was taken were excluded from any sleep 
analysis.
4.2.6 Mood Analysis
During the study subjects completed four mood ratings every two hours from waking until 
bedtime during the 2 day period when collecting urine, and once a day for the duration of the 
study (see Section 2.5.2 for details). Subjects were asked to rate their alertness on a scale of 1- 
9 with 1 being very alert and 9 being very sleepy.
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4.2.6.1 Alertness in Relation to the Time of Dav
Alertness data from the days when subjects collected urine were separated into two groups, 
placebo versus melatonin. Placebo data included data from days when no treatment was taken 
at either the end or beginning of the study. In the case of the two subjects (PRS51 and 
NOS78) who entrained after a lag, the data collected when they were free-running during 
melatonin administration was also included in the placebo data. All these data were binned 
into five time periods, 7.00 -  11.00 h, 11.00 -  15.00 h, 15.00 h to 19.00 h, 19.00 -  23.00 h 
and 23.00 -  7.00 h, and a mean was obtained for each subject for each time period for each 
treatment (melatonin and placebo). Paired Student’s t-tests were carried out to determine any 
differences between the treatments within individuals and as a group.
4.2.6.2 Alertness in Relation to Phase and Entrainment
Alertness data from the days when subjects collected urine were separated into three groups 
for subjects who had entrained, placebo when the subjects were in a normal phase (aMT6s 
acrophase between 2400 -  0600 h), placebo when the subjects were in an abnormal phase 
(aMT6s acrophase between 0600 -  2400 h) and melatonin (when all subjects were entrained 
at a normal phase). In the case of the two subjects (PRS51 and NOS78) who entrained after a 
lag, the melatonin data from when they free ran was also included in the placebo data. In the 
subject who exhibited a shortened period the data was split into three groups, placebo when 
the subject was in a normal phase, placebo when the subject was in an abnormal phase and 
melatonin (when the subject was at an abnormal phase). In subjects who did not entrain data 
were separated into six groups, placebo when the subjects were in a normal phase; placebo 
when the subjects were in an abnormal phase; melatonin when the subjects were in a normal 
phase; melatonin when the subjects were in an abnormal phase; all data when the subjects 
were in a normal phase, and all data when the subjects were in an abnormal phase. Placebo 
data included data from days where no treatment was taken at either the end or beginning of 
the study. Repeated measures ANOVA was carried out between the groups.
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4.3 Results
4.3.1 aMT6s and Cortisol Production
The subjects’ endogenous 24 h production of urinary aMT6s and cortisol (mean ± SD) ranged 
from 5.8 ± 2.7 to 36.9 ± 8.6 pg/24 h mid 43.3 ± 12.5 to 164.0 + 50.6 nmol/24 h during 
placebo treatment, respectively. These values were both within the normal ranges for blind 
subjects (mean ± 2SD; aMT6s: 11.0 ± 14.0 pg/24 h, n=50; cortisol: 89.2 ± 82.7 nmol/24 h, 
n=51; Lockley et al., unpublished data). There was no significant difference in daily aMT6s 
and cortisol production (mean ± SD) during placebo treatment between subjects who did 
entrain (n=6; aMT6s 18.3 ± 11.4 pg/24 h; cortisol 131.2 ± 23.7 nmol/24 h) and did not entrain 
(n=4; aMT6s 14.6 ± 7.0 pg/24 h; cortisol 84.8 ± 54.8 nmol/24 h) with melatonin treatment 
(paired Student’s t-test). For analysis of subjects who entrained after a lag period, the free- 
running data at the beginning of the melatonin treatment were grouped with the placebo data. 
There was no significant difference in 24 h cortisol output (mean ± SD) between melatonin 
(114.4 ± 48.2 nmol/24 h) and placebo (112.4 ± 43.2 nmol/24 h) treatments (paired Student’s 
t-test).
During melatonin treatment, 24 h endogenous aMT6s levels increased on average 23-fold 
(range 8 -4 2  fold), confirming subject compliance with the order of treatment.
There was a good correlation between cortisol and aMT6s periods (assessed by cosinor 
analysis) prior to melatonin treatment (r=0.85). There was also a good correlation between 
acrophases and periods derived by cosinor analysis and midpoint crossing analysis for both 
aMT6s (acrophase r=0.86; period r=0.88) and cortisol (acrophase r= 0.76; period r=0.97) 
rhythms (see Figure 4.1). Thus, in one subject (SLS44) who did not have significant aMT6s 
acrophases during placebo by cosinor analysis, acrophases determined by midpoint crossing 
analysis were used to determine the period.
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Figure 4.1: Correlation between midpoint crossing analysis and cosinor analysis for both cortisol and 
aMt6s acrophases and periods.
4.3.2 Effect of Melatonin Treatment on Free-Running Circadian Rhythms 
Table 4.2 shows the individual cortisol periods (mean ± SD = 24.47 ± 0.23 h; range 24.24 -  
24.96 h) and aMT6s periods (mean ± SD = 24.47 ± 0.23 h; range 24.23 -  24.95 h) before 
melatonin treatment. Figure 4.2 a-j also shows the free-running cortisol and aMT6s periods.
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Table 4.2 Effect of melatonin on the cortisol period
Cortisol x (h) ± 95% confidence limits
Subject
aMT6s t  (h) ± 95% 
confidence limits 
Pre-melatonin
Pre­
melatonin
During
melatonin
Post­
melatonin
CT of melatonin 
administration 
on day 1
Region of 
melatonin 
PRC
Entrained
SLS44 24.23 ±0.09 24.43 ±0.13 24.00 ± 0.07 _ 16 Advance
AAS70 24.35 ±0.06 24.33 ±0.09 23.99 ±0.19 24.43 ±0.13 10 Advance
DMS77 24.35 ±0.03 24.55 ±0.92 24.01 ± 0.07 24.10 ±0.12 12 Advance
MDS79 24.39 ±0.13 24.24 ± 0.26 24.00 ±0.03 - 12 Advance
Entrained after lag
PRS51 24.73 ± 0.35 24.69 ±1.88 24. 02 ± 0.16a 24.36 ±0.84 22 Delay
NOS78 24.27 ±0.08 24.26 ±0.10 23.93 ± 0.63b 24.28 ±0.72 3 Delay
Shortened tau
DNS45 24.95 ±0.05 24.96 ±0.23 24.45 ±2.48 24.96 ±0.23 18 Crossover
Not entrained
DHS66 24.28 ±0.18 24.29 ±0.15 c _ 3 Delay
JCS71 24.57 ±0.01 24.59 ±0.49 24.60 ± 0.65 24.58 ±0.16 22 Delay
MSS76 24.61 ±0.02 24.35 ±1.24 24.52 ±0.38 - 18 Crossover
a PRS51 entrained after 18 days of melatonin administration corresponding to administration at CT10 
b NOS78 entrained after 25 days of melatonin administration corresponding to administration at CT11 
c not enough points for regression analysis; no evidence of entrainment from visual inspection of the 
data
- not enough points for regression analysis
There was a differential effect of melatonin administration on entrainment of the cortisol 
rhythm. Six of the ten subjects had an entrained cortisol period during melatonin treatment 
with four of the subjects having a period that was indistinguishable from 24 h (x range 23.99-
24.01 h) (Table 4.2; Figure 4.2 a-f). The CT at which melatonin commenced in these four 
subjects ranged from CT10-CT16 (Table 4.2). The other two subjects (PRS51, NOS78) 
continued to free-run during the initial part of the melatonin treatment (CT of first melatonin 
dose was CT22 and CT3, respectively). In the case of one of these subjects (NOS78) a phase 
shift appears to have occurred within the first few days of melatonin treatment, but this was 
followed by an unchanged period for 25 days (24.32 ± 0.79 h). The cortisol rhythm became 
entrained with a period indistinguishable from 24 h in PRS51 (24.02 h) and NOS78 (23.99 h),
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after 18 and 25 days, respectively (Figure 4.2 e,f). The calculated CT of melatonin 
administration on these days was CT10 and CT11, respectively (Table 4.1).
One subject (DNS45) appeared to exhibit a shortened cortisol period (24.45 ± 2.48 h) during 
melatonin treatment (Table 4.2, Figure 4.2 g). This subject had a small number of data points 
because of the subject’s long period and consequent short duration of melatonin treatment 
{i.e., when % = 24.95 h, it takes only 26 days to complete one full cycle of t  and T=24.00 h). 
Analysis using acrophases determined by midrange crossing points confirmed a shortened 
period of 24.46 h. In addition, the timing of naps (Figure 4.2g) also suggests a shortened 
period, in that the number of days between episodes of daytime napping associated with 
circadian desynchrony, is increased during the melatonin treatment in this subject. This is 
suggestive of a longer beat cycle consistent with a shorter period (Figure 4.2 g; right panel).
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Figure 4.2: Acrophase times of the cortisol (O) and aMT6s ( • )  (left panel) and sleep wake cycles (right panel). Study days are shown
on the vertical axis and the time of day is shown on the horizontal axis. Sleep episodes (right panel) are represented by grey bars and
naps by black bars. Treatment durations are also shown (P = placebo, M = melatonin).
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The six subjects who entrained to melatonin had a mean (decimal time ± SD) cortisol 
acrophase (± SD) o f 11.3 ± 1.1 h which is within the range for normally entrained blind 
subjects (mean ± 2SD = 9.9 ± 3.6 h; Skene et al., 1999) indicating that they were all entrained 
to a normal circadian phase. The mean acrophase for each entrained subject was 10.3 ± 1.4 h 
(SLS44), 10.5 ± 1.0 h (PRS51), 10.6 ± 0.1 h (AAS70), 11.2 ± 0.6 h (NOS78), 12.3 ± 0.2 h 
(MDS79) and 13.1 ± 1.9 h (DMS77).
Three subjects failed to entrain to melatonin treatment. In these subjects, treatment 
commenced at CT3, CT18 and CT22 (Table 4.2). Although DHS66 appears to have some 
stabilisation of sleep onset and offset (Figure 4.2 h, right panel) this is more than likely due to 
the soporific effects of melatonin. The two cortisol acrophases that were obtained during 
melatonin treatment were at 16.3 h (day 134) and 7.0 h (day 152) indicating that the subject 
was still free-running. These two acrophases also correspond with the napping periods during 
melatonin treatment. Their cortisol periods did not differ during melatonin treatment 
compared to placebo (Table 4.2).
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Figure 4.3: Phase dependency of the initial dose of melatonin in the entrainment of free-running blind 
subjects (Adapted from Lewy et al., 1998).
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The aMT6s period for each individual, grouped as to the effect melatonin had can be seen in 
Figure 4.4.
25 1 
24.8
£  24.6
s
ffl 24.4 o,
24.2 
24
entrained entrained not shortened
after a lag entrained tau
Figure 4.4: Relationship between aMT6s period and whether subjects entrained. Black dots indicate an 
individuals period (as shown in Table 4.2), black bars indicate the average period for each group.
In those subjects from whom both pre- and post treatment periods were available for analysis 
(n=6), there was no significant difference in the cortisol periods before and after melatonin 
treatment within subjects.
4.3.3 Effects of Melatonin on Sleep
Melatonin significantly improved at least one measure of subjective sleep in 9/10 subjects.
Compared to placebo, melatonin significantly affected a number of sleep parameters (Table
4.3). Melatonin had a marked effect on napping, significantly reducing the number (t=4.341,
df=9, P=0.007) and duration (tr=3.295, df=9, P=0.009) of naps compared to placebo (p<0.01)
(Table 4.3). Melatonin treatment also significantly delayed sleep offset (t=2.704, df=9, 
*
P=0.02), decreased the duration of night awakenings (t=2.504, df=9, P=0.03) and increased 
total night sleep duration (t=3.470, df=9, P=0.007) (paired Student’s t-test) (Table 4.3).
Figure 4.2 shows the average number and duration of naps in each subject during placebo and 
melatonin treatment. Significant differences (shown as solid lines in Figure 4.5) between
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treatments were observed on 6/10 subjects (number of naps) and 7/10 subjects (duration of 
naps).
Table 4.3: Effects of melatonin on subjective sleep
Sleep Parameter Placebo (mean± SD) Melatonin (mean ± SD)
Sleep latency (h) 0.54 ±0.41 0.49 ±0.42
Sleep onset time (h) 24.10 ±0.73 24.01 ± 0.71
Sleep offset time (h) 6.78 ±1.09 7.03 ± 1.13 *
Number of night awakenings/day 1.59 ±1.02 1.51 ±0.84
Duration of night awakenings/day (h) 0.79 ±0.67 0.56 ±0.51 *
Total night sleep duration (h) 5.99 ±0.88 6.64 ±1.11 **
Sleep quality (1-9 scale; 1= best, 9=worst) 4.85 ± 0.80 4.70 ±0.95
Number of naps/day 1.09 ±1.45 0.76 ±1.27 **
Duration of naps/day (h) 0.45 ±0.35 0.14 ±0.12 **
* P < 0.05; ** P < 0.01 compared with placebo (paired Student’s t-test)
a. Number of naps b. Duration of naps
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Figure 4.5: The effect of melatonin on naps. Those individuals with significant differences between 
treatments (p<0.05, Student’s /-test) are shown by solid lines. Melatonin decreased the number of naps 
in all subjects, six of whom had significant reductions. Melatonin also decreased the duration of naps in 
all 10 subjects, 7 significantly.
4.3.4 Effects of Melatonin on Alertness
4.3.4.1 Alertness in Relation to Time of Day
Alertness data was collected once a day at the same time for the duration of the study and 
every two hours during urine collection periods (see Section 4.2.6.1 for details). The alertness 
data were analysed as a whole group and were also split into two groups, one for subjects who 
entrained, including those who entrained after a lag, and one for subjects who did not entrain, 
the latter including the subject with the shortened period. The results are shown in Figure 4.6..
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In all three groups alertness was approximately the same throughout the day (between 11.00 
and 2300 h). During the period between 2300 to 0700 h the subjects were significantly less 
alert during melatonin treatment (P < 0.05, all subjects and entrained subjects).
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Figure 4.6: Alertness in relation to the time of day, a) meaned (± SD) data for all 10 subjects; b) 
meaned (± SD) data for the 6 subjects who entrained; c) meaned group data (± SD) for the 3 subjects 
who did not entrain and the subject with a shortened period. P = placebo, M = melatonin. * = P < 0.05 
compared with placebo (paired Student’s t-test)
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4.3.4.2 Alertness in Relation to Phase and Entrainment
For the entrained group of subjects there was little variation between alertness during placebo 
when at a normal circadian phase (2400 -  0600 h), placebo when at an abnormal phase (0600 
-  2400 h) and during melatonin treatment when entrained at a normal phase (Figure 4.7). It 
may be expected that alertness would be better during placebo when the subject was in a 
normal circadian phase and during melatonin treatment, however, there was no significant 
difference between these three groups (P = 0.4; Repeated measures ANOVA). Only one 
subject (MDS79) showed a clear improvement in alertness during placebo (3.5 ± 1.0) in a 
normal phase and melatonin whilst entrained (3.4 ± 0.8), compared to placebo at an abnormal 
phase (5.2 ± 1.2) (Figure 4.6a).
In the subject with the shortened period during melatonin treatment, again there was little 
difference between alertness during placebo when at a normal phase (5.1 ± 0.5), placebo 
when at an abnormal phase (4.7 ± 0.4) and during melatonin treatment (4.6 + 0.4) when the 
subject was in an abnormal circadian phase throughout (Figure 4.7b). There does appear to be 
a slight improvement in alertness during placebo when the subject is in a normal phase, and 
also during melatonin which is unexpected considering the subject is at an abnormal phase.
For the non entrained group of subjects again there was not much difference between 
alertness during placebo and melatonin when at abnormal and normal phases (Figure 4.7c). 
Paired Student’s t-test comparing just the normal and abnormal phase data, regardless of 
treatment, showed no significant difference in alertness in the two phases (P=0.3). However 
the subject number is very small (only n=3).
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Figure 4.7: Alertness (± SD) in relation to circadian phase, a) data for entrained subjects; b) data for 
the subject with the shortened tau (DNS45); c) data for non-entrained subjects. P= placebo, M = 
melatonin, Ab = abnormal phase (0600 -  2400 h), n = normal phase (2400 -  0600 h). Each time point 
represents the mean alertness value for an individual subject.
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4.4 Discussion
The present results show that appropriately timed, low dose melatonin (0.5 mg) can entrain 
free-running circadian rhythms in most blind people. This finding confirms and extends 
previous reports of entrainment in three free-running blind people with 0.5 mg melatonin 
(Lewy et al., 2001a). In agreement with a previous study with 5 mg melatonin (Lockley et al., 
2000), entrainment was more likely when melatonin treatment was started in the phase 
advance portion of the melatonin PRC (CT6-18). When 0.5 mg melatonin was started in the 
phase delay region of the PRC, some individuals did not exhibit changes in phase or period 
during melatonin administration and continued to free-run, again in agreement with the 5 mg 
studies (Lockley et al., 2000). In contrast to the previous finding, however, it has been shown 
here that when 0.5 mg melatonin is initially administered in the phase delay portion of the 
PRC, free-running rhythms can eventually become entrained in some individuals when an 
appropriate circadian time (CT) for melatonin administration is reached, analogous to the first 
study in mammals (Redman et al., 1983).
The current study confirms and extends the finding that the CT of administration of melatonin 
is an important factor in determining whether entrainment occurs (Lockley et al., 2000). All 
subjects in the current study had an endogenous period > 24 h and therefore required a net 
advance in phase in order to become entrained to 24 h. The published PRCs for melatonin 
(see Section 1.5.3) predict that phase advances will occur when melatonin is administered 
between -CT6-18 (if CT14 represents plasma melatonin onset and CT21 represents urinary 
aMT6s peak). The subjects who entrained within 7 days did so when melatonin treatment 
commenced in this region of the PRC. Subjects who entrained part way through treatment 
also became entrained once the timing of melatonin treatment was within the phase advance 
region (CT10, CT11).
Subjects who did not entrain at all (n = 3) started melatonin treatment in the delay region or 
close to the ‘crossover’ portion of the PRC. It is not clear why these subjects did not become
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entrained later when melatonin treatment coincided with the phase advance portion of the 
PRC. While it would have been desirable to start and treat all subjects at the same circadian 
time in the advance portion of the melatonin PRC, this is presently exceedingly difficult to do 
in field studies such as this. Ideally the subjects who did not entrain should be restudied with 
melatonin treatment starting in the phase advance portion of the melatonin PRC. This would 
clarify the role of circadian phase of treatment in the ability of melatonin to entrain the 
circadian system. One reason for the lack of apparent entrainment may be the shortened 
duration of melatonin treatment the subjects received. If these subjects were treated with 
melatonin for longer then entrainment may have occurred.
Improvements to the protocol could be made for similar future studies in that the duration of 
melatonin treatment should be extended to cover at least one and a half beat cycles. This 
would be useful for a number of reasons. Firstly, it would provide more data points during 
melatonin treatment with subjects that have long periods. In the case of DNS45 (period 24.9 
h) the beat cycle is only 26 days long and during that time only three 48 hour urine collections 
were possible. This gave large confidence limits and if any of the acrophases were 
insignificant by cosinor analysis then period determination with two points would not have 
been possible. Also, in the case of MSS76 there are only acrophases at the start and end of 
melatonin treatment (due to the subject not being able to carry out many complete 24 or 48 h 
urine collection periods) which are approximately at the same time (Figure 4.2j). This makes 
it difficult to decide if the subject entrained as it is equally possible that the subject continued 
to free-run, as you would expect acrophases to be similar at the beginning and end of a beat 
cycle. The sleep data however showed that the subject was free-running. If melatonin 
treatment was extended and more urine collections carried out then this issue may have been 
solved more quickly. Finally, because melatonin shortened the period of DNS45, it meant that 
the subject never took melatonin during the phase advance portion of the PRC. With a period 
of 24.45 h the beat cycle was extended to 54 days. Because DNS45 started melatonin
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treatment at CT18 the CT after 26 days when melatonin treatment ceased would only be CT5 
which is still in the phase delay portion of the PRC. Lewy and colleagues (2002) 
demonstrated that a subject with a period of 24.9 h entrained with 0.5 mg melatonin after 47 
days, which certainly goes beyond one beat cycle. This subject also showed a shortened tau 
up until this point.
Determining why inter-individual differences may exist with respect to the efficacy of 
melatonin to entrain is vital to the development of melatonin administration regimes in the 
treatment of free-running circadian rhythms and non-24-hour sleep-wake disorder (Sack et 
al., 1992; Lockley et al., 1997b; 1999). The present finding that melatonin administration can 
entrain some, but not all, subjects when their endogenous circadian phase ‘drifts’ into an 
appropriate phase relationship with the melatonin treatment time, rather than having to initiate 
treatment at an appropriate phase, has the potential to make treatment regimes easier to 
develop. Within an individual, both dose and circadian time may play a role. For example, 
one of the individuals (S51) who entrained after a lag with 0.5 mg melatonin, failed to entrain 
when 5 mg melatonin was started at CT 3 (Lockley et al., 2000) but entrained when 5 mg was 
started at CT 7 (Lockley et al., unpublished results).
Overall, there does not appear to be a dose-dependent difference in the efficacy of 5 and 0.5 
mg melatonin to entrain free-running circadian rhythms in the blind. In the current 0.5 mg 
study, 6/10 (60%) subjects became entrained and 1/10 (10%) appeared to shorten period. In a 
previous study using a 10-fold higher dose (Lockley et al., 2000), 3/7 (43%) entrained and 1/7 
(14%) had a shortened period. The limits of entrainment (based on the subjects’ period) also 
do not appear to differ between the two melatonin doses (see below). One explanation for the 
lack of a clear dose-dependent effect is that both doses produce supra-physiological levels of 
circulating plasma melatonin shortly after ingestion that may be indistinguishable at a 
receptor level. Melatonin pharmacokinetics are known to vary greatly between individuals 
(Aldhous et al., 1985), however, there was no significant difference in daily aMT6s 24 h
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production between those subjects that did and did not entrain (see Section 4.3.1). There may 
also be individual differences in feedback of high circulating melatonin levels on the number 
and sensitivity of melatonin receptors (Gauer et al., 1993).
Another question is whether the differences in period between individuals, and therefore the 
relative zeitgeber strength of melatonin required to entrain, determined whether entrainment 
occurred. A clear relationship between period and entrainment is not apparent from the 
relatively small group of subjects presented here, as the range in aMT6s period overlaps 
between those who entrained (24.23-24.39 h), those who entrained after a lag (24.27-24.73 h) 
or those who failed to entrain (24.28-24.61 h) (see Table 4.2, Figure 4.4). Thus it is difficult 
to draw any conclusions about the relationship between individual period and entrainment by 
0.5 mg melatonin from this study.
In a previous case study of 0.5 mg melatonin administration given in the phase advance 
region of the PRC to free-running blind individuals, those (n=3) who became entrained after 
approximately 25 -  45 days of melatonin administration at 2000 -  2300 h, had periods of 
24.3, 24.4 and 24.5 h (Lewy et al., 2001a). Entrainment using higher doses of melatonin and 
other treatment regimes suggests similar limits of entrainment; up to 24.57 h (Lockley et al., 
2000) and 24.62 h (Lockley et al., unpublished results) using a daily 5 mg dose, up to 24.6 h 
using a daily 10 mg dose and up to 24.4 h when a 10 mg dose was gradually stepped down to 
0.5 mg over 12 weeks (Sack et al., 2000). To date however, no systematic study of the limits 
of entrainment for melatonin administration has been conducted. Lewy and colleagues 
predicted that periods > 24.75 h cannot be entrained by melatonin when their published PRC 
(Lewy et al., 1998) is used to predict the phase angle of entrainment between melatonin 
administration time and the endogenous melatonin onset (Lewy et al., 2001b). These findings 
are inconsistent with their claim that entrainment was observed in a subject with a period of 
24.9 h using 7.5 mg melatonin daily (Sack et al., 1991) and after 47 days of 0.5 mg treatment 
(Lewy et al., 2002). Further work is required to establish the range of entrainment to different
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doses of melatonin and how applicable such ranges are to a wider population in designing 
clinical treatments.
The subject (DNS45) with the longest period (24.96 h) appeared to show a shortening of 
period with 0.5 mg melatonin. As period shortened during the treatment, melatonin was not 
administered for a full beat cycle. It is not known, and as yet untested, whether entrainment 
would have occurred if the treatment was extended. A 5 mg dose of melatonin was also 
previously unsuccessful in entraining this individual when administered either at a phase 
advance (Lockley et al., 2000) or phase delay (Lockley et al., unpublished results) portion of 
the PRC, suggesting that insufficient dose or inappropriate circadian phase are unlikely 
explanations for the lack of entrainment. The shortening of the subjects > 24.9 h period by a 
lower dose of melatonin suggests that 0.5 mg melatonin can produce phase advances of ~0.4 
h but not the ~ 1 h advance required to entrain this subject. Recently, Lewy and colleagues 
(2002) have reported a similar finding in an individual with a similarly long period (24.9 h) 
who also did not entrain to 10 mg or 20 mg but did entrain after a period of 47 days when 
administered 0.5 mg daily melatonin. The long endogenous period of both individuals and the 
apparently counter-intuitive response to dose suggests that there are complex interactions 
between dose and an individual’s period, PRC and limits of entrainment to melatonin. 
Caution is required, however, if melatonin treatment only results in a shortening of period 
rather than entrainment, as this would result in longer episodes of poorer sleep by lengthening 
the duration of circadian misalignment. Although the episodes of good sleep would also be 
equally extended, the longer duration of poor sleep may have a greater impact on the 
individual due to cumulative chronic sleep loss.
The aim of developing melatonin treatment regimes to entrain the underlying circadian 
oscillator is to optimally treat the clinical condition ‘non-24-hour sleep-wake disorder’ that 
develops as a result of misalignment of the circadian system with the social 24-hour day. It is 
characterised by cyclic episodes of poor sleep and increased daytime napping when the
83
circadian system is out of phase with the 24-hour day (identified by aMT6s acrophase at an 
abnormal phase, 06.00 — 24.00 h), followed by episodes of better sleep and improved day­
time alertness when the aMT6s rhythm is at a relatively normal circadian phase (24.00 -  
06.00 h) (Lockley et al., 1997b; 1999). Free-running rhythms in sleep, without other 
endogenous circadian rhythm markers, are not always readily observed in field studies due to 
social factors such as the necessity to keep standard working hours.
Despite a differential effect on entrainment, melatonin significantly improved at least one 
aspect of subjective sleep in virtually all subjects. An effect on daytime alertness however 
was not so clear. In the non-entrained individuals these effects on sleep and alertness may be 
solely due to the soporific effects of exogenous melatonin compared to placebo. This suggests 
that administration of 0.5 mg melatonin at 2100 h affects the alertness 2 hours or more later. 
The direct soporific effects of melatonin on nighttime sleep in normal subjects have been 
described as modest (e.g Sack et al., 1997). Nevertheless, alertness during the period of 23.00 
-  7.00 h was significantly reduced during melatonin treatment.
The advantage of utilising the phase shifting properties of melatonin to treat non-24-hour 
sleep wake disorder is based on the fact that sleep quality and quantity are maximal if sleep 
occurs at the optimal circadian phase (Czeisler et al., 1980; Dijk and Czeisler, 1994), and it 
appears that even a small degree of desynchrony may result in insomnia symptoms (Morris et 
al., 1990). Recent evidence in the blind suggests that if the circadian system continues to free- 
run during melatonin treatment, the sleep-wake cycle also continues to free-run, despite the 
acute sleep-improving effects of melatonin (Lockley et al., 2002) and thus the underlying 
cause of the sleep disorder remains untreated. The findings indicate that optimal treatment for 
non-24-hour sleep disorder should utilise both the soporific and chronobiotic properties of 
melatonin by giving melatonin close to the desired bedtime and at the correct circadian phase, 
namely the phase advance portion of the melatonin PRC. An acute improvement of sleep 
alone without re-entrainment will fail to treat the underlying circadian disorder and only mask
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the influence of circadian phase on sleep (Lockley et al., 1999), although the quality and 
composition of such sleep remains to be investigated.
In conclusion, the current study confirms in a larger population than previously assessed that 
0.5 mg can entrain the free-running circadian system of blind subjects. The findings also 
show that entrainment depends on the circadian phase of melatonin administration. Melatonin 
administered initially in the phase advance portion of the PRC will entrain most free-running 
subjects whereas melatonin initially given in the phase delay portion will not entrain these 
subjects. However, it has been demonstrated that some individuals will free-run until the 
appropriate phase is reached before becoming entrained, in agreement with the original 
demonstration of entrainment by melatonin in mammals (Redman et al., 1983). Studies using 
different doses of melatonin at both phase delaying and phase advancing times within the 
same subjects needs to be carried out to have a better understanding of the results.
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5.0 The Melatonin PRC in Free-Running Blind Subjects
5.1 Introduction
See Section 1.5.3 for a description of the melatonin PRC and for the previous melatonin PRC 
studies. Current PRCs have some methodological problems such as using multiple doses 
before assessing the phase shift, light confounds, and the use of entrained subjects. To date a 
single dose of melatonin given to free-running subjects has not been performed.
The present study was designed to assess whether a single dose of melatonin (5 mg) can shift 
the phase of circadian rhythms (aMT6s, plasma/salivary melatonin, and CBT) in blind 
subjects with (defined) free-running circadian rhythms. Another objective was to see if the 
study could be carried out entirely in the field, thereby making it less demanding for the 
subjects and considerably reducing costs.
5.2 Methods
5.2.1 Subject Details
To date the protocol has been conducted with seven NPL subjects, one of whom took part in 
the study twice (DNS45). Table 5.1 summarises the subject details. Five of the subjects took 
melatonin in their everyday lives (KBS14, PLS18, JGS26, DNS45, MSS76), melatonin 
administration was discontinued at least 3 weeks before the start of the study.
Table 5.1: Subject details
Subject Year
studied
Age Diagnosis No. of 
intact eyes
Onset of 
visual loss
Rapidity of 
visual loss
KBS14 2000 38 Measles keratitis 1 1964 Years
PLS18 2000 50 Retinopathy of prematurity 0 Birth -
JGS26 2000 49 Buphthalmos 1 Birth -
SLS44 2001 65 Measles & ocular trauma 1 1940 Days
DNS45 2000/2001 46 Ocular trauma 0 1986 Days
MSS76 2001 44 Secondary glaucoma 1 1979 Years
NOS78 2001 49 Retinopathy of prematurity 2 Birth -
The circadian rhythms of all of the study subjects had been assessed previously. The aMT6s 
taus from these studies are shown in Table 5.2.
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Table 5.2: Subject aMT6s periods from previous studies
4 week*
5 mg study 
DNS4 
(see Lockle1
'1995 except 
5:1996) 
y et al. 2000)
5 mg study crossover (1999) 
(Lockley et al. unpublished 
data)
0.5 mg study (2000/2001) 
(Chapter 4)
PreMLT PostMLT PreMLT PostMLT PreMLT PostMLT
KBS14 24.79 ±0.09h (95) - - - - - -
FLS18 24.68 ± 0.2 lh (95) - 24.72 ±0.84 h 24.49 ± 1.02 h - - -
JGS26 2439 ± 0.24h (95) 24.43 hc 24.28 hc - - - -
SLS44 24.35 ± 03 lh (96) - - - - 24.23 ± 0.09 h -
DNS45 24.9 hb (96) 24.52 ±  0.34 h 24.91 ± 03  h 24.92 ± 0.12 h - 24.95 ±  0.05 h -
MSS76 24.6 ± 0.36h (00) - - - - 24.61 ±  0.02 h -
NOS78 24.58 ±0.25h (01) - - - - 24.27 ± 0.08 h 24.32 ± 0.74 h
a year of 4 week study shown in brackets 
b approximate tau from 24h aMT6s data doubled up 
c period without 95 % limits (based on 2 acrophases)
5.2.2 Study Design
The study was carried out on two occasions 19 months apart (referred to from here onwards 
as the 2000 and the 2001 studies). The 2000 study was carried out in the months of April and 
May, the 2001 study was carried out in the months of November and December. The 
University of Surrey Advisory Committee on Ethics approved the study and all subjects gave 
informed consent. Throughout the study subjects were instructed not to take any medication 
that could affect melatonin or cortisol production or sleep (e.g., P-blockers, monoamine 
oxidase inhibitors, tricyclic antidepressants, and benzodiazepines). Activity was monitored 
throughout using Actiwatches (see Section 2.5.8). Subjects undertook auditory performance 
tests and recorded mood scales once a day in the evening at a time of their choosing whilst at 
home, and every two hours during the days whilst in the Clinical Investigation Unit (CIU) at 
the University between the hours of 0700 -  2300 h. Subjects spent 3.5 days in the CIU 
(Thursday evening to Monday morning) on three occasions (Legs 1-3) at weekly intervals. 
The study design is shown in Figure 5.1. For full details of all methodology see Chapter 2. 
The 2000 study lasted for 32 days continuously. The 2001 study was extended by a week after 
the final leg (leg 3) in order to obtain a longer aMT6s data set from the field data. The 2001 
study thus ran for 43 days continuously. Throughout this extended period daily sleep/nap 
diaries, sequential urine sampling, and daily mood and performance tests were carried out 
daily (4 hourly plus an overnight collection).
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Figure 5.1: Overview of study schedule (2000). The 2001 study schedule was extended by 10 days at 
the end. Both study schedules included daily sleep and nap diaries, daily mood scales and performance 
tests, and continuous activity monitoring and urine collections.
During the time spent in the CIU, blood samples were taken 1-2 hourly, and saliva samples 
were taken 1-2 hourly during the day whilst awake (0700 -  2300 h). Urine was collected 
continuously and core body temperature was monitored continuously. Sleep, nap and mood 
diaries were recorded by the experimenters who asked subjects for details every two hours 
whilst the subjects were awake. The CIU study schedule is shown in Figure 5.2.
During each o f the three study legs spent in the CIU, the subjects took a pill on the three 
successive days at 0930 h. The first and last pills were always placebo (single blind design), 
with the second pill being either melatonin (5 mg) or placebo (double blind design). The 
administration o f melatonin or placebo was double-blind for the three study legs in the 2000 
study, with placebo being administered on one visit, and 5 mg melatonin being administered 
on the remaining two visits. After analysis o f this study, it was evident that by having placebo 
on Leg 2, longer data sets for aMT6s were obtained between leg 1 and 3 and the calculation 
of phase shifts was less problematic. It was therefore decided that for the 2001 study all 
treatment would be single-blind and melatonin would be given to all subjects on Legs 1 and 3.
! 1 1 !! 1 1 1 1 1 1 1 1 !! i [ n m u r m
"f I
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In the CIU the light levels were kept constant throughout the study (from 2000 h Friday night 
to 0700 h Monday morning; < 8 lux). Meals were eaten at scheduled times (breakfast 7:00- 
8:30 h, lunch 13:00-14:00 h, dinner 18:00-19:00 h). Meals were standardised between legs 
(i.e. the subjects were given the same meal each Friday night) but not between days within 
each leg (i.e. subjects ate a different meal on Friday and Saturday nights).
' Friday
7 day urine 
collection«4------- <-
Saturday Sunday
blood/saliva sam ples
urine collections
CBT constant
semi- i r semi- i I semi-
recumbent 1 [_ recumbent recumbent
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7 day urine
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20 24 8
I
24
I
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24
I
24
Figure 5.2: Measurements taken in the CIU, Legs 1-3. The dark bars represent times when the subjects 
were scheduled to sleep, during which time subjects were supine. P = placebo, M/P = 
melatonin/placebo.
There was a deviation from the protocol in the 2000 study in that two o f the subjects (PLS18 
and DNS45) were unable to come to the CIU for Leg 2 due to illness (PLS18 was suffering 
from a viral infection and preferred not to spend the weekend in the confines o f the CIU, 
DNS45 was experiencing back pain that prevented him from travelling), so they carried out 
the study and all the sampling (except for blood samples) in their homes. In addition, KBS 14 
finished the 2000 study after 24 days due to personal circumstances that prevented him from 
completing the study.
5.2.3 Assays
Urinary aMT6s levels were measured by RIA (Aldhous and Arendt, 1988) (see Section 2.6.1 
for details). The limit o f sensitivity for the assay was 2 ng/ml. The interassay CVs were 18 % 
at 4 ng/ml (n=37), 16 % at 23 ng/ml (n=37) and 12 % at 42 ng/ml (n=33).
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Plasma melatonin levels were measured by RIA (Fraser et a l, 1983) (see Section 2.6.3 for 
details). The limit of sensitivity for the assay was 6 pg/ml. The interassay CVs were 18 % at 
24 pg/ml (very low batch one, n=T0), 21 % at 34 pg/ml (very low batch two, n=8), 19% at 51 
pg/ml (n=19), 13 % at 131 pg/ml (n=10), 12 % at 185 pg/ml (n=10) and 17 at 356 pg/ml 
(n=9).
Salivary melatonin levels were measured by RIA (English et al, 1993) (see Section 2.6.4 for 
details). The limit of sensitivity for the assay was 2 pg/ml. The interassay CVs were 15 % at 
15 pg/ml (n=15), 15 % at 26 pg/ml (n=15), 16 % at 52 pg/ml (n=15) and 12 % at 112 pg/ml 
(n=15).
5.2.4 Methods of Analysis
5.2.4.1 aMT6s Analysis
The urine samples were assayed for aMT6s. Cosinor analysis and midrange crossing analysis 
was used to calculate the aMT6s acrophase (see Section 2.7.1 for details). Cosinor analysis 
and midrange crossing analysis gave closely correlated results for both acrophases (^=0.96) 
and the period calculated from the acrophases (^=0.70). The acrophases obtained by cosinor 
analysis were used in the regression analysis to calculate period, except when there were too 
few significant acrophases (less than 3), in which case acrophases from the midrange crossing 
data were used to calculate period instead (i.e. acrophases from cosinor analysis were not 
used).
For the aMT6s analysis it was essential to eliminate any of the samples from the data series 
that may have included exogenous melatonin, as this would cause an error in the 
determination of the timing of the endogenous peak and possibly give an incorrect phase shift. 
Removal of the effect of exogenous melatonin was done by first calculating the daily 
endogenous aMT6s jig/24 hour production. When exogenous melatonin was taken two peaks 
were clearly visible. Graphs of aMT6s ng/h were then plotted for each study leg to show more
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precisely when aMT6s levels returned back to endogenous levels. An example of this is 
shown in Figure 5.3. Urine samples suspected o f containing aMT6s dived from exogenous 
were not included in cosinor/midrange crossing analysis.
O)c
1000000
100000
10000
1000
100
10
8 8 8 £ $ 8 8 £ £ 8  
o  <b c n  <j>t-  S- co S-
& g g 8 Sh-'
T— T—
D6
$ & S £ „
N  o  i ;  (b  n  
D9
day/time period
8 8 2 £ §
0  i d  6> <Si ( 6
1 §  § i  »
CD O  LD O )  CNIT“ T— T—
D10
Figure 5.3: An example of aMT6s ng/h over 3 days of a study leg (JGS26 Leg 1, 2000 study). The red 
lines show the time period over which exogenous melatonin was present.
To assess what CT melatonin had been administered the regression line obtained from the 
cosinor/midrange crossing derived aMT6s acrophases was extended.
5.2.4.2 CBT Analysis
The nadir o f the subjects’ CBT rhythm was analysed using cosinor analysis and Tmin (see 
Section 2.7.5 for details).
5.2.4.3 Plasma Melatonin Analysis
The plasma samples were assayed for melatonin by RIA. The acrophase o f the plasma rhythm 
was determined using both cosinor analysis and midrange crossing analysis (see section 
2.7.3). Both methods were closely associated (r2=0.98). Midrange crossing analysis o f the 
plasma melatonin rhythm prior to melatonin/placebo administration was used to determine the 
CT of administration (plasma melatonin acrophase was taken as being CT19). Like with the 
aMT6s analysis it was essential to ensure that the plasma samples containing exogenous
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melatonin were not used in determining a phase shift. The effect of the exogenous melatonin 
was removed by visual inspection of the graphs and determination of the time of the 
endogenous peaks on the previous day. It was then possible to assess whether there could be 
an overlap of the exogenous melatonin with the onset of the endogenous melatonin rhythm. If 
this were the case then all data points (containing exogenous melatonin) preceding the 
endogenous melatonin rise were excluded from the analysis.
The time of plasma MO 50% and MOff 50% were also calculated. This was done by using 
50% of the peak value that was obtained from the midrange crossing analysis.
5.2.4.4 Salivary Melatonin Analysis
The same methods were used to determine the plasma melatonin acrophase and MO 50% and 
MOff 50% were used for the salivary melatonin analysis. Although saliva samples were 
collected for all subjects in the 2001 study, due to time constraints the saliva samples were 
only assayed if there had been difficulties with the plasma melatonin assay. This was the case 
for one subject (MSS76) as the binding for the plasma assay was very low.
5.2.4.5 Calculation of Phase Shift
Phase shifts following melatonin/placebo administration were calculated by determining the 
difference in the variable (e.g. the plasma melatonin acrophase) between the day before and 
the day after treatment. The calculations for phase shifts also took into account that the free- 
running rhythms would have naturally delayed in the absence of treatment. For example, if 
the subjects’ aMT6s period was 24.50 h, the rhythm would naturally have delayed by 0.50 h 
per day. As there were 2 days between phase assessments, a natural phase delay of 1.00 h was 
accounted for in the calculations.
A phase shift was also calculated from the aMT6s period regression lines. Phase shifts were 
calculated by extending the regression line from the days before melatonin/placebo and
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determining the difference between this regression line and the regression line for the days 
after the treatment.
5,3 Results
5.3.1 Effect of Exogenous Melatonin on the aMT6s Rhvthm
Figure 5.4 shows the aMT6s p.g/24 h output for the duration of the study, and confirms 
compliance with the order of melatonin treatment. PLS18 restarted self medication with daily 
melatonin following his last visit to the CIU which accounts for the high aMT6s peaks 
observed at the end of the study. These exogenous data was excluded from the analysis of 
PLS18. There was no second peak for DNS45 in the 2000 study urine as samples were not 
collected by mistake on the day of melatonin administration.
Plots of the significant acrophases determined by cosinor analysis/midpoint crossing analysis 
are shown in Figure 5.5. In PLS18 and SLS44, few significant acrophases were obtained from 
cosinor analysis so acrophases from midrange crossing analysis were used instead.
Table 5.3 shows the periods generated from the aMT6s regression lines. The aMT6s 
acrophase was defined as occurring at CT21 and the CT of melatonin administration was 
calculated from this (Table 5.4).
Table 5.3: aMT6s periods of each subject before and after melatonin administration.
aMT6s period (h)
Subject Pre first M treatment Pre second M treatment Post second M treatment
KBS14 24.50 ±2.93 24.51 ±0.10a ND
PLS18 24.93 ±0.50 ND ND
JGS26 24.12 ±0.07 24.33 ±0.09a 24.56 ±0.50
SLS44 24.27 ±1.42 24.20 ±0.21a 24.11 ±0.55
DNS45 2000 24.83 ±0.19a ND 24.42 ± 0.48
DNS45 2001 25.08 ± 7.88 24.76 ±0.48 24.87 ±0.16a
MSS76 ND 24.87 ±2.52 24.52 ±1.21“
NOS78 24.74 ±2.14 24.55 ±0.37a 24.29 ±0.82
ND = no data, e.g. no samples, or not enough significant acrophases for regression analysis 
a = the periods from the longest data set
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Figure 5.4: Plots of the 24 hour aMT6s outputs (pg/24 h) for each subject. Red arrows indicate days on 
which melatonin treatment was given.
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The raw aMT6s acrophase plots shown in Figure 5.5 show some signs of a phase shift 
occurring after melatonin administration. For example, in KBS 14 there appears to have been a 
phase delay after the second dose of melatonin, and in SLS44 a phase advance after the 
second dose of melatonin can be seen. For DNS45 in the 2001 study two regression lines are 
shown post leg 3 because with such an apparently large phase shift occurring (10 h) it is not 
possible to know if a phase advance or delay has occurred. The calculated phase shifts for all 
subjects are shown in Table 5.4. Table 5.4 also shows the calculated phase shifts from the 
aMT6s acrophase before (day 2) and after (day 2) treatment determined by cosinor analysis.
Plots of the subject aMT6s profiles on the day before (day 2) and after (day 4) treatment are 
shown in Figure 5.6. For PLS18 the aMT6s levels are abnormally high and there is little 
circadian variation.
Table 5.4: Calculated aMT6s phase shifts and CT of melatonin/placebo administration.
Subject StudyLeg
CT of 
administration
Expected phase 
shift
Phase shift from 
regression lines (h)
aMT6s acrophase (h)
Day 2 Day 4 Phaseshift
KBS14
Leg 1 (M) 15 Phase advance -2.0 14.3 18.1 -3.3
L eg2(P) 9.5 Phase advance ND 20.2 22.1 -1.4
Leg 3 (M) 6 None (crossover) ND ND ND ND
PLS18
Leg 1 (P) 4 Phase delay ND ND ND ND
Leg2 (M) 20.5 Phase delay +4.0 ND ND ND
Leg 3 (M) ND ND ND ND ND ND
JGS26
Leg 1 (M) 17.5 Phase advance -2.0 13.3 15.5 -1.9
Leg2 (P) 13.5 Phase advance ND 17.4 17.6 +0.1
Leg 3 (M) 11 Phase advance +1.25 ND 18.0 ND
SLS44
Leg 1 (M) 18.5 Phase delay -0.75 ND ND ND
L eg2(P) 16.5 Phase advance ND ND ND ND
Leg 3 (M) 14.5 Phase advance +1.0 ND ND ND
DNS45
2000
Study
Leg 1 (P) 12.5 Phase advance ND 18.3 20.4 -1.3
Leg 2 (M) 5.5 Phase delay NDb ND ND ND
Leg 3 (M) 0.5a Phase delay 1.75a ND ND ND
DNS45
2001
Study
Leg 1 (M) 16.5 Phase advance +0.25 ND ND ND
L eg2(P) 10.5 Phase advance ND 18.4 20.3 -1.0
Leg 3 (M) 6.5 Phase advance 10.0° 0.9 ND ND
MSS76
Leg 1 (M) ND ND ND ND ND ND
L eg2(P) 15.5 Phase advance ND ND ND ND
Leg 3 (M) 9.5 Phase advance +3.75 ND ND ND
NOS78
Leg 1 (M) 10.5 Phase advance +3.0 18.5 ND ND
Leg2 (P) 10.5 Phase advance ND 19.7 19.9 -0.1
Leg 3 (M) 6.5 Phase advance -0.75 23.3 23.2 -0.2
Expected phase shift was determined from the published PRC (Lewy et ah, 1998). The calculated phase shifts have been 
corrected for period (using the periods from the longest aMT6s data set in Table 5.3).
a CT and phase shift predicted using regression line extended from Pre Leg 2 data assuming there was no phase shift after the 
melatonin treatment in Leg 2
b no data to confirm a phase shift but acrophase between Leg 2 and 3 fits with previous regression line and therefore suggests 
there was no phase shift
c a phase delay or a phase advance could have occurred
+ advance in the aMT6s rhythm, - delay in the aMT6s rhythm, M = melatonin, P = placebo, ND = no data
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Figure 5.6: Plots of the subject aMT6s profiles for the day before (shown in blue) and the day 
after (shown in red) treatment for each leg and each subject.
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Figure 5.6: Plots of the subject aMT6s profiles for the day before (shown in blue) and the day 
after (shown in red) treatment for each leg and each subject.
Unfortunately using cosinor analysis there are few statistically significant acrophases on the 
day before and after treatment to calculate phase shifts from (Table 5.4). There were also few 
acrophases calculated from midrange crossing analysis. However, the majority o f phase shifts 
that occurred in the aMT6s rhythm were phase delays. The maximum phase delay that 
occurred from this method was 3.3 h (KBS 14 leg 1, melatonin administration) and the 
maximum phase advance that occurred was 0.1 h (JGS26 leg 2, placebo administration). 
Phase shifts calculated from aMT6s regression lines were approximately half phase delays 
and half phase advances. The maximum phase delay that occurred (not including the 10 h 
phase shift from DNS45) from this method was 2.0 h (KBS 14 leg 1, melatonin 
administration) and the maximum phase advance that occurred was 5.0 h (SLS44 leg 3, 
melatonin administration).
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5.3.2 Effect of Melatonin on the Plasma Melatonin Rhythm
The individual subject plots o f the melatonin plasma profile for the day before (day 2) and 
after (day 4) treatment are shown in Figure 5.7. There were no data for Leg 2 for PLS18 and 
DNS45 in the 2000 study because both subjects carried out this study leg in their homes 
where plasma samples could not be taken.
The plasma melatonin amplitude (taken as the average of the three highest points) does not 
vary a lot between day 2 and day 4 within subjects, neither does it vary between legs within 
subjects. The mean amplitude (±SD) for each subject is as follows, KBS14 62.4 ± 9.9 pg/ml; 
JGS26 37.8 ± 13.8 pg/ml; SLS44 35.4 ± 11.1 pg/ml; DNS45 2000 study 37.6 ± 17.9 pg/ml; 
DNS45 2001 study 57.4 ± 16.3 pg/ml; and NOS78 103.1 ± 26.3 pg/ml. This can be seen in 
Figure 5.7. For each subject plasma melatonin concentrations were measured for each subject 
(an example is shown in Appendix B), levels were 32-235 fold higher than endogenous 
melatonin after melatonin administration. Peak levels were generally achieved within 2.5 h, 
which decline over 12.5 -  17.5 h back to the endogenous range. For PLS18 the melatonin 
concentrations never drop down to baseline levels remaining at approximately the same level 
with little basal-peak variation. This is an unusually high level of basal melatonin.
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Figure 5.7: Plots of the plasma melatonin profiles for the day before (shown in blue) and 
the day after (shown in red) treatment for each leg and each subject
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Table 5.5 shows the CT of melatonin administration calculated using pre-treatment plasma 
melatonin data. For the plasma calculation it was assumed that the plasma melatonin 
acrophase occurs at CT19. The CT of administration was then calculated in the same way as 
for the aMT6s data. Also shown is the expected phase shift based on the published PRC 
(Lewy et al., 1998). Phase shifts in the plasma melatonin acrophase, MO 50% and MOff 50 
% are also shown (see Section 2.7.3 for how these variables were calculated).
Table 5.5: CT of melatonin administration according to the pre-treatment plasma melatonin and the 
expected and observed phase shifts. There was no plasma data for PLS18 or MSS76.
Aerophase Calculated phases iift(h)
Subject Study Leg CT of administration
Expected phase 
shift Day 2 Day 4 Acrophase
MO
50%
MOff
50%
KBS14
Leg 1 (M) 15.5 Phase advance 13.31 15.89 -2.1 -3.0 -1.1
Leg2(P) 9.5 Phase advance 18.75 21.72 -2.5 -1.2 -2.4
Leg 3 (M) ND ND ND ND ND ND ND
JGS26
Leg 1 (M) 16.5 Phase advance 11.89 13.28 -1.1 +1.1 -2.9
Leg2(P) 13.5 Phase advance 15.14 14.65 +1.0 +0.3 +1.7
Leg 3 (M) ND ND ND 16.82 ND ND ND
SLS44
Leg 1 (M) 20.5 Phase delay 7.75 5.30 +2.8 +4.5 +1.4
Leg2(P) 19 Phase delay 9.39 9.48 +0.4 +1.7 -0.9
Leg 3 (M) 16.5 Phase advance 12.2 ND ND ND +1.0
DNS45
2000
Study
Leg 1(F) 12.5 Phase advance 15.89 18.88 -2.2 -2.2 -2.1
Leg 2 (M) ND ND ND ND ND ND ND
Leg 3 (M) ND ND 6.57 ND ND ND ND
DNS45
2001
Study
Leg 1 (M) 18.5 Phase delay 10.30 ND ND ND -6.9
Leg2(P) 12.5 Phase advance 15.91 18.55 -1.8 -1.9 -1.6
Leg 3 (M) 6.5 Phase advance 22.40 23.95 -0.7 0 -1.4
NOS78
Leg 1 (M) 14 Phase advance 14.33 15.21 -0.3 +0.1 -0.8
Leg2(P) 10.5 Phase advance 18.14 19.35 -0.7 +0.3 -1.6
Leg 3 (M) 7 Phase advance 21.59 22.47 -0.3 -2.3 +1.6
Expected phase shift was determined from the published PRC (Lewy et al., 1998). The calculated phase shifts 
have been corrected for period (using the periods from the longest aMT6s data set in Table 5.3).
+ advance in the aMT6s rhythm, - delay in the aMT6s rhythm 
M = melatonin, P = placebo, ND = no data
5.3.3 Effect of Melatonin on the Salivary Melatonin Rhvthm
Figure 5.8 shows the individual salivary melatonin profiles for each leg the day before (day 2) 
and after (day 4) treatment. Table 5.6 shows the expected and calculated phase shifts in the 
salivary melatonin acrophase, MO 50% and MOff 50% on each leg determined by midrange 
crossing analysis. The Salivary melatonin analysis was not carried out for subjects SLS44, 
DNS45 2001 study and NOS78 due to time constraints. There were no data for Legs 1 and 2
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for PLS18 due to insufficient volumes of saliva needed to carry out the RIA. There were no 
data for DNS45 in the 2000 study for Leg 2 due to a mix up with the collection bottles at his 
home. Table 5.6 also shows the CT of administration. For the saliva calculation it was 
assumed that the saliva melatonin acrophase occurs at the same time as the plasma melatonin 
acrophase, CT19, as they have both been shown to run in parallel (McIntyre et al., 1987).
Table 5.6: Phase shifts in the salivary melatonin rhythm determined by midrange crossing analysis for 
treatment on Legs 1-3, and the calculated phase shift. Salivary melatonin was not assayed for subjects 
SLS44, DNS45 2001 study and NOS78.
Acroiphase Calculated phase shift (h)
Subject Study Leg CT of administration
Expected phase 
shift
Day 2 Day 4 Acrophase MO MOff
KBS14
Leg 1 (M) 14 Phase advance 14.27 15.15 -0.4 -1.7 +0.9
Leg2(P) 10 Phase advance 18.33 20.38 -1.5 -0.9 -2.4
Leg 3 (M) ND ND ND ND ND ND ND
PLS18
Leg 1 (P) ND ND ND ND ND ND ND
Leg 2 (M) ND ND ND ND ND ND ND
Leg 3 (M) ND ND ND ND ND ND ND
JGS26
Leg 1 (M) ND ND ND 13.22 ND ND ND
Leg2(P) 14.5 Phase advance 13.81 14.43 +0.3 +1.0 -1.5
Leg 3 (M) 10 Phase advance 17.39 15.85 +1.9 +2.9 +0.8
DNS45
2000
Study
Leg 1 (P) 14.5 Phase advance 14.12 20.84 -5.9 -6.3 -5.4
Leg 2 (M) ND ND ND ND ND ND ND
Leg 3 (M) ND ND ND 14.87 ND ND ND
MSS76
Leg 1 (M) ND ND ND ND ND ND +3.5
Leg2 (P) 14.5 Phase advance 14.24 15.86 -1.1 -0.9 -1.3
Leg 3 (M) ND ND ND ND ND ND ND
Expected phase shift was determined from the published PRC (Lewy et al, 1998). The calculated phase shifts 
have been corrected for period (using the periods from the longest aMT6s data set in Table 5.3)..
+ advance in the aMT6s rhythm, - delay in the aMT6s rhythm 
M = melatonin, P = placebo, ND = no data
There was little data obtained from the saliva melatonin analysis to be able to calculate phase 
shifts. The salivary melatonin amplitude (taken as the average of the three highest points) 
does not vary a lot between day 2 and day 4 within subjects, neither does it vary between legs 
within subjects. The mean amplitude (±SD) for each subject is as follows, KBS14 40.3 ± 10.0 
pg/ml; PLS18 10.2 ± 3.5 pg/ml; JGS26 14.8 ± 3.0 pg/ml; DNS45 2000 study 10.3 ± 1.3 
pg/ml; and MSS76 40.1 ± 8.1 pg/ml. This can be seen in Figure 5.8.
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Figure 5.8: Plots of the saliva melatonin profiles for the day before (shown in blue) and the day 
after (shown in red) treatment for each leg and each subject. There is no data for Legs 1 & 2 for 
PLS18 and Leg 2 for DNS45.
104
5.3.4 Effect o f Melatonin on the CBT Rhythm
The CBT rhythm and CBT nadir was only used to support the data from the melatonin 
variables as in the protocol performed the CBT would be masked. This was due to the fact 
that posture was not strictly controlled and subjects were allowed to get up to go to the toilet 
and to have brief walks inside the CIU. In addition the meals and sleep periods would have 
contributed to the masking of the endogenous CBT rhythm. This meant that the majority of 
CBT rhythms did not show a distinct 24 hour rhythm. One o f the better examples is subject 
KBS 14 as shown in Figure 5.9. This figure also shows the close association o f the three 
variables (visual nadir, cosinor nadir, Tmin nadir) used to calculate the CBT nadir (Section 
2.7.5.
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Figure 5.9: KBS 14 Leg 2 CBT data during placebo treatment. Numbers indicate the CBT nadir 
calculated from Tmin analysis. * = visual nadir, * = cosinor nadir, * = Tmin nadir
5.3.5 Effect of Melatonin on Sleep
Sleep maps for each subject are shown in Figure 5.10. These sleep records are all subjective, 
including the period in the CIU. Both sleep maps for DNS45 have more days than the other 
subjects because he takes melatonin in his everyday life and he started to record his sleep as 
soon as he stopped taking melatonin treatment. The sleep map of KBS 14 ends on day 24 due
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to personal circumstances preventing him from completing the study. Leg 2 for both PLS18 
and DNS45 occurs on a Sunday as this was the weekend when they were at home and both 
started leg 2 sampling on Friday night rather than Thursday night.
The (first week) 7 or 8 days prior to the first study leg in the CIU was used to determine the 
presence any of free-running sleep/wake rhythms. Linear regression analysis of the sleep 
onset, offset and the midpoint of naps during this period did not show free-running sleep in 
the majority of subjects (i.e. the 95% confidence limits cross 0) (Table 5.7). Sleep onset 
showed free-running rhythms in KBS14 and DNS45 2001 study, sleep offset in KBS14 and 
the midpoint of naps in SLS44.
Table 5.7: Periods of subjective sleep parameters of the first week of the study prior to the first leg in 
the CIU
Period (h)
Subject Sleep onset Sleep offset Midpoint of naps
KBS14 22.74 ± 0.55 22.15 ±0.83 ND
PLS18 24.48 ±0.67 24.02 ±0.64 24.51 ± 1.27
JGS26 24.06 ±0.61 23.40 ±1.29 24.18 ±1.92
SLS44 24.12 ±0.61 23.85 ±0.22 23.80 ±0.13
DNS45 2000 study 24.05 ±0.08 24.02 ±0.09 23.76 ± 0.33
DNS45 2001 study 24.09 ±0.06 24.03 ±0.05 ND
MSS76 24.03 ±0.13 22.39 ±3.93 ND
NOS78 23.72 ± 0.30 23.63 ± 0.70 24.19 ±3.31
ND = no data
The effect of a single 5 mg dose melatonin on subjective sleep and naps 24 h after
administration was also assessed (Table 5.8). Repeated measures ANOVA showed that the
difference in total sleep and nap duration (for 24 hours after the treatment) between placebo
and melatonin treatments were not statistically significant. Values are shown in Table 5.8.
Table 5.8: Total nap and sleep duration on the day/night after melatonin/placebo (from 0930 - 0930 the 
following day)____________________________________________________________
SUBJECT
Total daytime nap 
duration (h)
Total night time sleep (h)
P M l M2 P M l M2
KBS14 0.58 3.58 0.25 4.25 4.25 2.25
PLS18 1.00 2.50 1.00 3.67 3.83 4.67
JGS26 1.17 2.33 0.25 5.84 5.75 8.00
SLS44 0.75 0.67 2.08 4.25 6.50 3.92
DNS45 2000 study 1.50 2.42 2.13 4.33 6.42 4.42
DNS45 2001 study 2.50 0.92 2.83 5.67 0.50 4.50
MSS76 2.00 1.50 0.58 4.00 2.50 5.42
NOS78 0.92 4.08 1.00 6.91 5.62 5.92
P =  placebo, M l =  first time melatonin taken, M 2= second time melatonin taken
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Figure 5.10: Sleep maps for each subject throughout the study. Grey bars represent sleep periods, black bars 
represent naps. The vertical axis represents the study day with S being a Saturday or Sunday. Red circles 
represent melatonin administration, blue circles represent placebo administration. 10
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5.3.6 Effect of Melatonin on Alertness
The alertness data for 13.5 h (0930 -  2300 h) after melatonin/placebo administration is plotted 
in Figure 5.12. There was no difference in the alertness rating following melatonin/placebo 
administration. Four subjects (JGS26, SLS44, DNS45 2000 study and DNS45 2001 study) 
were more alert on the placebo leg than both melatonin legs until 13.00 h (3.5 h after 
treatment). In all but one subject (PLS18) alertness on the placebo leg was greater than on 
both melatonin legs for at least one time point up until 19.00 h (9.5 h after treatment). In five 
cases (KBS14, PLS18, JGS26, DNS45 2001 study, and NOS78) the subjects were actually 
more or just as sleepy at 23.00 h with placebo treatment than on both melatonin treatment 
legs.
sleepy 9
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7.00 9.00 11.00 13.00 15.00 17.00 19.00 21.00 23.00
M first 
placebo 
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time (h)
Figure 5.11: Mean alertness data (± SD) for the day of melatonin/placebo administration. The time at 
which the alertness rating was recorded has been rounded up or down to the nearest hour. The vertical 
red line shows the treatment time.
The mean alertness data shown in Figure 5.11 shows that there was not a big difference 
between placebo and the second melatonin treatment, but that for the first 5.5 h after 
treatment (until 15.00 h) the subjects were generally sleepier and after this time more alert. 
Repeated measures ANOVA of the mean alertness data from each leg for each subject shows 
that the data was not significantly different (p = 0.9).
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Figure 5.12: Plots of alertness (1 = alert, 9 = sleepy) for each subject on the day of melatonin or placebo treatment. 
The dark blue line represents the first melatonin treatment, the pink line represents the placebo treatment and the 
yellow line represents the second melatonin treatment. The vertical red line shows the treatment time.
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5.3.7 Effect of Melatonin on Phase Shifting the Circadian Rhythms
Figure 5.13 and Table 5.9 show the phase shifts for each subject in aMT6s, plasma and 
salivary melatonin for all the variables that were calculated (i.e. MO 50%, MOff 50%, 
acrophase etc).
The CTs obtained from each variable (plasma melatonin, aMT6s and salivary melatonin) are 
well correlated (r2 = 0.88) indicating that if a CT was not available from one of the variables 
then another CT can be used. For each subject the mean CT from all three variables has been 
used in Figure 5.13.
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Figure 5.13: Individual PRC plots o f  the phase shift for each variable in relation to CT o f  melatonin/placebo administration. The 
treatment is shown above the symbols. All phase shifts have been corrected for the individuals period.
(M = melatonin; P = placebo), - = phase delay, + = phase advance 
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Figure 5.14 shows the mean phase shift for the plasma melatonin variables (acrophase, MO 
50%, M Off 50%) unless it was not possible to calculate a phase shift in which case salivary 
melatonin was used instead.
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Figure 5.14: Plot of the mean plasma/salivary melatonin phase shift for each subject. The mean phase 
shift was taken for all plasma melatonin variables (acrophase, MO 50% and MOff 50%) unless plasma 
melatonin phase shifts were not calculated in which case salivary melatonin was used (MSS76 leg 2 
and JGS26 leg 3). Closed symbols are used for melatonin administration, open symbols for placebo. A 
different symbol and colour is used for each subject. The phase advance portion of the PRC (Lewy et 
al., 1998) is also shown.
5.4 Discussion
In all the study subjects the aMT6s acrophases showed a clear free running rhythm. However, 
only three of the seven subjects showed free running sleep-wake rhythms. This finding is in 
agreement with previous research showing that people with free running aMT6s rhythms do 
not always show a free running sleep-wake cycle (Lockley, 1997). Subjects live at home, 
some have family and children to care for, and work commitments and therefore their sleep- 
wake cycle is also influenced by these factors, particularly for example if  a subject needs to 
set their alarm clock to get up for work. This reinforces the fact that it is important to also 
look at endogenous hormonal circadian rhythms such as melatonin, aMT6s, cortisol when 
first characterising circadian rhythms and not just rely on the subject’s sleep pattern.
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Looking at the effect of an acute dose of melatonin on daytime napping and the night sleep 
following there was no difference in the duration of day time naps and night time sleep 
following melatonin treatment compared to placebo. In contrast, in sighted subjects if 
melatonin is taken late in the subjective day this phase advances circadian rhythms, including 
the sleep wake cycle (Arendt et al., 2000). Low doses of melatonin during the day has been 
shown to increase sleepiness (Dollins et al., 1994; Deacon and Arendt, 1995; Zhdanova et al., 
1996). This approximates to a circadian time of CT10-14 meaning that if melatonin is taken 
during this window then there may be an increase in sleep propensity. Only two subjects were 
given melatonin between CT10-14, which may therefore explain why no significant 
difference in napping and sleep time after the melatonin dose compared to placebo was seen.
The 5 mg melatonin treatment affected the subjects’ self rated alertness in that they were 
generally sleepier during the day after taking melatonin, however this was not significant. In 
addition, paradoxically five of the 7 subjects (one of which took part in the study twice) were 
sleepier at 23.00 h after placebo treatment than melatonin treatment, however this was not 
significant. This finding could be due to the fact that the subjects were sleepier and napped 
more during the day after melatonin treatment making them more alert in the evening. The 
difference between alertness ratings following placebo and melatonin administration may not 
be significant because of the small number of subjects. Also the ratings ranged from 1-9 and 
this gave little variation in the ratings as subjects tended to stay within the middle range (a 
rating of 4-6).
Using the urinaiy aMT6s data to calculate phase shifts did not yield consistent results. It was 
only possible to calculate a few phase shifts based on the amt6s acrophases the day before and 
day after treatment. This was due to subject profiles where amt6s acrophases are not clear, 
therefore cosinor analysis did not produce clear statistically significant amt6s peak times and 
midrange crossing analysis was not possible because the peaks were not clearly defined. 
Using the amt6s regression lines (from the daily aMT6s peak times) to calculate phase shifts
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following placebo/melatonin administration yielded phase shifts, however these are not 
always reliable, for example the 10 hour phase shift observed after Leg 3 in DNS45 for the 
2001 study is unlikely.
The aMT6s analysis for one subject (PLS18) was not satisfactory in that few significant 
amt6s peaks were observed. This phenomenon can now be explained by the subject’s plasma 
melatonin profiles (Figure 5.7) which also showed a lack of circadian rhythmicity. Further 
investigation of the subject’s medical history revealed that he was taking paroxetine (a 
serotonin re-uptake inhibitor). Another serotonin re-uptake inhibitor fluvoxamine has been to 
shown to increase the amplitude of the plasma melatonin profile (Skene et al., 1994). Recent 
research shows that this increase in plasma melatonin is due to inhibition of the metabolism of 
melatonin by the P450 enzyme CYP1A2 (Facciola et al., 2001; Skene et al., 2001; Ursing et 
al., 2002; Yeleswaram et al., 1999). This inhibition of melatonin metabolism may explain the 
high plasma melatonin concentration found in this subject taking paroxetine.
There was little data obtained from analysis of salivary melatonin from all subjects. This 
could be due to the fact that the amplitude of the saliva melatonin profile is much lower 
(approximately one third) than the plasma (McIntyre et al., 1987) therefore it was harder to 
identify acrophases, onsets and offsets. In addition, as the saliva samples were only obtained 
over a period of 15 hours each day (while the subjects were awake) it was possible that the 
melatonin onset, offset and acrophase would not occur within this time. It was also evident 
from both the plasma and salivary melatonin profiles that the melatonin from the exogenous 
melatonin dose sometimes overlapped with the endogenous melatonin rise making calculation 
of the endogenous melatonin onset impossible. All these factors may have contributed to the 
lack of salivary melatonin data.
In most of the subjects there was a good correlation between the direction of the phase shifts 
and the calculation of CT using plasma melatonin, salivary melatonin and aMT6s analysis.
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Phase shifts in the aMT6s rhythms tended to show larger phase shifts than the salivary and 
plasma melatonin data. Most of the expected phase shifts were phase advances (between 
CT6-18, the phase advance portion of the PRC; Lewy et al., 1998). However, most of the 
observed phase shifts in the present study were phase delays and therefore opposite to those 
expected on the basis of the published PRC (Lewy et al., 1997). However, the majority of 
these phase delays were of the same magnitude as those seen with placebo treatment. This 
may be due to the fact the original PRC was constructed from multiple doses of melatonin 
(0.5 mg daily for four days), and also the fact the subjects studied in the Lewy study were all 
sighted and entrained. The current study used a higher (5 mg) single dose of melatonin. This 
and the fact that blind subjects with characterised free-running rhythms were studied could 
explain the differences between these two PRCs. The assessment of more subjects should 
clarify this issue.
It is common practice to derive phase shifts from circadian parameters by calculating the 
difference in phase between the values from the day before and the day after the drug or light 
treatment (e.g. Minors et al., 1991; Khalsa et al., 2003; Lewy et al. 1998). This method does 
not however give much indication of the effect of the drug or light pulse on the circadian 
system a few days later. There was some evidence of an after effect of melatonin on the 
circadian rhythm more than a day after the treatment from the aMT6s acrophases obtained up 
to two weeks after the melatonin administration. If a phase shift occurred, it would be 
possible to see if the circadian system reverted back to its normal phase position (i.e. the time 
it would be if no phase shift had occurred) after a few days or if it continued to free run from 
the new phase position. A clue to this occurring would be an altered period after the 
melatonin treatment. Unfortunately, however, the only data set long enough to observe this 
would be post the last study leg (Leg 3). There was some evidence of this occurring in JGS26, 
DNS45 2000 study, MSS76 and NOS78 as the periods after Leg 3, are slightly different than 
those periods obtained before the first leg of the study (see Table 5.3).
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It is clear from the findings that more subjects need to be studied to obtain more data points 
and to eventually be able to construct a PRC, particularly the delay portion of the postulated 
PRC because only 3 points were obtained between CT18-6. Analysis of additional subjects 
would also be able to answer the question of whether the subjects’ intrinsic period affects the 
degree of phase shift that occurs. This is important because if the PRC for free-running people 
is different to that of entrained people then this may be why some subjects do not entrain to 
melatonin at specific circadian times
117
6.0 Effects of a Single Dose of Melatonin in an Advancing Free-
Runner
6.1 Introduction
The subject discussed in this chapter has circadian rhythms that free-run at a period shorter 
than 24 hours. She took part in the melatonin PRC study discussed in Chapter 5 but because 
of the difference in her circadian period the data are presented here as a separate chapter.
6.2 Methods
6.2.1 The Subject
The subject (MWHS67) was a 51 year old female (menopausal status unknown) who had lost 
sight in both eyes, which are still present, over a course of a number of days in 1953 (when 
the subject was 4 years of age) due to detached retinas. MWHS67 has previously been shown 
to have free-running rhythms aMT6s (acrophase time (mean ± SD), 23.92 ± 0.05 h; Lockley, 
unpublished data). The subject had also been shown previously to have no light perception in 
either eye from tests carried out at Moorefields Eye Hospital, London, UK.
6.2.2 Study Design
The protocol carried out was the same protocol used in the melatonin PRC 2000 study 
(Section 5.2.2). The University of Surrey Advisory Committee on Ethics approved the study 
and the subject gave informed consent. Throughout the study the subject was instructed not to 
take any medication that could affect melatonin or cortisol production or sleep (e.g., p- 
blockers, monoamine oxidase inhibitors, tricyclic antidepressants, and benzodiazepines). A 
slight deviation from the protocol was made in that few blood samples were obtained during 
Leg 1 of the study due to the discomfort of the subject and difficulty getting enough blood 
from the cannula. It was therefore decided that the subject would only give saliva samples for 
the remaining two study legs including hourly night-time samples. See Chapters 2 (Section 
2.5) and 5 (Section 5.2.2) for details of the methodology.
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6.2.3 Assays
Urinary aMT6s levels were measured by RIA (see Section 2.6.1 for details). The limit of 
sensitivity for the assay was 1.6 ng/ml. The interassay CVs were 12 % at 4 ng/ml (n=6), 20 % 
at 21 ng/ml (n=6) and 8 % at 43 ng/ml (n=6).
Plasma melatonin levels were measured by RIA (see Section 2.6.3 for details). The limit of 
sensitivity for the assay was 5 pg/ml. As plasma samples were only taken during the first 
study leg only 1 assay was performed and therefore it was not possible to calculate interassay 
CVs. The QCs were within the correct range (very low QC was measured at 17 pg/ml, the low 
QC at 40 pg/ml, the medium QC at 146 pg/ml and the high QC at 217 pg/ml).
Salivary melatonin levels were measured by RIA (see Section 2.6.4 for details). The limit of 
sensitivity for the assay was 2.0 pg/ml. The interassay CVs were 17 % at 9 pg/ml (n=5), 11 % 
at 26 pg/ml (n=5), 10 % at 57 pg/ml (n=5) and 10 % at 105 pg/ml (n=5).
6.2.4 Methods of Analysis
Analysis of all circadian phase markers was carried out as detailed in the melatonin PRC 
study (Sections 2.7 and 5.2.4). The calculation of phase shifts by melatonin takes into account 
that the rhythms would have naturally advanced without any treatment. The aMT6s period 
calculated from the longest duration of continuous urine collection (from the end of Leg 2 to 
the end of the study) is 23.88 h, therefore the rhythm would have naturally advanced by 0.12 
h per day. As there were 2 days between the day before and after melatonin/placebo 
administration, a natural phase advance of 0.24 h was accounted for in all the subsequent 
calculations.
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6.3 Results
6.3.1 Effect of Melatonin on the aMT6s Rhythm
Figure 6.1 shows the aMT6s pg/24 h output for the duration o f the study and confirms 
compliance with the order o f treatment in that 5 mg melatonin was given on the first two legs 
o f the study.
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Figure 6.1: aMT6s pg/24 h output for each study day. The red arrows indicate days (9, 16, 23) on 
which melatonin/placebo was given (0930 h), melatonin being administered on the first two study legs 
and placebo on the last study leg.
The statistically significant aMT6s acrophases determined by cosinor analysis and the 
circadian period determined by regression analysis are plotted in Figure 6.2. The significant 
aMT6s acrophases found by cosinor analysis are also plotted on the subjects sleep map 
(Figure 6.7). The aMT6s acrophases show a clear free-running rhythm which follows the 
pattern o f sleep and naps. Table 6.1 shows the aMT6s periods during the study.
Table 6.1: aMT6s periods throughout the study
Study time period aMt6s period ± 9 5 %  confidence limits
Pre leg 1 23.99 ± 0.51 h
Pre leg 2 23.68 ± 0.47 h
Pre leg 3, leg 3, post leg 3 23.88 ± 0.16 h
Melatonin treatment was administered on Leg 1 & 2, placebo treatment on Leg 3
To assess the circadian time at which melatonin had been administered the regression line 
through the aMT6s acrophases was extended to the day o f melatonin administration (see
T
V
1
 1
t f
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Study day
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Figure 6.2, dotted lines). The aMT6s acrophase is defined as occurring at CT21. The actual 
CT of melatonin administration was calculated from this. The circadian time of melatonin 
administration was calculated to be CT8 and CT10 on legs 1 and 2 respectively.
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Figure 6.2: Plot of the significant aMT6s acrophases determined by cosinor analysis. Time of day is 
shown as a continuous sequence on the horizontal axis. Treatment days are also shown (P = placebo, M 
= melatonin). Best-fit regression lines and the associated period between each treatment are shown for 
aMT6s as solid lines. Black dotted lines show the line extended to calculate the circadian time of 
melatonin administration.
The seemingly unstable, or wobbly, pattern of the aMT6s acrophases makes the phase shift 
calculated by determining the time difference between the regression lines before and after 
melatonin treatment an estimate which may be unreliable. The data (Figure 6.2) points 
towards a phase advance on Leg 1 and a phase delay on Leg 2 after melatonin administration. 
The raw aMT6s acrophase plots show some signs of a phase shift occurring after melatonin
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administration (Figure 6.3), particularly a phase advance in the aMT6s acrophase on Leg 2. 
Table 6.2 shows the aMT6s acrophases determined by midrange crossing analysis on the days 
before and after treatment for each leg. Cosinor analysis is often more reliable when data 
taken over a 48 hour period is analysed. Because data for up to 24 hours after melatonin 
administration can not be used (interference from exogenous melatonin dose) there were few 
statistically significant aMT6s acrophases determined by cosinor analysis for the days 
immediately before and after treatment consequently acrophases calculated by midrange 
crossing analysis were used to calculate resulting phase shifts.
Table 6.2: aMT6s acrophases determined by midrange crossing analysis for the day before (day 2) and 
after (day 4) melatonin/placebo treatment for Legs 1-3, and the calculate phase shift.
Study Leg
a Vf T6s acroiphase
Day 2 Day 4 Phase shift
Leg 1 (M) 
Leg 2 (M) 
Leg 3 (P)
No data 
22.6 h 
21.2 h
No data
20.0 h
19.0 h
No data 
-2.4 h 
-2.0 h
Calculations have taken into consideration the natural phase advance that would have occurred 
+ = advance in the aMT6s rhythm 
- = delay in the aMT6s rhythm 
M = melatonin, P = placebo
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Figure 6.3: Plots of the raw aMT6s profiles for study legs 1 - 3 for the days before (day 2, shown in 
blue) and after (day 4, shown in red) melatonin/placebo administration.
6.3.2 Effect of Melatonin on the Plasma Melatonin Rhythm
Blood samples were taken hourly throughout the course o f the time spent in the CIU 
weekends. Due to the discomfort to the subject and difficulty in obtaining blood samples, 
only a few samples were taken for Leg 1 o f the study and no samples were taken for Legs 2
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and 3. The majority o f the plasma data points precede the melatonin administration on leg 1 
thus making it impossible to determine if  a phase shift has occurred using the plasma data. 
The plasma melatonin profile for Leg 1 is shown in Figure 6.4.
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Figure 6.4: The plasma melatonin profile for leg 1 of the study and the acrophase time determined by 
midrange crossing analysis for day 2 of the leg.
6.3.3 Effect of Melatonin on the Salivary Melatonin Rhythm
Figure 6.5 shows the salivary melatonin profiles for each study leg on the day before (day 2) 
and after (day 4) melatonin/placebo administration. The raw data show an advance in both the 
salivary melatonin acrophases and melatonin onset (MO) on all study legs. Table 6.3 shows 
the calculated salivary melatonin acrophase and MO 50% on each study leg determined by 
midrange crossing analysis.
Table 6.3: Salivary melatonin acrophase and MO 50% on the day before (day 2) and the day after (day 
4) treatment for Legs 1-3 and the calculated phase shift.
Salivary melatonin acrophase Salivary MO 50%
Study Leg Day 2 Day 4 Phase shift Day 2 Day 4 Phase shift
Leg 1 (M) 18.28 h 15.85 h +2.2 h 17.08 h 10.47 h +6.4 h
Leg 2 (M) 15.36 h 15.33 h -0.2 h 12.03 h 11.23 h +0.6 h
Leg 3 (P) 17.6 h 15.87 h +1.5 h 15.37 h 13.12 h +2.0 h
The calculated phase shifts have been corrected for period (using the aMT6s period, 23.88 h) 
+ = advance, - = delay 
M = melatonin, P = placebo
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Figure 6.5: Salivary melatonin profiles for each study leg the day before (day 2, shown in blue) and 
after (day 4, shown in red) melatonin/placebo administration.
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6.3.4 Effect of Melatonin on the CBT Rhythm
Figure 6.6 shows the CBT profiles for each study leg, including the treatment day (day 3) so 
that the effect of melatonin treatment on the CBT can be seen.
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Figure 6.6: CBT profiles for study legs 1-3, showing the day before (day2, shown in blue) and day 
after (day 4, shown in red) melatonin/placebo administration. The CBT in the day of administration 
(day 3) is also shown (dotted light blue lines). The red arrow indicates the time of treatment (0930 h).
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Table 6.4 shows the calculated CBT nadir for each study leg, the day before and after 
treatment, and the calculated phase shift. It can be seen from these that the data is somewhat 
unreliable due to the masking as a phase shift of 6 hours is unlikely.
Table 6.4: CBT nadir determined by Tmin analysis for the day before (day 2) and after (day 4) 
treatment for Legs 1-3, and the calculate phase shift.
Study Leg
CBT nadir
Day 2 Day 4 Phase shift
Leg 1 (M) 2.08 h 23.77 h +2.1h
Leg 2 (M) 8.48 h 1.88 h +6.3h
Leg3(P) 18.38 h 1.55 h +6.9 h
The calculated phase shifts have been corrected for period (using the aMT6s period, 23.88 h)
+ = advance in the CBT rhythm, - = delay in the CBT rhythm 
M = melatonin, P = placebo
There is a slight decrease in CBT after melatonin treatment on Legs 1 and 2.
6.3.5 Effect of Melatonin on Sleep
Figure 6.7 shows the subjects sleep-wake cycle for the duration of the study. The sleep 
records are all subjective including whilst in the CIU. It also shows the aMT6s acrophases 
determined by cosinor analysis.
There was an increase in the number of night awakenings during the periods when the subject 
was in the CIU (Leg 1, days 8-11; Leg 2, days 15-18; Leg 3, days 22-25) due to the subject 
waking up to give saliva and blood samples.
The first week (7 or 8 days) prior to the first study leg in the CIU was used to determine the 
presence of free-running sleep-wake rhythms. Linear regression analysis of the sleep onset 
and offset was 21.87 ± 0.68 h and was 23.47 ± 0.08 h respectively before the first study leg. 
There was not enough data to calculate a free-running period using the midpoint of naps. 
These findings show the sleep-wake cycle was also free-running at a period shorter than 24 h, 
confirming that the period observed in the aMT6s rhythm.
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The effect o f melatonin on subjective sleep 24 h after the dose was also assessed. Values are 
shown in Table 6.5.
Table 6.5: Total nap and sleep duration on the day/night after the treatment (until 0930 h the following 
day). Circadian time calculated from aMT6s is shown in brackets.
Total daytime nap duration (h) Total night time sleep (h)
Leg 1 (M) Leg 2 (M) Leg 3 (P) Leg 1 (M) Leg 2 (M) Leg 3 (P)
0.5
(CT8)
2.08
(CT10)
1.67 4
(CT8)
0.41
(CT10)
3.33
P = placebo, M = melatonin 
The effect on sleep and napping for 24 hours after treatment is varied. The greatest amount of 
napping occurs after melatonin administration on Leg 2, as does the total night time sleep 
after melatonin administration on Leg 1. However, there is more napping and total night sleep 
after placebo treatment than after melatonin administration on Leg 3 and Leg 2 respectively.
6.3.6 Effect of Melatonin on Alertness
The alertness data for 13.5 hours after treatment is plotted in Figure 6.8. The data shows that 
on Legs 1 and 2 when melatonin was administered alertness is reduced for at least 1.5 hours 
immediately after treatment compared with placebo (Leg 3). For the rest o f the day there 
appears to be no difference in alertness with only a slight dip in alertness compared to placebo 
at 1900 h.
L1 M 
L2 M 
L3P
Figure 6.8: Alertness data (1 = alert, 9 = sleepy) for the days of treatment for study legs 1 - 3 .  Each 
line represents a different study leg. The vertical red line indicates the treatment time (0930 h).
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6.3.7 Effect o f Melatonin on Phase Shifting the Circadian Rhythms
The phase shifts calculated from the aMT6s and salivary melatonin data are presented in 
Table 6.6 and Figure 6.9. The table also shows the circadian time of administration and the 
expected phase shift.
Table 6.6: Comparison of phase shifts calculated from the different variables from aMT6s and saliva 
analysis. _________________________________________
Phase shift (h)
aMT6s
acrophase
Saliva
acrophase Saliva MO
CT of 
administration
Expected 
phase shift
Leg 1 (M) No data +2.2 h +6.4 h 8 Advance
Leg 2 (M) -2.4 h -0.2 h +0.6 h 10 Advance
Leg 3 (P) -2.0 h +1.5 h +2.0 h - -
+ = advance in the CBT rhythm, - = delay in the CBT rhythm 
M = melatonin, P = placebo
Melatonin was administered on both legs at a time when phase advances would have been 
expected.
♦  aMTBs acrophase 
■ saliva acrophase 
saliva MO
Figure 6.9: Plot showing the phase shifts on each Leg for each variable considered. The Y axis shows 
the calculated phase shift (- = phase delay, + = phase advance). Treatment (P = placebo, M = 
melatonin) is shown under each leg.
6.4 Discussion
Visual inspection of the sleep map shows a clear relationship between daytime napping and 
aMT6s acrophases that has been previously demonstrated in free-running rhythms (Lockley et 
al., 1997). There is a difference in the duration o f day time naps and night time sleep
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following melatonin treatment compared to placebo. There is also a difference between the 
melatonin treatments indicating that perhaps the effects of melatonin on sleep are related to 
the circadian time at which melatonin is given as discussed in Section 5.4.
Salivary melatonin analysis did not agree with the aMT6s analysis in terms of the direction of 
phase shifts that occurred. The difficulty with the aMT6s data is that it appears to be showing 
the phenomenon of relative co-ordination, making calculations in phase shifts unreliable. The 
majority of phase shifts in the salivary melatonin data were as expected on the basis of the 
published PRC (Lewy et al., 1997).
It is apparent that even in conditions used in this protocol, such as remaining semi-recumbent 
for the majority of the day and having meals at specific times, that the CBT data is heavily 
masked and can not be used for the main purpose of the protocol which was to calculate phase 
shifts. It is impractical to impose a strict constant routine for 84 hours to avoid masking, so 
CBT data can only be used to support data from other variables.
It is evident that improvements could be made to the protocol as discussed in Section 5.4. 
More subjects need to be studied to get more data points to eventually be able to construct a 
PRC.
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Chapter 7: Discussion
7.1 Rationale
The initial rationale of this thesis was to conduct a number of investigations into the effect of 
exogenous melatonin on the free-running circadian rhythms in blind people.
Previous work had established that free-running blind subjects could be entrained with 5 
(Lockley et al., 2000) and 10 mg melatonin (Sack et a l, 2000). Both of these doses of 
melatonin are pharmacological and the studies showed that not all subjects entrained. 
Lockley et al., (2000) showed that those who entrained did so when melatonin was started in 
the phase advance portion on the melatonin PRC (CT6-18). A number of reasons were 
proposed as to why some blind subjects did not entrain to melatonin (e.g. inappropriate 
circadian time of melatonin administration, subsensitivity of melatonin receptors following 
days of melatonin administration, insufficient time of melatonin treatment). Another reason 
for lack of entrainment might be that such a high dose of melatonin did not clear within 12 h 
and thus melatonin could be stimulating the melatonin PRC in both the phase advance and 
phase delay portions. A lower dose of melatonin which would be eliminated more quickly 
could therefore be more effective as an entraining plus being limited to one portion of the 
PRC. Melatonin has to be used chronically in order to maintain entrainment of free-running 
rhythms thus a lower dose would minimise any possible long term side effects. During the 
course of this thesis Lewy and co-workers showed that 0.5 mg melatonin could also entrain 
three free-running blind subjects (Lewy et al., 2001a). In this paper the authors disagreed with 
the theory put forward by Lockley and co-authors (2000) that blind subjects would only 
entrain if melatonin was started in the phase advance portion of the PRC. Further 
investigation was thus needed into the optimum dose of melatonin for entrainment as well as 
whether the circadian time at which melatonin treatment was started was important.
Many melatonin PRCs in humans have been published (Lewy et al., 1992; Zaidan et al., 
1994; Middleton et al., 1997; Lewy et al., 1998), however there are several problems
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regarding the protocols used. Classically PRCs should be carried out in free-running subjects 
or animals using a single dose/pulse of the stimulus (Section 1.5.3). The published melatonin 
PRC studies have limitations for a number of reasons. In three of the protocols (Lewy et al., 
1992; Zaidan et al., 1994; Lewy et al., 1998) sighted, entrained subjects in light/dark (LD) 
conditions have been studied, whereas subjects with free-running rhythms in constant lighting 
condition (i.e. in darkness) would be preferable. In the other protocol (Middleton et al., 1997) 
free-running subjects kept in dim light (< 8 lux) were used. All the studied subjects had a self­
selected sleep wake cycle (not constant) that in effect meant their light dark cycle was not 
maintained to the same regular hours. It would be important therefore to try to establish a 
melatonin PRC in which light confounds were eliminated (i.e. in totally blind people) and in 
which the subjects were free-running prior to administration of a single dose of melatonin. 
The preliminary melatonin PRC study (Chapters 5 and 6) was designed with this in mind.
Knowing the extent to which melatonin is able to phase shift circadian rhythms and how this 
relates to the CT of melatonin administration (i.e. establishment of a melatonin PRC) is 
important for treating people with non 24 free running sleep wake problems.
7.2 Entrainment of Free-Running Rhythms Using Low Dose Melatonin (Chapters 3 & 41
It has been shown that melatonin administration is effective in treating blind subjects with 
abnormal and free-running circadian rhythms to improve their sleep problems and entrain 
their free-running circadian clock to a 24 h day. The present data have shown that a lower 
dose of 0.5 mg is able to entrain free-running circadian rhythms and improve sleep (Chapters 
3 and 4). Some subjects entrained when melatonin was started in the phase advance portion of 
the melatonin PRC confirming the findings of the Lockley et al., (2000) study. However, in 
addition, the study showed for the first time that when melatonin was started in the phase 
delay portion of the PRC that the subjects can eventually entrain when an appropriate CT for 
melatonin administration is reached (i.e. the phase advance portion of the PRC).
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To date there is conflicting data about melatonin’s ability to phase delay circadian rhythms 
(Wirz-Justice et al., 2000; 2002), thus a staggered melatonin regime was designed to produce 
cumulative phase delays. This was tested in a blind person who had abnormally advanced, but 
entrained, circadian rhythms (Chapter 3). Compared with placebo, melatonin significantly 
improved the subject’s sleep (sleep onset was delayed, there were less night awakenings of 
shorter duration, and a reduced number and duration of naps). The melatonin treatment also 
caused a cumulative delay in the cortisol rhythm of 2.5 h. This case study is the first 
demonstration of daily melatonin able to phase shift the circadian rhythms of a blind person 
most likely by phase delay. This protocol could also be adapted to treat free-running blind 
people who have advancing free running rhythms (period < 24 h) as they would need to delay 
in order to become entrained.
These results show that 0.5 mg melatonin is as good as 5 mg in entraining free running blind 
subjects (Lockley et al., 2000). The ability of 0.5 mg to capture free-running circadian 
rhythms when an appropriate circadian phase was reached makes it the dose of choice as this 
was not seen in the 5 mg study.
7.3 The Melatonin PRC
The data from the preliminary PRC study (Chapters 5 and 6) shows that phase shifts can be 
produced following a single dose of 5mg melatonin. Phase shifts were observed in plasma and 
salivary melatonin as well as in the urinary aMT6s rhythms. Although CBT was recorded 
continuously in the subjects while in the 3 day laboratory legs of the study, the protocol did 
not control for posture, sleep and meals thus the CBT data were too masked to draw any 
reliable conclusions. One of the objectives of the study was to see if it could be carried out 
entirely in the subject’s home (without plasma sampling), thereby making it less demanding 
for the subjects and considerably reducing the costs of any future experiments. Masking of 
CBT will also have to be taken into consideration if the study were to be done in the field as
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the subject’s posture, eating habits etc. would be even less controlled than if they were in the 
laboratory. The fact that the salivary melatonin data will not always be obtainable is also an 
important factor. Because saliva samples are only taken during the day over a period of 15 
hours while the subject is awake, it would not be possible to guarantee that the endogenous 
melatonin onset, offset and acrophase will occur within this time period.
The findings show that some phase delays were seen at CTs (CT 6-18) when a phase advance 
was expected based on the published Lewy et al., PRC (1998). The phase delays were also of 
the same magnitude as phase shifts seen when placebo was administered. The discrepancy 
between the present results and Lewy et al., may suggest that each individual has their own 
individual PRC, which may be related to an individual’s endogenous circadian period. This 
may also suggest that PRCs in entrained subjects are different to those in free-running 
subjects. A closer look at the most recent melatonin PRC (Lewy et al., 1998) shows that 
individual subjects have different PRCs and these PRCs do not all have the same shape (see 
Figure 7.1) and do not conform to the strict statement that phase advances occur between 
CT6-18 and phase delays occur between CT18-6. The inter-individual difference in PRC 
shape may help to explain why some subjects who take melatonin daily do not entrain at 
certain CTs (Chapter 4). Investigation into PRCs established in other species shows that even 
a small difference in period does make a difference to the shape of the PRC (see Johnson, 
1990; 1999) thus there is good reason to propose that the same occurs in humans. To date no 
studies have addressed this relationship between tau and PRC in humans and it will be 
important to investigate this in future studies.
The differences between the PRC presented here and the Lewy PRCs may also be explained 
by the light input that the subjects receive. Lewy et al., (1998) has only studied sighted 
subjects who have light input into the circadian system. Even if sighted subjects are kept in 
dim lighting conditions, the difference between the dim light and the darkness when they 
close and open their eyes to sleep or wake could still represent a change in light intensity that
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may be interpreted by the circadian system as dawn and dusk signals. Recent work (Wright et 
at., 2001) showing that the human circadian system in sensitive to low intensity light supports 
this idea. In addition, changes in photoperiod have been shown to change the shape of PRCs 
in sparrows (Binkley and Mosher, 1986). Blind people with free-running circadian rhythms 
have no photic input into the circadian system, therefore all light confounds to their circadian 
system are eliminated. Removing the circadian effects of light may produce a different PRC. 
This remains to be tested.
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Figure 7.1: The individual PRCs for each subject as adapted from Lewy et al., 1998.
137
1A Analysis Methods
The midrange crossing analysis of melatonin and aMT6s rhythms has proved useful in the 
present studies. One subject (SLS44) had low amplitude aMT6s rhythms with few significant 
acrophases determined from cosinor analysis in both the 0.5 mg melatonin administration 
study (Chapter 4) and the melatonin PRC study (Chapter 5). The amplitude of the aMT6s 
rhythm does not affect the midrange crossing analysis and therefore in both studies these data 
were used instead as a good correlation was noted between the two different methods. It was 
also found that the midrange crossing analysis was better suited to plasma and salivary 
melatonin analysis than cosinor analysis because the plasma and saliva profiles did not always 
fit a sine wave.
All of the present studies have shown that the aMT6s data collected during a short period of 
time does not always produce reliable regression analysis. In the case of LPS22 (Chapter 3), 
the data sets ran over a period of 4 weeks, and this resulted in the cortisol data looking like the 
subject started to phase delay before melatonin treatment started. Fortunately this is unlikely 
because the subject had been studied before and was confirmed to have abnormally entrained 
aMT6s rhythms (Lockley et al., unpublished results). The subjects could have made errors 
when collecting her urine which could also explain this phenomenon (e.g. recording the 
wrong volume or not collecting some of the urine). In the 0.5 mg melatonin administration 
study (Chapter 4), large 95% confidence limits were observed in subjects who received 
placebo or melatonin for short periods of time and thus few aMT6s data points were obtained 
(for example DNS45 only had melatonin for 26 days due to his long aMT6s period of 24.96 
h). In the PRC studies (Chapters 5 and 6) very short data sets before, after, and in between 
study legs (6-14 days) meant that few aMT6s acrophases were obtainable, making the 
calculation of phase shifts in aMT6s difficult if not impossible. Longer aMT6s data sets such 
as those observed in most of the subjects who took part in the 0.5 mg melatonin 
administration study (Chapter 4), take into account any scalloping (curving) of the rhythm.
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However, even in the longer data sets the acrophases do not always follow the exact line 
determined by regression analysis. This scalloping may be caused by the free-running rhythm 
being influenced by environmental zeitgebers or even a forced sleep wake cycle as subjects 
struggle to live in a normal 24 h day society. Thus, unless the time period between study legs 
is lengthened beyond a week, urine collections and aMT6s 'measurements would not provide 
any reliable phase shift data. Elimination of daily timed sequential urine collections would 
also make it easier to recruit volunteers for the study as one of the most demanding parts 
would be removed.
7,5 Final Comments
In conclusion these studies have shown that melatonin is an effective phase shifting and 
entraining agent (chronobiotic) for blind people with abnormal and free-running circadian 
rhythms. Entrainment of these circadian rhythms (including the sleep/wake cycle) to a normal 
circadian phase is essential for the subjects to feel fully the benefits of melatonin treatment in 
terms of reducing daytime sleepiness and improving sleep efficiency, rather than just using 
the soporific properties of melatonin to improve sleep. Subjects whose underlying circadian 
system was entrained generally experienced more improvements in the subjective sleep 
parameters. More investigation into the most effective dose of melatonin and the CT of 
melatonin administration needs to be carried out. Whether these parameters depend on an 
individual tau needs more study. The duration of melatonin treatment also needs further 
investigation as it is not yet possible to be sure that the subjects who did not entrain to 0.5 mg 
(Chapter 4) may have done so at a later point if melatonin treatment had been continued for a 
longer period. The PRC data point to the possibility that individuals may have different PRCs 
and/or that the CTs of the phase delay and phase advance portions of the PRC may depend on 
an individuals’ circadian period. However, no relationship appears to exist in the few subjects 
that have been studied so far. The study of more blind subjects with different circadian
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periods will be able to clarify this relationship. In order to construct a complete PRC 
studies with more subjects need to be carried out.
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APPENDIX A
CIRCADIAN RHYTHM STUDY
DATE: CLINIC: SUBJECT NO:
NAME HOSPITAL NO: DOB.:
ADDRESS: AGE:
TEL: SEX: OCCUP:
GPs NAME & ADDRESS:
DIAGNOSIS:
DIAGNOSTIC CATEGORY: ARMD[~~|
Uveitis
OTHER EYE CONDITIONS:
DATE OF ONSET OF VISUAL LOSS: 
DATE OF REGISTRATION:
Retinal dystrophy I I
Optic Nerve Dis./ Glaucoma | |
RAPIDITY OF VISUAL LOSS: |~~| Days [~J Weeks Months | |Years
CORRECTED VISUAL ACUITY: 
HOW MANY EYES HAVE YOU?:
RT: LT:
VISUAL FIELDS: 
(Goldman Perimetry)
Details:
GENERAL HEALTH:
RT. LT.
MEDICATIONS:
Central Loss 
Peripheral Loss 
Others
DM
BP
Neurological Disorders 
Endocine Disease 
Psychiatric Conditions 
Others
Anti-depressants 
Beta-blockers 
M ajor Tranquillisers 
M inor Tranquillisers 
Sleeping Tablets 
Corticosteroids 
Others
ALCOHOL CONSUMPTION:
ACTIVITIES: Actiivities/Hobbies
Outdoor: f n < l  day 
Mobility: I- ] Good
SOCIAL: Lives with:
Units/week
□  Id;
□  Fai
day
Fair B> 1 day Poor
GENERAL EXAMINATION: BP URINE
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Circadian Rhythm Study Questionnaire
1. What time do you normally go to bed?___________
2. How many hours per night do you sleep on average?_________
3. How long does it take you to fall asleep? I |<10min I 110-30 mins □  >30 mins
4. How often do you wake up during the night?___________
5. How often do you get up during the night and why?
6. Do you go through phases of getting to sleep earlier and earlier or later and later each 
night?
Yes/No
7. Do you have any difficulty getting up in the mornings? Yes/No
If yes, what kind of difficulty?
8. Do you fall asleep during the day? Yes/No
If yes, how often, for how long and at what time of day?
9. Do you feel that your sleep pattern has changed since the deterioration of your vision?
Yes/No
10. Do you feel you have any problems sleeping? Yes/No
If yes, what kind of problems?
Is it recurrent? Yes/No
Can you estimate how often it occurs? Yes/No 
Does it recur regularly? Yes/No
11. Do you do anything to try to overcome this problem? (e.g. sleeping pills, relaxation 
techniques, making yourself go to bed at a particular time?) Yes/No
If yes, what do you do?
Are these strategies effective? Yes/No
12. Duration of sleep problem: [ ] < 6  months | |6 -  12 months Q  >12 months
13. Do you feel that you sleep problems are related to your visual loss? Yes/No
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14. Do you ever skip a night’s sleep? Yes/No
15. Is your sleep pattern different during work-free periods (eg. Holidays, weekends,)? 
Yes/No
If yes -  how is it different?
16. Does your sleep pattern affect your social or occupational life? Yes/No 
If yes -  please describe how
Any further comments you have would be veiy welcome
168
pg
/m
l 
pg
/m
l
A p p e n d ix  B
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Examples o f two subjects plasma melatonin profiles throughout the course o f one study 
leg. The red arrow indicates the day and time on which melatonin administration was 
given.
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